

# Queensland Health List of Approved Medicines

Drug	Form	Strength	Restriction
Abacavir	Oral liquid	20 mg/ml	* For use in accord with PBS Section 100 indications *
			See above
	Tablet	300 mg	See above
			See above
Abacavir + lamivudine	Tablet	600 mg + 300 mg	* For use in accord with PBS Section 100 indications *
			See above
Abatacept	Injection	250 mg	* For use in accord with PBS Section 100 indications *
Abciximab	Injection	10 mg/5 mL	(a) Interventional Cardiologists for complex angioplasty
			(b) Interventional and Neuro-interventional Radiologists for rescue treatment of thromboembolic events that occur during neuroendovascular procedures.
			* Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
Abemaciclib	Tablet	50 mg 100 mg 150 mg	See above
			See above
			See above
			See above
			See above
Abiraterone	Tablet	250 mg	* For discharge and outpatient use as per the PBS indications *
		500 mg	See above
Acalabrutinib	Tablet	100 mg	Specialist haematologists for discharge and outpatient use as per the PBS indications.
			Drug and alcohol treatment physicians for use with a comprehensive treatment program for alcohol dependence with the goal of maintaining abstinence.
Acamprosate	Enteric tablet	333 mg	See above
			See above
Acarbose	Tablet	50 mg	For non-insulin dependent diabetics with inadequate control despite diet; exercise and maximal tolerated doses of other anti-diabetic agents
		100 mg	See above
			See above
Acetazolamide	Injection	500 mg	
	Tablet	250 mg	
acetic acid	ear drops		

Drug	Form	Strength	Restriction
Acetylcysteine	solution	3% 15mL	
		2% 100mL green 3% 1 litre 6% 1 Litre 6% 200mL	
Aciclovir	Injection	2 g/10 mL	For management of paracetamol overdose <i>See above</i>
		6 g/30 mL	<i>See above</i>
Aciclovir	Cream		Infectious disease physicians, haematologists and oncologists <i>See above</i>
	Eye ointment	5%	For use on the advice of Ophthalmologists only. <i>See above</i>
	Injection	3%	Herpes simplex encephalitis Cutaneous or mucosal herpes simplex in immunosuppressed patients Disseminated herpes zoster in immunocompromised patients Varicella zoster encephalitis or pneumonia in all patients <i>See above</i>
		250 mg/10 mL	<i>See above</i>
		500 mg/20 mL	<i>See above</i>
	Tablet		For treatment of patients with: Genital herpes simplex infections Herpes zoster in immunocompetent patients in whom the duration of rash is less than 72 hours Herpes zoster in immunocompromised patients Ophthalmic herpes zoster <i>See above</i>
Acitretin	Capsule	200 mg	<i>See above</i>
		800 mg	<i>See above</i>
			Specialist Dermatologists and Specialist Physicians <i>See above</i>
Activated charcoal	Oral liquid	10 mg	<i>See above</i>
		25 mg	<i>See above</i>
Activated charcoal + sorbitol	Oral liquid	200 mg/ml	250mL
		200 mg/ml + 400 mg/ml	250mL
Adalimumab	Injection	20 mg/0.4 mL	For use in accord with PBS General Schedule/Section 100 indications [Brand Note: 'Amgevita' is the sole brand listed for the 20mg strength].
		40 mg/0.8 mL	For use in accord with PBS General Schedule/Section 100 indications [Brand Note: 'Hyrimoz' is the sole brand listed for the 40mg strength].
Adefovir	Tablet		* For use in accord with PBS Section 100 indications *
		10 mg	<i>See above</i>
Adenosine	Injection		
		6 mg/2 mL 30 mg/10 mL	Nuclear medicine for use in cardiac stress testing.

Drug	Form	Strength	Restriction
Adrenaline (epinephrine)	Injection	1 in 10 000 (1 mg/10 mL) injection and minijet	<p>EpiPen Jr® brand - For discharge and outpatient use as per the PBS indications.  Note: EpiPen Jr® has a substantially different administration technique to that of Anapen Junior®. Specific training is required for each brand of autoinjector. For patients previously prescribed an adrenaline autoinjector, subsequent prescriptions should be for the same brand, where possible.</p> <p>EpiPen® brand - For discharge and outpatient use as per the PBS indications.  Note: EpiPen® has a substantially different administration technique to that of Anapen®. Specific training is required for each brand of autoinjector. For patients previously prescribed an adrenaline autoinjector, subsequent prescriptions should be for the same brand, where possible.</p> <p>Anapen 500® brand - For discharge and outpatient use as per the PBS indications.  Note: Anapen® has a substantially different administration technique to that of EpiPen®. Specific training is required for each brand of autoinjector. For patients previously prescribed an adrenaline autoinjector, subsequent prescriptions should be for the same brand, where possible.</p>
		1 in 1000 (1 mg/mL)	
		150 microgram/0.3 mL	
Aflibercept	Injection	300 microgram/0.3 mL	<p>* For discharge and outpatient use as per the PBS indications *</p> <p>See above</p> <p>See above</p>
		500 microgram/0.3 mL	
Agalsidase alfa	Injection	2 mg/0.05 mL (3.6 mg/0.09 mL) syringe	
		2 mg/0.05 mL (4 mg/0.1 mL) vial	
		8 mg/0.07 mL, Vial	
Agalsidase beta	Injection	3.5 mg/3.5 mL	<p>For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program</p>
		5 mg	
		35 mg	
Albendazole	Tablet		<p>(a) Treatment of adults and children with Ancylostoma caninum (Eosinophilic enterocolitis), Ancylostoma duodenale/Necator americanus (Hookworm), Ascaris lumbricoides (Roundworm), Trichuris trichiuria (Whipworm) or Enterobius vermicularis (Pinworm).  (b) Treatment after approval by an Infectious Diseases physician or a Clinical Microbiologist or when used in accord with an infectious diseases approved protocol of adults and children with Echinococcus granulosus (Hydatids).  (c) Alternative treatment of adults and children with Strongyloides stercoralis.</p>
		200 mg	
		400 mg	
alcohol (ethanol)	gel	61.5% 75mL and 125mL	
	injection	96% 10mL 100% 5mL	
	lotion	47.5%-1% 1 litre	
	solution	specialty methylated (S.V.M.) 15mL	
		specialty methylated (S.V.M.) 20 litre 20 litre and 1 litre	
		rectified (S.V.R.) 96% 2 litre and 20 litre	
		absolute 1 litre	
		industrial methylated 1 litre	
		industrial methylated 4 litre	

Drug	Form	Strength	Restriction
Alectinib	with 10% propanol - foam	absolute 20 litre specially methylated 70% 2 litre	
		70% 1 litre 70% 50mL 70% 400mL	
Alectinib	Capsule	150 mg	Specialist medical oncology staff * For discharge and outpatient use as per the PBS indications *
Alemtuzumab	Injection	12 mg/1.2 mL	* For use in accord with PBS Section 100 indications *
Alendronate	Tablet	70 mg	* For use as per the PBS indications *
Alfentanil	Injection	1 mg/2 mL	Specialist Anaesthetists and their trainees for use as an analgesic supplement given by incremental intravenous boluses or continuous infusion. * CONTROLLED DRUG *
		5 mg/10 mL	For poor risk patients (eg elderly and ischaemic heart disease) * CONTROLLED DRUG *
alginic acid compound (sodium alginate)	liquid		For infant use only
		500mL liquid	See above See above
Alglucosidase alfa	Injection	50 mg	For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program
Allopurinol	Tablet	100 mg	
		300 mg	
Alprazolam	Tablet	1 mg	Specialist Psychiatrists
		500 microgram	See above See above
Alprostadil	Injection	10 microgram	Specialist Urologists and Spinal Injuries Units for in-hospital use for training purposes
		20 microgram 500 microgram/mL	See above Neonatal and Paediatric Staff Specialists to use to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon a patent ductus for survival.
alteplase	pre-filled syringe		For prevention of central venous catheter malfunction and central venous catheter associated bacterial infection in children on maintenance haemodialysis who are under the care of Specialist Renal Physicians. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		1mg in 1mL	See above See above
Alteplase			

Drug	Form	Strength	Restriction
	Injection		a) treatment of acute ST elevation myocardial infarction;b) treatment of acute massive pulmonary embolism.c) fibrinolytic management of obstructed IV access;d) treatment of acute ischaemic stroke under the authority of a physician (including Emergency Department physicians) trained and experienced in acute stroke management or in accordance with an approved written protocol, and in line with the Australian "Clinical Guidelines for Stroke Management". e) fibrinolytic treatment of complex pleural effusions. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		10 mg	See above
		50 mg	See above
Aluminium hydroxide	Tablet		For lowering of serum organic phosphates in patients with chronic renal failure
		600 mg	See above
aluminium hydroxide + magnesium hydroxide + simethicone (double strength)	Chewable tablet		
		400 mg + 400 mg + 40 mg	
Aluminium hydroxide + magnesium trisilicate + magnesium hydroxide	Oral liquid		
		250 mg/5 ml + 120 mg/5 ml + 120 mg/5 ml	
Amantadine	Capsule		For the treatment of Parkinson Disease
		100 mg	See above
			See above
Ambrisentan	Tablet		* For use in accord with PBS Section 100 indications *
		5 mg	See above
		10 mg	See above
Amidotrizoic acid	Solution		
		660 mg/ml + 100 mg/ml	For use as a radiographic contrast medium for examination of the gastrointestinal tract; For use by general surgeons for adhesive small bowel obstruction (obtain individual patient supplies from pharmacy for administration as a single 100mL dose). * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
Amikacin	Injection		
		500 mg/2 mL	On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. Caution: Only use DBL brand for nebulised route as it has a lower sodium metabisulfite content. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
Amiloride	Tablet		* For use in accord with Special Access Scheme (SAS) arrangements *
		5 mg (SAS)	See above
			See above

Drug	Form	Strength	Restriction
Amiloride + hydrochlorothiazide	Tablet	5 mg + 50 mg	
amino acids (synthamin 17) with electrolytes 100g (446 Cal.)/litre, (Na 70,K 60, Mg 5, Cl 70, Ac 150, PO4 30 mmol/L)	Injection	10.35 g/500 mL + 5.75 g/500 mL + 5.15 g/500 mL + ...	For prolonged intravenous therapy when oral or enteral feeding is not possible
amino acids (Synthamin 17) without electrolytes 100g/litre (Ac 82, Cl 40mmol/L)	Injection	10.35 g/500 mL + 5.75 g/500 mL + 5.15 g/500 mL + ...	For prolonged intravenous therapy when oral or enteral feeding is not possible
Aminolevulinic acid	Powder for oral liquid	1.5 g	Neurosurgeons who have undergone training in fluorescence guided surgery for use in patients with suspected high grade glioma in whom complete resection of enhancing tissue is feasible. <i>See above</i>
Aminophylline	Injection	250 mg/10 mL	
amiodarone	oral liquid suspension	5mg/mL 80mL	Paediatric cardiac specialists <i>See above</i> <i>See above</i>
Amiodarone	Injection	150 mg/3 mL	All preparations restricted to Cardiologists for resistant cardiac arrhythmias <i>See above</i>
	Tablet	100 mg 200 mg	<i>See above</i> <i>See above</i>
Amisulpride	Oral liquid	100 mg/ml	* For use as per the PBS indications *
	Tablet	100 mg 200 mg 400 mg	* For use as per the PBS indications * <i>See above</i> <i>See above</i>
Amitriptyline	Tablet	10 mg 25 mg 50 mg	
Amlodipine	Tablet	5 mg 10 mg	
Amorolfine	Solution	5%	Dermatologists for the treatment of proven fungal infections <i>See above</i> <i>See above</i>
Amoxicillin	Capsule	250 mg	

Drug	Form	Strength	Restriction
	Powder for oral liquid	500 mg	
		250 mg/5 ml 500 mg/5 ml	
	Tablet	1 g	
Amoxicillin + clavulanic acid	Injection	1 g + 200 mg	a) Infectious diseases physician and gastroenterologist for discharge and outpatient use as part of combination therapy for resistant <i>Helicobacter pylori</i> ; b) For discharge and outpatient use for community acquired pneumonia.
		2 g + 200 mg	
		500 mg + 100 mg	
	Powder for oral liquid	125 mg/5 ml + 31.25 mg/5 ml	On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. <i>See above</i>
		400 mg/5 ml + 57 mg/5 ml	
	Tablet	500 mg + 125 mg 875 mg + 125 mg	In conjunction with an antimicrobial stewardship (AMS) team protocol <i>See above</i>
Amphotericin B	injection "Fungizone" (SAS)	50 mg	For treatment of fungal infections where lipid amphotericin preparations are not initially indicated * On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. ** Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained * Caution: Amphotericin B injection formulations are not interchangeable. IV formulations of Amphotericin B available on the LAM and their relevant restrictions are linked below: Amphotericin B - "Fungizone" 50mg Inj Amphotericin B lipid complex - "Abelcet" 100mg Inj Amphotericin B liposomal "AmBisome" 50mg Inj
	lozenge "Fungilin"	10 mg	Treatment of oral moniliasis
amphotericin B	powder for tissue culture	50mg	
amphotericin B lipid complex "Abelcet" (SAS)	Injection	100 mg/20 mL	For treatment/prophylaxis of fungal infections * On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. * Caution: Amphotericin B injection formulations are not interchangeable. IV formulations of Amphotericin B available on the LAM and their relevant restrictions are linked below: Amphotericin B - "Fungizone" 50mg Inj Amphotericin B lipid complex - "Abelcet" 100mg Inj Amphotericin B liposomal "AmBisome" 50mg Inj
amphotericin B liposomal "AmBisome"			Use where therapy with "Abelcet" cannot be tolerated. For treatment/prophylaxis of fungal infections * On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. * Caution: Amphotericin B injection formulations are not interchangeable. IV formulations of Amphotericin B available on the LAM and their relevant restrictions are linked below: Amphotericin B - "Fungizone" 50mg Inj

Drug	Form	Strength	Restriction
	Injection	50 mg	Amphotericin B lipid complex - "Abelcet" 100mg Inj Amphotericin B liposomal "AmBisome" 50mg Inj
			See above See above
Ampicillin	Injection	1 g 500 mg	
amsacrine (AMSA)	injection	75mg in 1.5mL	
Anakinra	Injection	100 mg/0.67 mL	* For use in accord with PBS Section 100 indications * See above See above
Anastrozole	Tablet	1 mg	* For use as per the PBS indications * See above See above
Anifrolumab	Injection	300 mg/2 ml, Vial	For discharge, outpatient and day admitted patient use in accord with PBS Section 100 indications. See above
Antithymocyte immunoglobulin equine	Injection	250 mg/5 mL	
Antithymocyte immunoglobulin rabbit	Injection	25 mg	Transplant Specialists, Oncologists and Haematologists for: a) Prophylaxis of graft rejection in renal transplantation patients with a history of graft rejection; and b) Treatment of steroid resistant or moderate to severe renal transplant rejection. See above See above
Apomorphine	Injection	30 mg/3 mL pen device and cartridge 50 mg/5 mL ampoule 50 mg/10 mL syringe 100 mg/20 mL vial	* For use in accord with PBS Section 100 indications * See above See above See above
Apraclonidine	Eye drops	0.5% 5mL and 10mL	Specialist Ophthalmologists See above See above
Aprepitant	Capsule	165 mg	For use as per the PBS indications for Related Pharmaceutical Benefits used in conjunction with Efficient Funding of Chemotherapy - Section 100 arrangements.
aprepitant	oral liquid suspension	20mg/mL, 30mL	Paediatric oncology staff for the prevention and treatment of antineoplastic induced nausea and vomiting in paediatric patients under the care of the oncology service when other oral dosage forms are inappropriate. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
aqueous cream (A.P.F) with coal tar solution			



Drug	Form	Strength	Restriction
aqueous cream (A.P.F.)	cream	aqueous cream (A.P.F.) with coal tar 3% solution 100g	
	cream	100g 500g	
	cream	6%-6% 100g	
	cream	1% 100g	
aqueous cream (A.P.F.) with salicylic acid and sulfur	cream	3%-10% 100g 5%-5% 100g	
argatroban			For use as an alternative anticoagulant therapy for management of heparin-induced thrombocytopenia (HIT) in patients where rivaroxaban or fondaparinux is inappropriate. Note: patients must be under the care of a Consultant Physician with consideration for an additional Haematology consultation. * For use in accord with Special Access Scheme (SAS) arrangements ** Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
	injection (SAS)	250mg in 2.5mL	See above See above
Arginine hydrochloride	Injection	60% (15 g/25 mL)	For pituitary function testing See above See above
Aripiprazole	Modified release injection	300 mg 400 mg	Specialist Psychiatrists for the treatment of schizophrenia See above
	Tablet	5 mg	On the advice of psychiatrists and paediatricians for second-line treatment, following a trial of risperidone or clinical contraindications to the use of risperidone, for managing behavioural disturbance in autism spectrum disorder in children and adolescents up to 18 years of age. Note: Restrict use to where other tablet strengths cannot be used. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		10 mg	a) For use as per the PBS indications. b) On the advice of psychiatrists and paediatricians for second-line treatment, following a trial of risperidone or clinical contraindications to the use of risperidone, for managing behavioural disturbance in autism spectrum disorder in children and adolescents up to 18 years of age. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *

Drug	Form	Strength	Restriction
Arsenic	Injection	15 mg	See above
		20 mg	See above
		30 mg	See above
		10 mg/10 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * See above See above
Artemether + lumefantrine	Tablet	20 mg + 120 mg	For treatment of Plasmodium falciparum infection on the advice of an Infectious Diseases Physician or a Clinical Microbiologist See above
artesunate	powder for injection	60mg	For use in accord with Category A Special Access Scheme (SAS) arrangements. Approval from the Medical Superintendent (or delegate) must also be received in line with the Individual Patient Approval (IPA) guidelines. Initiation of therapy should be on the advice of an Infectious Diseases Physician. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained * QHMAC guidance on artesunate provided below - see 'Guidelines and Other Resources' section. See above See above
Articaine + adrenaline (epinephrine)	Injection	4% (88 mg/2.2 mL) + 1 in 100 000 (22 microgram/2.2 mL)	For dental use
artificial saliva	liquid	2 Litres "oralube" 125mL	
Ascorbic acid	Chewable tablet	500 mg	
Aspirin	Dispersible tablet	300 mg	
	Tablet	100 mg	
Atazanavir	Capsule	200 mg 300 mg	* For use in accord with PBS Section 100 indications * See above
Atazanavir + cobicistat	Tablet	300 mg + 150 mg	* For use in accord with PBS Section 100 indications * See above See above
Atenolol	Tablet	50 mg	
atenolol	oral liquid suspension	2mg/mL 200mL	Paediatric cardiac specialists See above See above
Atezolizumab	Injection		

Drug	Form	Strength	Restriction
Atomoxetine	Capsule	1.2 g/20 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		1.875 g/15 mL (subcutaneous)	a) For discharge and outpatient use as per PBS indications; b) For use as per PBS indications for Related Pharmaceutical Benefits used in conjunction with Efficient Funding of Chemotherapy - Section 100 arrangements
		840 mg/14 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		10 mg	For use as per the PBS indications (ADHD)
		18 mg	See above
Atorvastatin	Tablet	25 mg	See above
		40 mg	See above
		60 mg	See above
		10 mg	* For use as per the PBS indications *
		20 mg	See above
Atovaquone + proguanil	Tablet	40 mg	See above
		80 mg	See above
		250 mg + 100 mg	For treatment of Plasmodium falciparum infection on the advice of an Infectious Diseases Physician or a Clinical Microbiologist
			Medical staff skilled in airway support
			See above
Atracurium	Injection	25 mg/2.5 mL	See above
		50 mg/5 mL	See above
			See above
Atropine sulfate	Eye drops	1% unit dose 0.5mL x 20 and 15mL	0.5mL x 20 unit dose: For inpatient use only 15mL: Unrestricted Caution: Oral ingestion of atropine eye drops for clozapine-induced hypersalivation has been associated with accidental oral ingestion of a toxic quantity causing patient harm. Consider hyoscine hydrobromide chewable tablets as a LAM-listed alternative.
Avelumab	Injection	1 mg/10 mL	
		1.2 mg/mL	
		600 microgram/mL	
		600 microgram	For organophosphate poisoning
Azacitidine	Injection	200 mg/10 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
Azacitidine	Tablet	100 mg	* For use in accord with PBS Section 100 indications *
			See above
			* For discharge and outpatient use as per the PBS indications *
			See above
		200 mg	

Drug	Form	Strength	Restriction
		300 mg	See above
Azathioprine	Injection	50 mg	
	Tablet	25 mg 50 mg	
azathioprine	oral liquid suspension	5mg/mL, 100mL (QH-CP)	For oral or enteral dosing where administration of the solid dose form is not appropriate. Refer to 'Don't Rush to Crush' and local procedures for guidance. Note: Monitor patient on transition between different dose forms. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
Azithromycin	Injection	500 mg	On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol.
	Powder for oral liquid	200 mg/5 ml	For use as per the PBS indications for trachoma; and For the treatment and prophylaxis of laboratory proven or suspected Bordetella pertussis infection in children and infants. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
	Tablet	500 mg	(a) For treatment of Chlamydia trachomatis where alternative therapy is ineffective or inappropriate; (b) Cystic fibrosis specialists treating cystic fibrosis patients (six years and older) as prophylaxis of exacerbations of chronic Pseudomonas aeruginosa infection; (c) For the treatment of laboratory proven Bordetella pertussis infection in adults; (d) For the prophylaxis of Bordetella pertussis infection in susceptible contacts of proven cases as advised by an infectious diseases or public health physician; (e) Thoracic physicians for the treatment of Mycobacterium avium complex pulmonary infection in adults; (f) Specialist immunology staff for antimicrobial prophylaxis in patients with chronic infection-related pulmonary disease (e.g. bronchiectasis) in the setting of primary antibody deficiency (i.e. common variable immune deficiency, x-linked agammaglobulinemia and related conditions) where non-tuberculosis mycobacterial infection has been excluded. (g) For the treatment of confirmed Mycoplasma genitalium infection in patients 16 years or older, known or suspected to be macrolide susceptible, or in patients whose partner has infection which is known or suspected to be macrolide susceptible in accordance with the Australian STI Management Guidelines * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		600 mg	For use in accord with PBS Section 100 indications; Specialist Staff for prophylaxis of Mycobacterium Avium Complex in severe immune deficiency
Aztreonam	Injection	1 g	* On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
Baclofen	Intrathecal injection		

Drug	Form	Strength	Restriction
	Tablet	10 mg/5 mL	* For use in accord with PBS Section 100 indications *
		50 microgram/mL	Spinal unit patients only
		10 mg	Suppression of voluntary muscle spasm in multiple sclerosis Spinal lesions causing skeletal hypertonus Spastic and dys-synergic bladder dysfunction
		25 mg	See above
balanced salt solution concentrate (plus) 500mL	irrigation solution		Ophthalmologists
		Sodium Chloride 0.64%; Potassium Chloride 0.075%;Magnesium Chloride 0.03%; Calcium Chloride 0.048%;Sodium Acetate 0.39%;Sodium Citrate 0.17%	See above See above
Balsalazide	Capsule		For use as per the PBS indications (for ulcerative colitis)
		750 mg	See above See above
balsam of peru	ointment		
		15g	
Baricitinib	Tablet		On the advice of a specialist physician for the treatment of patients hospitalised with severe or critical COVID-19 with evidence of systemic inflammation.
		2 mg	See above
		4 mg	See above
Basiliximab	Injection		
		20 mg	Specialist Nephrologist staff as induction therapy for renal transplant recipients.
Beclometasone	Inhalation		
		50 microgram/actuation	For use as per the PBS indications.
		100 microgram/actuation	See above
	Nasal spray		
		50 microgram/actuation	
Beclometasone + formoterol + glycopyrronium	Inhalation		For use as per the PBS indications.
		100 microgram/actuation + 6 microgram/actuation + 10 microgram/actuation	See above
		200 microgram/actuation + 6 microgram/actuation + 10 microgram/actuation	See above
Bendamustine	Injection		* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		25 mg	See above
		100 mg	See above
Benralizumab	Injection		
		30 mg/mL	For discharge, outpatient and day admitted patient use in accord with PBS Section 100 indications.
Benzathine benzylpenicillin	Injection		

Drug	Form	Strength	Restriction
		1.2 million units/2.3 mL	Note: The TGA anticipates, from 30 May 2025, a further supply shortage of benzathine benzylpenicillin tetrahydrate (Bicillin L-A) 1,200,000 units injection pre-filled syringe presentation. Refer to the TGA Medicine shortage reports database for further details. [There continues to be a shortage of the non-LAM 600,000 units strength].
Benzatropine	Injection		
	Tablet	2 mg/2 mL	
		2 mg	
Benzoic acid + salicylic acid	Ointment	6% + 3%	
Benzoin Sumatra + storax prepared + Aloes cape	Tincture		
		9.78% + 4.6% + 6.22%	25mL
Benzoyl peroxide	Gel	5%	50g
Benzylamine	Mouthwash		200mL: For the treatment of mucositis associated with radiotherapy and cytotoxic chemotherapy
		0.15%	See above
Benzyl benzoate	Lotion		200mL
			See above
		25%	See above
Benzylpenicillin	Injection		
		1.2 g	
		3 g	
		600 mg	
Betamethasone acetate + betamethasone sodium phosphate	Injection		
		3 mg/mL + 3.9 mg/mL (total betamethasone 5.7 mg/mL)	
Betamethasone dipropionate	Cream		
	Lotion	0.05% 15g and 50g, 0.05% modified cream 30g	
	Ointment	0.05%	30mL
		0.05% 15g and 50g and modified ointment 30g	Betamethasone Dipropionate Ointment 15g (Eleuphrat) and 50g (Diprosone) - unrestricted Betamethasone Dipropionate Glycol Ointment 30g (Diprosone OV) - Specialist Dermatologists
Betamethasone valerate	Cream	0.02%	100g
		0.05%	15g
		0.1%	30g
	Ointment		
		0.1%	30g
betamethasone valerate and clioquinol			

Drug	Form	Strength	Restriction
Betaxolol	cream	0.03%-0.9% 50g	
	Eye drops	0.5%	
Bethanechol	Tablet	10 mg	Inpatient use only. <i>See above</i> <i>See above</i>
Bevacizumab	Injection	100 mg/4 mL 400 mg/16 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * <i>See above</i> <i>See above</i> <i>See above</i>
Bicalutamide	Tablet	50 mg	* For discharge and outpatient use as per the PBS indications *
Bicarbonate + calcium lactate pentahydrate + glucose + potassium chloride + sodium chloride	Solution	0.015% + 0.032% + 0.085% + ...	For initial supply post ENT surgery; and sinus irrigation for children with chronic rhinosinusitis which may co-exist with cystic fibrosis and asthma. Note: Pack of 12 sachets (starter kit) only
Bicarbonate + citric acid + tartaric acid	Powder for oral liquid	1.76 g + 630 mg + 720 mg + ...	
Bictegravir + emtricitabine + tenofovir alafenamide	Tablet	50 mg + 200 mg + 25 mg	* For use in accord with PBS Section 100 indications *  <i>See above</i> <i>See above</i>
Binimetinib	Tablet	15 mg	Specialist oncologists * For discharge and outpatient use as per the PBS indications *
Biperiden	Tablet	2 mg	
Bisacodyl	Enema	10 mg/5 ml	For inpatient use only <i>See above</i>
	Enteric tablet	5 mg	
	Suppository	10 mg	
	Suppository	10 mg + 100 mg	
bisacodyl-magnesium citrate (pack containing 3 x 5mg bisacodyl tablets and 1 x sachet magnesium citrate effervescent)			

Drug	Form	Strength	Restriction
(equiv to 3g magnesium oxide) "Go Kit"	*combination pack*	pack containing 3 x 5mg bisacodyl tablets and 1 x sachet magnesium citrate effervescent (equiv to 3g magnesium oxide)	
bismuth subcitrate (colloidal)	tablet	107.7mg	For radiologically or endoscopically proven ulcer <i>See above</i> <i>See above</i>
Bismuth subnitrate + iodoform	Paste	250 mg/g + 500 mg/g	
bismuth subnitrate and iodoform	dressing	1-2-1 (12.5mm x 1m)	
Bisoprolol	Tablet	2.5 mg 5 mg 10 mg	* For use as per the PBS indications * <i>See above</i> <i>See above</i>
Bivalirudin	Injection	250 mg	a) For patients undergoing non-urgent percutaneous coronary intervention; or b) For use as an alternative anticoagulant therapy for management of heparin-induced thrombocytopenia (HIT) in patients where rivaroxaban or fondaparinux is inappropriate. Note: patients must be under the care of a Consultant Physician with consideration for an additional Haematology consultation. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines ( <a href="http://www.catag.org.au">www.catag.org.au</a> ) *
Bleomycin	Injection	15 000 international units	Interventional radiologists and/or surgeons as a first-line sclerotherapy agent for the treatment of microcystic lymphatic malformations and as an alternative sclerotherapy agent for treatment of other subtypes of veno-lymphatic malformations (at the discretion of the treating clinician). or For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS or For treatment of malignant lymphoma or squamous carcinoma unresponsive to any other therapy or, when owing to severe depression of bone marrow, other therapy cannot be used * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines ( <a href="http://www.catag.org.au">www.catag.org.au</a> ) *
blood detection in faeces - hematest	tablet	50	
blood detection in faeces - coloscreen	tape	pack of 2 x 100 tests	



Drug	Form	Strength	Restriction
blood detection in urine - hemastix	diagnostic strip	test strips	
bone cement with antibiotic - gentamicin 0.5g "Palacos MV+G" "Palacos R+G"	40g	gentamicin 0.5g - Palacos MV+G ; Palacos R+G	For use in hip, and high risk knee, arthroplasty.
bone cement with antibiotic - gentamicin 0.5g "Palacos R+G Pro"	55g	gentamicin 0.5g "Palacos R+G Pro" 55g	For use in hip, and high risk knee, arthroplasty
Bone cement with antibiotic - gentamicin 0.5g "Palacos R+G Pro"	75g	gentamicin 0.5g "Palacos R+G Pro" 75g	For use in hip, and high risk knee, arthroplasty
bone cement with antibiotic - gentamicin 1g "CMW2"	40g	gentamicin 1g "CMW2"	See above See above
bone cement with antibiotic - tobramycin 1g "Antibiotic Simplex"	40g	tobramycin 1g "Antibiotic Simplex"	For use in hip, and high risk knee, arthroplasty.
boric acid 5% in 96% ethanol	ear drops	5% 15mL	
boric acid, olive oil, zinc oxide with salicylic acid	ointment	2.5% 100g	
boric acid, olive oil, zinc oxide with salicylic acid and coal tar solution	ointment	2.5%-2.5% 50g	
Bortezomib	Injection	1 mg 2.5 mg 3 mg 3.5 mg	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * See above See above See above See above
Bosentan	Tablet	62.5 mg 125 mg	* For use in accord with PBS Section 100 indications * See above See above See above
Botulinum toxin type A			

Drug	Form	Strength	Restriction
	Injection	100 units	<p>a) For use in outpatients, day admitted patients or inpatients admitted for less than 24 hours duration in accord with PBS Section 100 indications</p> <p>b) Specialist Colorectal Surgeons for the treatment of female patients with chronic anal fissure (where Crohn disease has been excluded) who have failed a two month trial of conservative therapy (including glyceryl trinitrate ointment 0.2%). Maximum of two treatment doses.</p> <p>c) Specialist ophthalmologists only for protective ptosis.</p> <p>d) Specialist paediatric surgeons and paediatric gastroenterologists for treatment in children with pain (proctalgia fugax) secondary to anal sphincter spasm or anal fissure refractory to standard treatment with laxatives.</p> <p>e) For the endoscopic management of achalasia in patients who are not candidates for surgical myotomy or endoscopic dilatation treatment.</p> <p>f) Specialist Paediatric Urology Surgical Teams for</p> <p>(i) Treatment of overactive bladder with symptoms of urinary incontinence, urgency and frequency, in paediatric patients who have an inadequate response to or are intolerant of an anticholinergic medication;</p> <p>(ii) Treatment of urinary incontinence due to neurogenic detrusor overactivity resulting from a defined neurological illness (such as spinal cord injury or multiple sclerosis) in paediatric patients who have an inadequate response to or are intolerant of an anticholinergic medication.</p> <p>* When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *</p>
Box jellyfish antivenom	Injection	20 000 units, Vial	
Brentuximab vedotin	Injection	50 mg	<p>* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *</p> <p>See above</p> <p>See above</p>
Brexpiprazole	Tablet	<p>1 mg</p> <p>2 mg</p> <p>3 mg</p> <p>4 mg</p>	<p>For use as per the PBS indications following failure of aripiprazole, risperidone, olanzapine, amisulpride or lurasidone.</p> <p>See above</p> <p>See above</p> <p>See above</p> <p>See above</p>
Brilliant green + crystal violet	Paint	0.5% + 0.5%	
Brimonidine	Eye drops	0.2%	5mL
Bromhexine	Tablet	8 mg	
Bromocriptine	Capsule	10 mg	
	Tablet	2.5 mg	
Brown snake antivenom	Injection	1000 units, Vial	

Drug	Form	Strength	Restriction
Budesonide	Inhalation solution		(a) For patients with severe chronic asthma requiring long term steroid therapy and unable to use other forms of inhaled steroid therapy; (b) For the treatment of moderate to severe croup.
		1 mg/2 mL	See above
		500 microgram/2 mL	See above
	Modified release capsule	3 mg	* For use as per the PBS indications * See above
	Orally disintegrating tablet	1 mg	For use in eosinophilic oesophagitis as per the PBS indications. See above
		500 microgram	See above
	Powder for inhalation		For use as per the PBS indications.
		100 microgram/actuation	See above
		200 microgram/actuation	See above
		400 microgram/actuation	See above
Budesonide + formoterol	Inhalation		* For use as per the PBS indications *
		50 microgram/actuation + 3 microgram/actuation	See above
		100 microgram/actuation + 3 microgram/actuation	See above
	Powder for inhalation	200 microgram/actuation + 6 microgram/actuation	See above
			See above
		100 microgram/actuation + 6 microgram/actuation	See above
		200 microgram/actuation + 6 microgram/actuation	See above
		400 microgram/actuation + 12 microgram/actuation	See above
Bumetanide	Tablet	1 mg	
Bupivacaine	Injection		
		0.125% (250 mg/200 ml), Bag	
		0.25% (50 mg/20 mL)	
		0.25% (250 mg/100 ml), Bag	
		0.5% (50 mg/10 mL)	
Intrathecal injection	0.5% (100 mg/20 mL)		
	0.5% (20 mg/4 mL)		
bupivacaine (Baxter)	infusion	(0.0625%) 125mg in 200mL	
Bupivacaine + adrenaline (epinephrine)	Injection		
		0.5% (11 mg/2.2 ml) + 1 in 200 000 (11 microgram/2.2 ml), Cartridge	Maxillofacial Surgeons
	Injection		
		0.25% (50 mg/20 mL) + 1 in 400 000 (50 microgram/20 mL)	Specialist Staff, Country Medical Superintendents and Endorsed Podiatrists
		0.5% (100 mg/20 mL) + 1 in 200 000 (100 microgram/20 mL)	See above
Bupivacaine + fentanyl	Injection		

Drug	Form	Strength	Restriction	
bupivacaine + fentanyl	epidural infusion	0.125% (25 mg/20 mL) + 100 microgram/20 mL	* CONTROLLED DRUG *	
			* CONTROLLED DRUG *	
		0.125% (250mcg/200mL) + 400mcg/200mL	See above	
		0.125% (250mcg/200mL) + 1000mcg/200mL	See above	
bupivacaine + glucose "marcaine spinal 0.5% heavy"	injection	0.5% + 8% 4mL		
Buprenorphine	Injection	300 microgram/mL	* For severe disabling pain not responsive to non-narcotic analgesicsCaution: The risk of drug dependence is high. ** CONTROLLED DRUG *	
		Patch	5 Microgram/hour	a) For use in patients with chronic severe pain requiring daily, continuous, long term therapy which is not responding to non-opioid or first line opioid analgesics or where these agents are inappropriate or not tolerated. b) For use in palliative care, for patients with chronic severe pain requiring daily, continuous, long term therapy which is not responding to non-opioid analgesics or where these agents are inappropriate or not tolerated. Caution: The risk of drug dependence is high. * CONTROLLED DRUG *
		10 Microgram/hour	See above	
		15 Microgram/hour	See above	
		20 Microgram/hour	See above	
		25 Microgram/hour	See above	
		30 Microgram/hour	See above	
		40 Microgram/hour	See above	
	Sublingual tablet	2 mg	a) For use in accord with PBS Section 100 indications; b) Patients participating in opioid detoxification (withdrawal management) in a hospital setting. * CONTROLLED DRUG *	
		8 mg	See above	
		200 microgram	Therapy to be initiated/managed by a persistent pain management service for use in patients with chronic severe pain which is not responding to non-opioid or first/second line opioid analgesics or where these agents are inappropriate or not tolerated. Caution: The risk of drug dependence is high. * CONTROLLED DRUG ** When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *	
		400 microgram	a) For use in accord with PBS Section 100 indications; b) Patients participating in opioid detoxification (withdrawal management) in a hospital setting. * CONTROLLED DRUG *	
	Buprenorphine (Buvidal Monthly)			For use in accord with PBS Section 100 indications. Caution: Buvidal Weekly, Buvidal Monthly and Sublocade are all available on the LAM but these brands are NOT interchangeable. Note: These presentations are only for administration by subcutaneous injection. * CONTROLLED DRUG *
		Modified release injection		Queensland Opioid Dependence Treatment Guidelines 2023
	64 mg/0.18 mL		See above	

Drug	Form	Strength	Restriction
Buprenorphine (Buprenorphine Weekly)	Modified release injection	96 mg/0.27 mL	See above
		128 mg/0.36 mL	See above
		160 mg/0.45 mL	See above
			For use in accord with PBS Section 100 indications. Caution: Buprenorphine Weekly, Buprenorphine Monthly and Sublocade are all available on the LAM but these brands are NOT interchangeable Note: These presentations are only for administration by subcutaneous injection. * CONTROLLED DRUG * Queensland Opioid Dependence Treatment Guidelines 2023
		8 mg/0.16 mL	See above
		16 mg/0.32 mL	See above
Buprenorphine (Sublocade)	Modified release injection	24 mg/0.48 mL	See above
		32 mg/0.64 mL	See above
			For use in accord with PBS Section 100 indications. Caution: Buprenorphine Weekly, Buprenorphine Monthly and Sublocade are all available on the LAM but these brands are NOT interchangeable Note: These presentations are only for administration by subcutaneous injection. *CONTROLLED DRUG*
			Queensland Opioid Dependence Treatment Guideline 2023
		100 mg/0.5 mL	See above
		300 mg/1.5 mL	See above
Buprenorphine + naloxone	Sublingual film		a) For use in accord with PBS Section 100 indications. b) Patients participating in opioid detoxification (withdrawal management) in a hospital setting. * CONTROLLED DRUG *
		2 mg + 500 microgram	See above
		8 mg + 2 mg	See above
Burosumab	Injection		For discharge, outpatient and day admitted patient use in accord with PBS Section 100 indications.
		10 mg/ml, Vial	See above
		20 mg/ml, Vial	See above
		30 mg/ml, Vial	See above
Busulfan	Tablet		
		2 mg	
C1 esterase inhibitor	Injection		
		500 units	For inpatient use in line with National Blood Authority funded indications (Type I or Type II hereditary angioedema).
		1500 units	See above
		2000 units	For use in line with National Blood Authority funded indications (Type I or Type II hereditary angioedema).
		3000 units	See above
Cabazitaxel	Injection		* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
			See above
		60 mg/1.5 mL	See above

Cabergoline

Drug	Form	Strength	Restriction
	Tablet	1 mg 2 mg 500 microgram	For the treatment of Parkinson Disease <i>See above</i> Specialist endocrinologists for treatment of prolactinomas or hyperprolactinaemia as per the PBS indications where the patient is intolerant of bromocriptine despite maximum tolerated therapy; For lactation suppression as per the PBS indications
Cabotegravir	Tablet	30 mg	* For use in accord with PBS Section 100 indications * <i>See above</i>
Cabotegravir (&) Rilpivirine	modified release injection + rilpivirine modified release injection	600 mg/3 mL + 900 mg/3 mL	* For use in accord with PBS Section 100 indications *
Caffeine	Injection	40 mg/2 mL	Specialist Paediatric Staff for use in premature babies born under 36 weeks gestation who have apnoea of prematurity when enteral caffeine is inappropriate <i>See above</i>
caffeine citrate	oral liquid solution	20mg per mL, 50mL	Specialist Paediatric Staff for use in premature babies born under 36 weeks gestation who have apnoea of prematurity
calamine lotion (B.P.)	lotion	calamine lotion (B.P)	200mL
calamine with coal tar solution	lotion	calamine with coal tar solution 3%	
calamine with zinc oxide and almond oil	cream	calamine with zinc oxide and almond oil	100g <i>See above</i> <i>See above</i>
Calcipotriol	Cream	0.005%	Specialist Dermatologists for use as per the PBS indications <i>See above</i> <i>See above</i>
Calcipotriol + betamethasone dipropionate	Foam	0.005% + 0.05%	Specialist Dermatologists for outpatients for the treatment of chronic stable plaque type psoriasis vulgaris of the scalp as per the PBS indications. <i>See above</i>
	Ointment	0.005% + 0.05%	30g: Specialist Dermatologists for the treatment of chronic stable plaque type psoriasis vulgaris as per the PBS indications. <i>See above</i>
Calcitonin salmon	Injection	100 units/mL	
Calcitriol	Capsule	0.25 microgram	
calcitriol	oral solution (SAS)		For use in patients unable to swallow capsules.

Drug	Form	Strength	Restriction
			* For use in accord with Special Access Scheme (SAS) arrangements ** Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
Calcium	effervescent tablet	1 microgram/mL, 15mL	See above
		(1000 mg elemental calcium)	For treatment of hypocalcaemia where LAM listed solid dose forms are not appropriate. See above
Calcium carbonate	Tablet	1.25 g (calcium 500 mg) 1.5 g (calcium 600 mg)	
Calcium carbonate oral suspension (Auspman) 100mg/mL, 200mL	oral liquid suspension	200mL	For treatment of hypocalcaemia in children too young to swallow tablets or capsules.
Calcium chloride	Injection	1 g/10 mL (contains 0.68 mmol/mL of calcium), vial	
	injection (Baxter)	10%, 5g/50mL (contains 0.68mmol/mL of calcium), 50mL syringe	Specialist Intensive Care and Renal Staff for use in specialist areas that undertake continuous renal replacement therapy with citrate regional dialysis, requiring systemic calcium replacement.
Calcium gluconate monohydrate	Injection	931 mg/10 mL (Calcium 2.2mmol/10mL)	
Calcium polystyrene sulfonate	Powder	999.3 mg/g	For use when polystyrene sulfonate sodium is inappropriate. See above
			See above
camphor compound linctus A.P.F. with or without syrup	oral liquid		100mL
		Camphor compound linctus A.P.F.	See above See above
Capecitabine	Tablet	150 mg	Note: As of 1/5/2024 capecitabine tablet 150mg is non-PBS. Consider reserving for when the dosage regimen is unable to be achieved with the 500mg tablets alone.
		500 mg	
Capreomycin	Injection	1 g	
Capsaicin	Cream		45g: For use in treatment of neuralgic pain
		0.075%	See above See above
Captopril	Oral liquid	5 mg/ml	For patients unable to take a solid dose form of an ACE inhibitor
			See above
	Tablet	25 mg	
Carbachol	Eye drops		15mL
		3%	See above
	Intraocular injection		Specialist Ophthalmologists

Drug	Form	Strength	Restriction
carbachol 1.5% 15mL	eye drops	0.01% (150 microgram/1.5 mL)	See above
		1.5% 15mL	
Carbamazepine	Modified release tablet	200 mg	
		400 mg	
	Oral liquid	100 mg/5 ml	
	Tablet	100 mg 200 mg	
Carbimazole	Tablet	5 mg	
Carbomer-980	Eye gel		10g: Specialist Ophthalmologists
		0.2%	See above
Carboplatin	Injection		
		50 mg/5 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		150 mg/15 mL	See above
		450 mg/45 mL	See above
carboprost (15-methyl prostaglandin F2α)	injection		Specialist Obstetricians and Gynaecologists and Rural Generalists/General Practitioners granted current scope of clinical practice in obstetrics and gynaecology, for second line management of severe life-threatening primary postpartum haemorrhage within the guidance of the Queensland Maternity and Neonatal Clinical Guideline "Primary Postpartum Haemorrhage".
			* Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
		250microgram/mL	See above
Carfilzomib	Injection		* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		10 mg	See above
		30 mg	See above
		60 mg	See above
Carmellose sodium (Cellufresh)	Eye drops		
		0.5%	0.4mL: Specialist ophthalmologists
Carmellose sodium (Celluvisc)	Eye drops		
		1%	0.4mL: Specialist Ophthalmologists
Carmustine	Injection		
		100 mg	
Carvedilol	Tablet		* For use as per the PBS indications *
		3.125 mg	See above



Drug	Form	Strength	Restriction
carvedilol	oral liquid suspension	6.25 mg	See above
		12.5 mg	See above
		25 mg	See above
		carvedilol 1.67mg per mL	90mL: Paediatric cardiac specialists See above See above
Caspofungin	Injection	50 mg 70 mg	For use in adults and paediatrics on the advice of an infectious diseases physician or a clinical microbiologist for treatment of severe systemic candida infections that are resistant to fluconazole therapy, or where fluconazole is strongly contraindicated; or in accord with an infectious diseases approved protocol. See above See above See above
castor oil	oil	castor oil	200mL See above See above
castor oil and zinc oxide	ointment	castor oil and zinc oxide	100g See above See above
Cefaclor	Powder for oral liquid	125 mg/5 ml	100mL: For treatment of respiratory tract infections in patients unable to swallow cefuroxime tablets and who are hypersensitive to penicillin (excluding immediate hypersensitivity) See above
Cefalexin	Capsule	250 mg 500 mg	Children too young to swallow tablets or capsules See above
	Powder for oral liquid	250 mg/5 ml	
Cefalotin	Injection	1 g	On the advice of an infectious diseases physician or microbiologist in situations where it may be preferred to cefazolin. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained * See above See above
Cefazolin	Injection	1 g	Ophthalmologists. See above
Cefazolin (with preservative) (QH-CP)	eye drops	5%, 10mL	
Cefepime	Injection	1 g	(a) On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol (b) For patients under the care of Specialist Renal Physicians for empiric treatment of paediatric peritoneal dialysis peritonitis according to the statewide paediatric clinical pathway. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label

Drug	Form	Strength	Restriction
Cefotaxime	Injection	2 g	medicines (www.catag.org.au) *
			On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol.
		1 g	* On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
		2 g	See above
Cefoxitin	Injection	1 g	See above
		2 g	See above
			See above
Ceftazidime	Injection	1 g	For treatment of
			(a) infections caused by non-tuberculous mycobacteria;
			(b) biliary reconstructive surgery in children;
			(c) on the advice of an infectious diseases physician or a clinical microbiologist
Ceftriaxone	Injection	1 g	See above
			See above
			* On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
			See above
Cefuroxime	Tablet	1 g	See above
		2 g	See above
			See above
			See above
Celecoxib	Capsule	250 mg	For treatment of respiratory tract infections in patients hypersensitive to penicillin (excluding immediate hypersensitivity)
			See above
		200 mg	See above
Cemiplimab	Injection		a) For use as a single peri-operative dose for the management of post-operative pain
			b) Short term treatment of acute pain in patients undergoing or who have undergone a surgical procedure
cerliponase alpha	injection solution	350 mg/7 ml, Vial	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
			See above
Cetirizine	Oral liquid	150mg/5mL	For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program
	Tablet	5 mg/5 ml	For use in children where a solid oral dosage form is unsuitable.
		10 mg	
cetomacrogol	cream		
		100g	
cetomacrogol cream with clioquinol	cream	500g	

Drug	Form	Strength	Restriction
cetomacrogol with crude coal tar	cream	1% 100g	
		cetomacrogol cream with crude coal tar 1% 100g	
cetomacrogol with salicylic acid	cream	3% 100g	
		12% 50g	
cetomacrogol with salicylic acid and coal tar solution	cream	3%-3% 100g	
		3%-6% 100g	
Cetuximab	Injection	100 mg/20 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		500 mg/100 mL	See above
Cetylpyridinium + benzocaine	Mouthwash	0.05% + 0.4%	200mL
Chloral hydrate	Oral liquid	1 g/10 ml	200mL
Chlorambucil	Tablet	2 mg	
Chloramphenicol	Ear drops	0.5%	5mL
	Eye drops	0.5% 0.5mL x 20	Inpatient use only
	Eye ointment	0.5% 10mL	
		1%	4g: For ophthalmic use only
chlorhexidine	cream	1% 50g	
	digluconate alcohol free mouthwash	0.2% 200mL	(a) Mucositis in oncology patients and in paediatric intensive therapy units; (b) As an antibacterial mouthwash following maxillo-facial surgery; (c) As an in-clinic antibacterial rinse when undergoing dental treatment for correctional centre patients, paediatric patients or those with a religious objection to ethanol.
	gluconate mouthwash	0.2% 200mL	
	hand and body wash/skin cleanser	2% 125mL	
		2% 500mL	
	lotion	1% 200mL obstetric	
	pre op-wash	4% 50 mL	

Drug	Form	Strength	Restriction
chlorhexidine in alcohol	surgical hand scrub/surgical hand wash	4% 1.5L	Restricted to specially approved areas
		4% 125mL	See above
		4% 500mL	See above
chlorhexidine sterile aqueous	handrub	chlorhexidine 0.5% alcohol 70% -125mL, 500mL	
		chlorhexidine 2% alcohol 70% - 30mL, 100mL, 500mL	
		chlorhexidine 0.5% alcohol 70% - 100mL, 500mL	
		chlorhexidine 2% alcohol 70% - 30mL, 100mL	
Chlorhexidine + cetrimide	solution	0.02% 100mL	Can be used for bladder irrigation
		0.02% - 500 mL, 1 Litre	
		0.1% - 30 mL, 100 mL, 1 Litre	
Chloroquine	Solution	0.015% (150 mg/L) + 0.15% (1.5 g/L) - 30mL, 500mL, 1Litre	
chlorpromazine	Tablet	250 mg	200mL
			See above
		20mg per mL	See above
Chlorpromazine	Injection	50 mg/2 mL	
		Oral liquid	100mL, 500mL
		5 mg/ml	To view LAM status of QH Central Pharmacy manufactured STRONG syrup: Refer to separate listing for chlorpromazine - oral liquid strong - 20mg per mL, 200mL
		Tablet	
Chlortalidone	Tablet	10 mg	
		25 mg	
		100 mg	
Cholera vaccine	Tablet	25 mg	
Ciclosporin	Oral liquid	3 mL Vial	
	Capsule	10 mg	
		25 mg	
		50 mg	
		100 mg	
	Eye drops	0.1%, 0.3mL unit dose	On the advice of an ophthalmologist for discharge and outpatient use as per the PBS indications.
	Injection		

Drug	Form	Strength	Restriction
	Oral liquid	50 mg/mL	* For use in accord with PBS Section 100 indications * Acute severe ulcerative colitis with inadequate or no response to intravenous hydrocortisone by day 4 of treatment. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guideline principles for the quality use of off-label medicines (www.catag.org.au) *
		250 mg/5 mL	Acute severe ulcerative colitis with inadequate or no response to intravenous hydrocortisone by day 4 of treatment. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		100 mg/ml	For use where a dose is unable to be given via a capsule. Note: Monitor patient on transition between different brands and dose forms.
Cidofovir	Injection	375 mg/5 mL	Ear, nose and throat surgeons and respiratory physicians for the treatment of recurrent respiratory papillomatosis on the approval of an infectious diseases physician or antimicrobial stewardship team. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
Cinacalcet	Tablet	30 mg 60 mg 90 mg	For use in accord with PBS General Schedule/Section 100 indications <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i>
Cinchocaine + zinc oxide	Ointment	0.5% + 20%	50g <i>See above</i> <i>See above</i>
Ciprofloxacin	Ear drops		(a) For use in paediatric patients under the care of an ENT specialist as per the PBS indications (b) For use as per the Qld Govt/RFDS Primary Clinical Care Manual in Aboriginal and Torres Strait Islander persons only.
		0.3%	<i>See above</i>
	Injection		* On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
		200 mg/100 mL	<i>See above</i>
	Tablet		<i>See above</i>
		250 mg	<i>See above</i>
		500 mg	<i>See above</i>
		750 mg	<i>See above</i>
Ciprofloxacin + hydrocortisone			For treatment of infection and inflammation of the ear by the Deadly Ears ENT outreach service (Acute Otitis Externa, Otitis Media with granulation tissue or myringitis present) where the tympanic membrane is perforated and/or a tympanostomy tube is present and framycetin sulfate + gramicidin + dexamethasone - ear drops - 0.5% + 0.005% + 0.05% (Sofradex®/ Otodex®), and flumetasone pivalate + clioquinol - ear drops - 0.02% + 1% (Locacorten-Vioform®) are not suitable.

Drug	Form	Strength	Restriction
			* When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
	Ear drops	0.2% + 1%	See above See above
Cisatracurium	Injection	5 mg/2.5 mL 10 mg/5 mL 150 mg/30 mL	Medical staff skilled in airway support See above See above See above
Cisplatin	Injection	50 mg/50 mL 100 mg/100 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * See above See above
Citalopram	Tablet	10 mg 20 mg 40 mg	For major depressive disorders See above See above See above See above
Citric acid	Oral liquid	2.64 g/30 ml	For patients at risk of aspiration requiring emergency procedures
Citric acid + lauryl sulfoacetate sodium + sorbitol	Enema	450 mg/5 ml + 45 mg/5 ml + 3.125 g/5 ml	
citric acid powder 1kg	powder	citric acid 1kg	Haemodialysis Unit cleaning solution
Cladribine	Injection	10 mg/5 mL 10 mg/10 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * See above See above
Clarithromycin	Tablet	250 mg	Haemophilus infections where alternatives such as tetracycline or erythromycin are inappropriate or not tolerated; Thoracic physicians for the treatment of Mycobacterium avium complex pulmonary infection in adults.
Clindamycin	Capsule	150 mg	Specialist Staff and Endorsed Podiatrists * On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
	Cream	2%	For gynaecological conditions
	Injection	600 mg/4 mL	* On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *

Drug	Form	Strength	Restriction
Clobazam	Tablet	10 mg	Specialist Neurologists for the treatment of refractory Lennox-Gastaut epilepsy. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) * <i>See above</i> <i>See above</i>
	Capsule	50 mg	Only available for the World Health Organisation (WHO) program for leprosy <i>See above</i> <i>See above</i>
Clomifene	Tablet	50 mg	Persons approved by Director General of Health and Medical Services <i>See above</i> <i>See above</i>
	Tablet	25 mg	Cataplexy associated with narcolepsy; obsessive-compulsive disorder; phobic disorders in adults. <i>See above</i> <i>See above</i>
Clonazepam	Injection	1 mg/mL	a) Children too young to swallow tablets; b) The prevention of epilepsy; c) The treatment of anxiety, seizures, hiccups and neuropathic pain in patients unable to swallow tablets. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
	Oral liquid	2.5 mg/ml (0.1 mg/drop)	
	Tablet	2 mg 500 microgram	
	Tablet	150 microgram/mL	
Clonidine	Tablet	100 microgram 150 microgram	
	Tablet	75 mg	
Clopidogrel	Tablet	75 mg	
clopidogrel	(QH-CP) oral liquid suspension	5 mg/mL	For use when tablets are not suitable such as for administration via enteral tubes, or for doses unable to be measured by using a whole, half or quarter tablet. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
Clostridium botulinum type A toxin-haemagglutinin complex	Injection	300 units	For use in outpatients, day admitted patients or inpatients admitted for less than 24 hours duration in accord with PBS Section 100 indications. <i>See above</i>
		500 units	<i>See above</i>

Drug	Form	Strength	Restriction
Clotrimazole	Cream		
	Lotion	1%	20mL Caution - recurrent or persistent symptoms of vulvovaginal candidiasis require microbiological assessment.
	Pessary	100 mg	Caution - recurrent or persistent symptoms of vulvovaginal candidiasis require microbiological assessment.
	Vaginal cream	1%	35g Caution - recurrent or persistent symptoms of vulvovaginal candidiasis require microbiological assessment.
Clozapine	Tablet	25 mg 100 mg	* For use in accord with PBS Section 100 indications * <i>See above</i> <i>See above</i> <i>See above</i>
coal tar (B.P.) solution	solution	200mL	
coal tar solution and salicylic acid	ointment	6%-2% 100g	
cocaine	mouthwash	cocaine hydrochloride 2%	100mL * CONTROLLED DRUG *
	powder	cocaine hydrochloride powder 100mg	* CONTROLLED DRUG *
Cocaine	Eye drops	5%	2mL * CONTROLLED DRUG *
cocaine + atropine + phenylephrine	eye drops	cocaine 4% + atropine 4% + phenylephrine 10%	2mL * CONTROLLED DRUG * <i>See above</i> <i>See above</i>
Codeine	Tablet	30 mg	For gastrointestinal hypermotility disorders. Not to be used for pain control. In view of safety concerns, codeine is not recommended for use in children under 12 years of age or in breastfeeding women. Caution: The risk of drug dependence is high. * CONTROLLED DRUG * <i>See above</i> <i>See above</i>
Colchicine	Tablet	500 microgram	
Colecalciferol	Oral liquid	5 microgram/0.04 ml 25 microgram/0.2 ml	15mL: For neonates on discharge 50mL



Drug	Form	Strength	Restriction
colecalfiferol	Tablet	25 microgram (1000 units)	
	capsule	1.25mg (50,000 units)	For single high dose therapy in: a) Cystic Fibrosis patients, or b) paediatric patients where daily supplemental therapy has failed or is inappropriate.
colecalfiferol (SAS)			For use in paediatric patients where daily supplemental therapy and oral single high dose therapy with colecalfiferol has failed or is inappropriate. * For use in accord with Special Access Scheme (SAS) arrangements ** Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
	injection	2.5mg/mL (100,000 International Units/mL)	See above See above
Colestyramine	Powder for oral liquid	4 g	
Colistin	Injection	150 mg (4.5 million units)	* On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
	powder for inhalation "Tadim"	1 million units	On the advice of an Infectious Diseases Physician or a Clinical Microbiologist or in accordance with an Infectious Diseases/Clinical Microbiology approved written protocol, as second-line treatment to nebulised tobramycin for treatment of pulmonary infection with Pseudomonas aeruginosa in patients with cystic fibrosis. Cases where colistimethate therapy would be appropriate include demonstrated resistance by pseudomonas to tobramycin, adverse reactions due to tobramycin or where aminoglycoside therapy is otherwise contraindicated.
Colonoscopy preparation - macrogol-3350 + sodium chloride + potassium chloride + sodium sulfate	Powder for oral liquid	52.9 g + 2.6 g + 740 mg (potassium 9.9 mmol) + ...	
colonoscopy preparation kit - containing 3 x 70 g sachets macrogol 3350 powder concentrate and 3 bisacodyl 5mg tablets and 1 sachet magnesium citrate "Glycoprep-O Kit"	*combination pack*	containing 3 x 70 g sachets macrogol 3350 powder concentrate and 3 bisacodyl 5mg tablets and 1 sachet magnesium citrate "Glycoprep-O Kit"	
colonoscopy preparation kit - powder for oral liquid: dose 1 – macrogol 100g; dose 2 sachet A – macrogol 40g; dose 2 sachet B – sodium ascorbate 48.1g + ascorbic acid 7.5g) "Plenvu"	*combination pack*	colonoscopy preparation kit - powder for oral liquid: dose 1 – macrogol 100g; dose 2 sachet A – macrogol	For bowel preparation in patients who have undergone bariatric surgery. See above

Drug	Form	Strength	Restriction
colonoscopy preparation kit containing 3 x 70 g sachets macrogol 3350 powder concentrate and 2 x 20 g sachets each with sodium picosulfate 10.3 mg and magnesium "Prepkit Orange"	*combination pack*	40g; dose 2 sachet B – sodium ascorbate 48.1g + ascorbic acid 7.5g) "Plenvu"	
		containing 3 x 70 g sachets macrogol 3350 powder concentrate and 2 x 20 g sachets each with sodium picosulfate 10.3 mg and magnesium	
Conjugated estrogens	Tablet	300 microgram 625 microgram	
copper sulfate	crystals (large)	25g	
cornea preserving solution	solution	cornea preserving solution 20mL	For corneal transplantation only <i>See above</i> <i>See above</i>
Cortisone	Tablet	5 mg 25 mg	
Crizotinib	Capsule	200 mg 250 mg	Specialist medical oncology staff * For discharge and outpatient use as per the PBS indications * <i>See above</i> <i>See above</i> <i>See above</i>
Cromoglycate	Eye drops	2%	
	Inhalation	5 mg/actuation	
crude coal tar in soft paraffin	ointment	1% 100g 2.5% 100g 5% 50g	
Cyclizine	Injection	50 mg/mL	Paediatric specialist staff for use in children as second line therapy in prevention and treatment of postoperative nausea and vomiting, and third line therapy in chemotherapy-induced emesis. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) * <i>See above</i>
	Tablet	50 mg	<i>See above</i> <i>See above</i> <i>See above</i>
Cyclopentolate	Eye drops		

Drug	Form	Strength	Restriction
cyclopentolate with phenylephrine	eye drops	0.5%	Specialist Ophthalmology staff for use in paediatric inpatients and outpatients undergoing treatment in eye clinic.
		1%	0.5mL: For inpatient use only
			Specialist Ophthalmologists
			See above
			See above
Cyclophosphamide	Injection	0.2%-1%, 5mL (QH-CP)	See above
		1%-2.5%, 5mL (QH-CP)	See above
	Tablet	1 g	(a) * For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
			(b) For the treatment of severe organ- or life-threatening autoimmune diseases and immunopathies.
		2 g	See above
		500 mg	See above
Cycloserine	Capsule	50 mg	
		250 mg	For treatment after approval by the Medical Advisor Tuberculosis and Infectious Diseases, Communicable Diseases Branch or delegate OR Director Regional Tuberculosis Control Unit. The Medical Advisor Tuberculosis and Infectious Diseases should be contacted for any multi-drug or extremely drug resistant cases and can be contacted during business hours via (07) 3328 9724 or email at: cdmu@health.qld.gov.au
			Contact information for Regional TB Control Units is available here.
Cyproheptadine	Tablet		* Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
Cyproterone	Tablet	4 mg	For treatment of idiopathic precocious puberty or inoperable carcinoma of the prostate
			See above
		50 mg	See above
		100 mg	See above
Cytarabine	Injection		
		100 mg/5 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
Dabigatran	Capsule		* For use as per the PBS indications *
			See above
		75 mg	See above
		110 mg	See above
		150 mg	See above
Dabrafenib	Capsule		Specialist Oncologists for discharge and outpatient use as per the PBS indications.
		50 mg	See above
		75 mg	See above
	Dispersible tablet		See above
		10 mg	See above
Dacarbazine	Injection		

Drug	Form	Strength	Restriction
Dactinomycin	Injection	200 mg	
d-alpha-tocopherol (vitamin E)	Capsule	500 microgram 67 mg (100 units) 335 mg (500 units)	For malabsorption syndrome For use in combination with pentoxifylline modified release tablet 400mg, on the advice of Maxillofacial surgery team (MaxFacs) and Ear Nose and Throat (ENT) team for use in combination with surgical intervention for the treatment of osteonecrosis of the jaw for up to six months.
d-alpha-tocopheryl acetate	Oral liquid	115 mg/ml	
Danaparoid sodium	Injection	750 anti-Xa units/0.6 mL	a) For use as VTE prophylaxis in patients with a history of heparin-induced thrombocytopenia (HIT) where rivaroxaban or fondaparinux is inappropriate; or b) For use as an alternative anticoagulant therapy for management of HIT in patients where rivaroxaban or fondaparinux is inappropriate. Note: patients must be under the care of a Consultant Physician with consideration for an additional Haematology consultation; or c) Anticoagulation for intermittent haemodialysis in patients with a history of HIT * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) * <i>See above</i> <i>See above</i>
Danazol	Capsule	100 mg 200 mg	Treatment of visually proven (ie by laparoscopy) endometriosis if surgery has been unsuccessful or contraindicated and the required endpoint of treatment is fertility; and For primary intractable menorrhagia <i>See above</i> <i>See above</i> <i>See above</i>
Dantrolene	Capsule Injection	25 mg 50 mg 20 mg	Specialist Anaesthetists
Dapagliflozin	Tablet	10 mg	* For use as per the PBS indications *
Dapsone	Tablet	25 mg 100 mg	
Daratumumab	Injection	1.8 g/15 mL (subcutaneous)  100 mg/5 mL 400 mg/20 mL	a) For discharge and outpatient use as per PBS indications; b) For use as per PBS indications for Related Pharmaceutical Benefits used in conjunction with Efficient Funding of Chemotherapy - Section 100 arrangements. * For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * <i>See above</i>
Darbepoetin alfa			

Drug	Form	Strength	Restriction
	Injection	10 microgram/0.4 mL pre-filled syringe	* For use in accord with PBS Section 100 indications *
		20 microgram/0.5 mL pre-filled syringe and pen	See above
		30 microgram/0.3 mL pre-filled syringe	See above
		40 microgram/0.4 mL pre-filled syringe and pen	See above
		50 microgram/0.5 mL pre-filled syringe	See above
		60 microgram/0.3 mL pre-filled syringe and pen	See above
		80 microgram/0.4 mL pre-filled syringe and pen	See above
		100 microgram/0.5 mL pre-filled syringe and pen	See above
		150 microgram/0.3 mL pre-filled syringe and pen	See above
Darolutamide	Tablet		* For discharge and outpatient use as per the PBS indications *
		300 mg	See above
Darunavir	Tablet		* For use in accord with PBS Section 100 indications *
		600 mg	See above
		800 mg	See above
Darunavir + cobicistat	Tablet		* For use in accord with PBS Section 100 indications *
			See above
		800 mg + 150 mg	See above
Darunavir + cobicistat + emtricitabine + tenofovir alafenamide	Tablet		* For use in accord with PBS Section 100 indications *
			See above
		800 mg + 150 mg + 200 mg + ...	See above
Dasatinib	Tablet		* For use as per the PBS indications *
		20 mg	See above
		50 mg	See above
		70 mg	See above
		100 mg	See above
Daunorubicin	Injection		
		20 mg/10 mL	
Daunorubicin + cytarabine	Injection		* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		44 mg + 100 mg, Vial	See above
Death adder antivenom	Injection		
		6000 units, Vial	
Decitabine + cedazuridine	Tablet		
		35 mg + 100 mg	* For discharge and outpatient use as per the PBS indications *
Deferasirox	Dispersible tablet		* For use in accord with PBS Section 100 indications *
		125 mg	See above
		250 mg	See above
		500 mg	See above

Drug	Form	Strength	Restriction
Deferiprone	Tablet	90 mg	See above
		180 mg	See above
		360 mg	See above
			See above
	Oral liquid	100 mg/ml	* For use in accord with PBS Section 100 indications *
Degarelix	Tablet	1 g	See above
		500 mg	See above
			See above
			See above
	Injection	80 mg	For the treatment of outpatients only with advanced carcinoma of the prostate in whom androgen deprivation is warranted and who comply with the PBS authority indications.
Denosumab	Injection	120 mg	See above
			See above
			See above
			See above
	Injection	60 mg/mL	* For discharge and outpatient use as per the PBS indications *
Depilatory	cream	120 mg/1.7 mL	See above
			See above
			See above
			See above
		(e.g. Veet) 100mL	Emergency or surgical staff to release hair tourniquet in paediatric patients.
Desferrioxamine	Injection		See above
		2 g	See above
		500 mg	See above
			See above
	Injection	4 microgram/mL	* For use in accord with PBS Section 100 indications *
Desmopressin	Injection	15 microgram/mL	See above
			See above
			See above
			See above
	Nasal drops	100 microgram/ml	For use for haemostasis by specialist haematologists or on the advice of a specialist haematologist.
	Sublingual wafer	120 microgram	* When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
Dexamethasone	Tablet	200 microgram	For treatment of cranial diabetes insipidus as per the PBS indications
			For primary nocturnal enuresis as per the PBS indications. Clinicians should bear in mind the increased bioavailability of this wafer presentation compared to the tablet.
			For cranial diabetes insipidus and primary nocturnal enuresis as per the PBS indications
	Eye drops	0.1%	
	Implanted drug delivery system	700 Microgram	Specialist Ophthalmologists for discharge and outpatient use as per the PBS indications.
	Tablet		See above
		4 mg	For special circumstances when prednisolone is not suitable
		500 microgram	See above
			See above
			See above

Drug	Form	Strength	Restriction
Dexamethasone phosphate	Injection	4 mg/mL 8 mg/2 mL	
dexamethasone phosphate	oral liquid solution	1mg per mL 50mL	For use in accordance with croup protocol <i>See above</i> <i>See above</i>
Dexamfetamine	Tablet	5 mg	Schedule 8 substance restricted to treatment of narcolepsy and attention deficit hyperactivity disorder in children * CONTROLLED DRUG * <i>See above</i> <i>See above</i>
Dexchlorpheniramine	Tablet	2 mg	
Dexmedetomidine	Injection	200 microgram/2 mL  200 microgram/50 mL 400 microgram/100 mL	a) Intensive care specialists and anaesthetists for use not exceeding 24 hours; b) Paediatric intensive care specialists for managing sedation of critically ill neonatal and paediatric patients. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) * Intensive care specialists and anaesthetists for use not exceeding 24 hours. <i>See above</i>
dexrazoxane (SAS)	injection	500mg	a) Specialist paediatric oncology staff for use in patients prior to anthracycline treatment. b) Treatment of anthracycline extravasation under the direction of a paediatric oncologist. * For use in accord with Special Access Scheme (SAS) arrangements ** Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
Dextran-1	Injection	3 g/20 mL	
Dextran-70 + hypromellose	Eye drops	0.1% + 0.3% with polyquaternium 0.1% + 0.3% + 0.001%	Specialist Ophthalmologists for patients unable to tolerate alternative preparations
dextranomer in hyaluronic acid	pre-filled syringe	50mg in 1mL	Specialist paediatric surgeons, or in consultation with a specialist paediatric surgeon, for treatment of children with vesicoureteral reflux (VUR) grades II-IV. <i>See above</i> <i>See above</i>
Diazepam	Injection	10 mg/2 mL	
	Oral liquid	10 mg/10 ml	Patients unable to swallow tablets
	Tablet	2 mg 5 mg	
Diazoxide			

Drug	Form	Strength	Restriction
	capsule	25mg (SAS)	a) On the advice of an endocrinologist for the management of hypoglycaemia due to hyperinsulinism; b) For neonatal hypoglycaemia according to the Queensland Clinical Guideline: Hypoglycaemia-Newborn (health.qld.gov.au). * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
		100mg (SAS)	a) On the advice of an endocrinologist for the management of hypoglycaemia due to hyperinsulinism; b) For neonatal hypoglycaemia according to the Queensland Clinical Guideline: Hypoglycaemia-Newborn * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
	Injection	300 mg/20 mL	
	oral liquid suspension	10mg/mL (QH-CP)	a) On the advice of an endocrinologist for the management of hypoglycaemia due to hyperinsulinism; b) For neonatal hypoglycaemia according to the Queensland Clinical Guideline: Hypoglycaemia-Newborn * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
Diclofenac	Eye drops	0.1%	Specialist Ophthalmologists
	Suppository	12.5 mg 25 mg 50 mg 100 mg	For use in children over 12 months of age. <i>See above</i> <i>See above</i>
Dicloxacillin	Capsule	250 mg 500 mg	For treatment of Staphylococcal infections <i>See above</i> <i>See above</i>
Dicobalt edetate	Injection	300 mg/20 mL	Cyanide poisoning <i>See above</i> <i>See above</i>
Difelikefalin	Injection	50 microgram/ml, Vial	* For use in accord with PBS Section 100 indications *
Digoxin	Injection	50 microgram/2 mL 500 microgram/2 mL	Note: The time to effect for intravenous digoxin is not significantly faster than the oral route. Use oral digoxin where suitable.
	Oral liquid	50 microgram/ml	Children too young to swallow tablets or capsules
	Tablet	62.5 microgram 250 microgram	
Digoxin-specific antibody fragment F(Ab)			



Drug	Form	Strength	Restriction
Diltiazem	Injection	40 mg	For the treatment of cardiac glycoside intoxication resulting in life-threatening cardiac arrhythmias; cardiac arrest; cardiac decompensation with hypotension; serum potassium >5.5mmol/L with cardiovascular instability or compromise. In the absence of these recognised indications of cardiac glycoside toxicity, digoxin immune Fab is not indicated based solely on a serum digoxin concentration. <i>See above</i>
	Modified release capsule	180 mg 240 mg 360 mg	
	Tablet	60 mg	For angina where treatment with verapamil or nifedipine has failed <i>See above</i>
dimercaprol	injection	10% 2mL	
dimethylether "Medi Freeze Tick Off"	spray	38mL	
dimeticone (Hedrin)	gel, 100mL	dimeticone 4%	
Dinoprost	Injection	5 mg/mL	Specialist Obstetricians and Gynaecologists and Rural Generalists/General Practitioners granted current scope of clinical practice in obstetrics and gynaecology, for second line management of severe life-threatening primary postpartum haemorrhage within the guidance of the Queensland Maternity and Neonatal Clinical Guideline "Primary Postpartum Haemorrhage". Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained.
Dinoprostone			Specialist Obstetricians and Rural Generalists/General Practitioners granted current scope of clinical practice in obstetrics and gynaecology for patients with unripe cervix (Bishop score 4 or less).
	Pessary	10 mg	<i>See above</i>
	Vaginal gel	1 mg/3 g 2 mg/3 g	<i>See above</i> <i>See above</i>
Diphenoxylate + atropine sulfate	Tablet	2.5 mg + 25 microgram	
diphtheria + tetanus + pertussis + poliomyelitis vaccine "Boostrix-IPV"	injection	0.5 mL	For haematopoietic stem cell transplant recipients aged >10 years who are not eligible for National Immunisation Program (NIP) funded vaccines.  <i>See above</i> <i>See above</i>
diphtheria + tetanus + pertussis acellular vaccine "Boostrix"	injection	0.5 mL	(a) For use in accord with QH policy for staff immunisation. (b) For patients ≥10 years of age who require tetanus prophylaxis and are not eligible for National

Drug	Form	Strength	Restriction
			Immunisation Program (NIP) funded vaccines. For children and adolescents, refer to Children's Health Queensland "Tetanus Prophylaxis in Wound Management" guideline Note: National Immunisation Program (NIP) funded vaccines should be used for all eligible patients. If using NIP vaccines ensure adherence to eligibility criteria and any documentation requirements.
Diphtheria + tetanus vaccine	Injection	0.5 mL	For patients >10 years who are not eligible for National Immunisation Program (NIP) funded vaccines and pertussis immunisation is not indicated. <i>See above</i> <i>See above</i>
diphtheria antitoxin	injection	10,000 units	* For use in accord with Special Access Scheme (SAS) arrangements *
Dipyridamole	Injection	10 mg/2 mL	For use with nuclear medicine thallium scans <i>See above</i>
Dipyridamole + aspirin	Modified release capsule	200 mg + 25 mg	For the secondary prevention of ischaemic stroke or transient cerebral ischaemic events <i>See above</i> <i>See above</i>
disodium edetate	eye drops	3% 10mL	
disopyramide	injection	50mg in 5mL	
Disopyramide	Capsule	100 mg 150 mg	
Disulfiram	Effervescent tablet	200 mg	
dithranol and salicylic acid in soft paraffin	ointment	1%-2% 100g 2%-2% 100g	
dithranol in soft paraffin	ointment	0.1% 100g	
Dobutamine	Injection	250 mg	Intensive Care and Coronary Care Units only <i>See above</i> <i>See above</i>
Docetaxel	Injection	20 mg/2 mL 80 mg/4 mL 80 mg/8 mL 160 mg/8 mL 160 mg/16 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i>
Docusate	Tablet	50 mg	

Drug	Form	Strength	Restriction
Docusate + sennoside B		120 mg	
	Tablet		
Dolutegravir		50 mg + 8 mg	* For use in accord with PBS Section 100 indications *
	Tablet		See above
Dolutegravir + abacavir + lamivudine		50 mg	See above
	Tablet		* For use in accord with PBS Section 100 indications *
Dolutegravir + lamivudine		50 mg + 600 mg + 300 mg	See above
	Tablet		See above
Dolutegravir + rilpivirine		50 mg + 300 mg	* For use in accord with PBS Section 100 indications *
	Tablet		* For use in accord with PBS Section 100 indications *
Domperidone		50 mg + 25 mg	See above
	Tablet		See above
Dopamine		10 mg	
	Injection		
Dornase alfa		200 mg/5 mL	* For use in accord with PBS Section 100 indications *
	Inhalation solution		See above
Dorzolamide		2.5 mg/2.5 mL	See above
	Eye drops		Where other treatments are ineffective or inappropriate
Dorzolamide + timolol		2%	See above
	Eye drops		For reduction of elevated intra-ocular pressure in patients with open-angle glaucoma and ocular hypertension who are not adequately controlled with timolol maleate (0.5%) eye drops or latanoprost eye drops.
Dostarlimab		2% + 0.5%	See above
	Injection		
Dosulepin (dothiepin)		500 mg/10 ml, Vial	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
	Capsule		
Doxepin		25 mg	
	Tablet		
Doxorubicin		75 mg	
	Capsule		
		10 mg	
	Tablet		
		25 mg	
	Tablet		
		50 mg	
	Injection		

Drug	Form	Strength	Restriction
Doxorubicin hydrochloride (as pegylated liposomal)	Injection	50 mg/25 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		200 mg/100 mL	See above
		20 mg/10 mL	* For use in accord with PBS Section 100 indications *
		50 mg/25 mL	or For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS Maximum amount 100mg * For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
Doxycycline	Tablet	50 mg 100 mg	
doxycycline	injection	100mg	For the treatment of severe infections in patients unable to take oral doxycycline on the advice of an infectious diseases physician or clinical microbiologist. Physicians trained in interventional radiology and with proper skills in sclerotherapy - for use in sclerotherapy for treatment of lymphatic malformations in paediatric patients. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained * See above See above
Doxylamine	Tablet	25 mg	For use in pregnant women for the treatment of nausea, vomiting and hyperemesis See above See above
Droperidol	Injection	2.5 mg/mL  10mg in 2mL	(a) patients with post-operative nausea and vomiting which is not responsive to metoclopramide; and (b) for use by emergency physicians, rural generalists or psychiatrists to sedate severely agitated patients in the emergency setting. For use by emergency physicians, rural generalists or psychiatrists to sedate severely agitated patients in the emergency setting.
Dulaglutide	Injection	1.5 mg/0.5 mL	* For use as per the PBS indications *
Duloxetine	Enteric capsule	30 mg 60 mg	Specialist Staff and Country Medical Superintendents for major depressive disorders See above See above
Dupilumab	Injection	200 mg/1.14 mL 300 mg/2 mL	For discharge, outpatient and day admitted patient use in accord with PBS Section 100 indications See above See above
Durvalumab	Injection	120 mg/2.4 mL  500 mg/10 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * See above

Drug	Form	Strength	Restriction
Dutasteride + tamsulosin	Modified release capsule	500 microgram + 400 microgram	Urologists for use as per the PBS indications. Caution - prior to prescribing, confirm whether the patient has a prior history of cataract surgery or impending cataract surgery. <i>See above</i> <i>See above</i>
Eculizumab	Injection	300 mg/30 mL	(a) For inpatient, discharge, outpatient and day admitted patient use in accord with PBS Section 100 indications for the treatment of atypical haemolytic uraemic syndrome (aHUS). Note: access to PBS-subsidised eculizumab under the National Health (Highly Specialised Drugs Program) Special Arrangement 2021, will still be available to public hospital inpatients, but only for the treatment of aHUS. See (b) below for restrictions relating to paroxysmal nocturnal haemoglobinuria. (b) For discharge, outpatient and day admitted patient use in accord with PBS Section 100 indications for the treatment of paroxysmal nocturnal haemoglobinuria (PNH). <i>See above</i> <i>See above</i>
edrophonium	injection	10mg in 1mL	Restricted by availability from manufacturer <i>See above</i> <i>See above</i>
electrolyte replacement oral (contains sodium chloride, potassium chloride, sodium citrate, citric acid, sucrose, glucose) "Gluco-lyte"	powder for oral liquid	40g sachet "Gluco-lyte"	
Elexacaftor + tezacaftor + ivacaftor (&) Ivacaftor	combination pack	50 mg + 25 mg + 37.5 mg tablet (&) 75 mg tablet 80 mg + 40 mg + 60 mg, Sachet (&) 59.5 mg, Sachet 100 mg + 50 mg + 75 mg, Sachet (&) 75 mg, Sachet 100 mg + 50 mg + 75 mg tablet (&) 150 mg tablet	* For use in accord with PBS Section 100 indications * <i>See above</i> <i>See above</i> <i>See above</i>
Elosulfase alfa	Injection	5 mg/5 mL	For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program
Elotuzumab	Injection	300 mg 400 mg	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * <i>See above</i> <i>See above</i>
Eltrombopag	Tablet	25 mg 50 mg	* For use in accord with PBS Section 100 indications * <i>See above</i>
Emicizumab	Injection	30 mg/mL 60 mg/0.4 mL	Specialist Haematologists or Haemophilia Nurse Practitioners prescribing under the oversight of a Queensland Haemophilia Centre Director or delegate, for routine prophylaxis to prevent bleeding or reduce the frequency of bleeding episodes in patients with moderate or severe congenital haemophilia A or congenital haemophilia A with inhibitors. <i>See above</i> <i>See above</i> <i>See above</i>

Drug	Form	Strength	Restriction
emollient	cream	105 mg/0.7 mL	See above
		150 mg/mL	See above
Empagliflozin	Tablet	100g	* For use as per the PBS indications *
			See above
		10 mg	See above
		25 mg	See above
Emtricitabine + rilpivirine + tenofovir alafenamide	Tablet		* For use in accord with PBS Section 100 indications *
			See above
		200 mg + 25 mg + 25 mg	See above
Emtricitabine + tenofovir alafenamide	Tablet		* For use in accord with PBS Section 100 indications *
			See above
		200 mg + 10 mg	See above
		200 mg + 25 mg	See above
emulsifying ointment	ointment		
		100g	
Encorafenib	Capsule		Specialist oncologists for discharge and outpatient use as per the PBS indications
		50 mg	See above
		75 mg	See above
Enfortumab vedotin	Injection		* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		20 mg, Vial	See above
		30 mg, Vial	See above
Enoxaparin sodium	Injection		For use in line with TGA approved indications; QHMAC also endorses 'off-label' use of enoxaparin in children - refer to relevant QH guidelines: Guideline for the Prevention of Venous Thromboembolism (VTE) in Adult Hospitalised Patients Venous thromboembolism (VTE) prophylaxis in pregnancy and the puerperium Enoxaparin - Paediatric Medication Guideline * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
			See above
		20 mg/0.2 mL	See above
		40 mg/0.4 mL	See above
		60 mg/0.6 mL	See above
		80 mg/0.8 mL	See above
		100 mg/mL	See above
Entacapone	Tablet		
		200 mg	* For use as per the PBS indications *
Entecavir	Tablet		

Drug	Form	Strength	Restriction
		1 mg	* For use in accord with PBS Section 100 indications *
		500 microgram	(a) For use in accord with PBS Section 100 indications; (b) For use by specialist staff for the prevention of Hepatitis B reactivation in patients with serological evidence of prior infection who are receiving immunosuppressive therapy. Therapy should be in consultation with or managed by a Hepatology or Infectious Diseases Service and follow established protocols for treatment duration, monitoring whilst on therapy and follow up. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
enteral nutrition products and food supplements	(various formulations)	see link below for specific products available	Please see LAM attachment Enteral Nutrition and Food Supplements list to view which specific products. This list includes products, forms and packs sizes that are available on the list of approved medicines. <a href="https://www.health.qld.gov.au/clinical-practice/guidelines-procedures/medicines/approved-list/nutrition-and-food">https://www.health.qld.gov.au/clinical-practice/guidelines-procedures/medicines/approved-list/nutrition-and-food</a>
Enzalutamide	Capsule	40 mg	* For discharge and outpatient use as per the PBS indications * <i>See above</i>
Ephedrine	hydrochloride injection	30 mg/mL	Ephedrine Hydrochloride Note: Preference the more cost-effective ephedrine hydrochloride 30mg/mL injection over ephedrine sulfate 30mg/mL injection if clinically appropriate. Note: Consider their different TGA approved indications and routes of administration.
		30 mg/10 mL	Ephedrine Hydrochloride 10mL pre-filled syringe
	sulfate injection	30 mg/mL	Ephedrine Sulfate Note: Preference the more cost-effective ephedrine hydrochloride 30mg/mL injection over ephedrine sulfate 30mg/mL injection if clinically appropriate. Note: Consider their different TGA approved indications and routes of administration.
ephedrine and potassium iodide	mixture A.P.F.	1mg-25mg per mL 200mL	
Epirubicin	Injection	50 mg/25 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		100 mg/50 mL	<i>See above</i>
		200 mg/100 mL	<i>See above</i>
Epoetin alfa	Injection	10 000 units/mL	* For use in accord with PBS Section 100 indications *
		20 000 units/0.5 mL	<i>See above</i>
		40 000 units/mL	<i>See above</i>
		1000 units/0.5 mL	<i>See above</i>
		2000 units/0.5 mL	<i>See above</i>
		3000 units/0.3 mL	<i>See above</i>
		4000 units/0.4 mL	<i>See above</i>
		5000 units/0.5 mL	<i>See above</i>

Drug	Form	Strength	Restriction
Epoprostenol	Injection	6000 units/0.6 mL	See above
		8000 units/0.8 mL	See above
			* For use in accord with PBS Section 100 indications *
Eptifibatide	Injection	1.5 mg	See above
		500 microgram	See above
			For use commencing immediately prior to percutaneous intervention with intracoronary stenting and not to exceed 24 hours infusion.
Ergometrine	Injection	20 mg/10 mL	See above
		75 mg/100 mL	See above
Eribulin	Injection	500 microgram/mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
			See above
		1 mg/2 mL	See above
Ertapenem	Injection		On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol.
			See above
		1 g	See above
Erythromycin	Enteric capsule		
		250 mg	
		1 g	
Erythromycin ethylsuccinate	Powder for oral liquid		
		200 mg/5 ml	Children too young to swallow tablets or capsules
Escitalopram	Tablet		
		10 mg	* For use as per the PBS indications *
		20 mg	See above
Esmolol	Injection		
		100 mg/10 mL	Specialists in Anaesthetics, Cardiology or Intensive Care
Esomeprazole	Enteric coated granules		
		10 mg	For use in line with the enteral proton pump inhibitor (PPI) table available on the QH LAM website. Caution – need for ongoing therapy/dose to be reviewed every 3 – 6 months.
Esomeprazole (&) Amoxicillin (&) Clarithromycin	Injection	40 mg	For use in children aged 1 to 18 years (a) in ICU; (b) after endoscopy with high risk stigmata of re-bleeding; or (c) in major upper gastrointestinal haemorrhage
			For eradication of Helicobacter pylori in newly diagnosed or past duodenal or gastric ulcers
Estradiol	combination pack		See above
		20 mg (&) 500 mg (&) 500 mg	See above



Drug	Form	Strength	Restriction
Estradiol (& Estradiol + norethisterone acetate (& Estradiol	Gel	0.1% (1 mg/g)	For use when oral oestrogen therapy cannot be tolerated or is contraindicated
	modified release pessary "Vagifem Low"	10 microgram	
	Patch	25 Microgram/24 hours	For use when oral oestrogen therapy cannot be tolerated or is contraindicated
	Tablet	1 mg	
		2 mg	
Estradiol + norethisterone acetate	combination pack	2 mg (&) 2 mg + 1 mg (&) 1 mg	
	Tablet	1 mg + 500 microgram 2 mg + 1 mg	
Estriol	Cream	0.1% (1 mg/g)	
Etanercept	Injection	25 mg 50mg (pre-filled syringe and auto-injector)	* For use in accord with PBS Section 100 indications * For use in accord with PBS Section 100 indications [Brand Note: Use Brenzys (biosimilar) brand for all PBS indications except for severe active juvenile idiopathic arthritis]
Ethambutol	Tablet	100 mg 400 mg	
Ethosuximide	Capsule	250 mg	
	Oral liquid	250 mg/5 ml	Children too young to swallow tablets or capsules <i>See above</i>
Etonogestrel	Implanted drug delivery system	68 mg	Specialist Staff, Nurse Practitioners and authorised nurses (only in remote areas where there is no medical specialist or nurse practitioner) for treatment of menstrual disorders and/or contraception. <i>See above</i> <i>See above</i>
Etoposide	Capsule	50 mg 100 mg	
	Injection	1.136 g (etoposide 1 g)	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
	Injection	100 mg/5 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
Etravirine			

Drug	Form	Strength	Restriction
Everolimus	Tablet	200 mg	* For use in accord with PBS Section 100 indications *
	Tablet	1 mg	* For use in accord with PBS Section 100 indications *
		5 mg	* For discharge and outpatient use as per the PBS indications *
		10 mg	See above
		250 microgram	* For use in accord with PBS Section 100 indications *
		500 microgram	See above
Evolocumab	Injection	750 microgram	See above
		140 mg/mL	* For discharge and outpatient use as per the PBS indications *
Exemestane	Tablet		See above
			For treatment of hormone-dependent advanced breast cancer in post-menopausal women with disease progression following treatment with tamoxifen citrate and a non-steroidal aromatase inhibitor.
			See above
Ezetimibe	Tablet	25 mg	See above
		10 mg	
Famciclovir	Tablet		
		125 mg	Treatment of immunocompetent patients with herpes zoster in whom the duration of rash is less than 72 hours
			Intermittent treatment of moderate to severe recurrent genital herpes
Famotidine	Tablet		Herpes zoster in immunocompromised patients
		250 mg	Ophthalmic herpes zoster
			See above
famotidine (SAS)	injection	20 mg	
		40 mg	
			* Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
Faricimab	Intraocular injection		See above
		10mg/mL	See above
fat emulsion - olive oil and soya oil (eg 'Clinoleic')	Injection	6 mg/0.05 ml (28.8 mg/0.24 mL) Vial	* For discharge and outpatient use as per the PBS indications *
		80 g/500 mL + 20 g/500 mL	For intravenous therapy when 'SMOFlipid' cannot be used and oral or enteral feeding is not possible.
Felodipine	Modified release tablet		
		2.5 mg	
		5 mg	
Fenofibrate	Tablet	10 mg	

Drug	Form	Strength	Restriction
Fentanyl	Injection	48 mg	For severe disabling pain not responsive to non-narcotic analgesics. For intranasal use in paediatric patients in the Emergency Department. * CONTROLLED DRUG ** When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		145 mg	
		100 microgram/2 mL	
	Patch	500 microgram/10 mL	Specialist Staff for severe disabling pain not responsive to non-narcotic analgesics. Caution: The risk of drug dependence is high. * CONTROLLED DRUG *
		12 Microgram/hour	a) For use in persistent pain clinics and cancer pain or on the advice of a persistent pain specialist, for patients with chronic severe disabling pain requiring daily, continuous, long term therapy which is not responding to non-opioid and first/second line opioid analgesics or where these agents are inappropriate or not tolerated. b) For use in palliative care for patients with chronic severe disabling pain which is not responding to non-opioid and first line opioid analgesics or where these agents are inappropriate or not tolerated. Caution: The risk of drug dependence is high. Patient must not be opioid naïve. * CONTROLLED DRUG *
		25 Microgram/hour	See above
	Sublingual tablet	50 Microgram/hour	See above
		75 Microgram/hour	See above
		100 Microgram/hour	See above
		100 microgram	Palliative Care Physicians and Radiation Oncology Staff for use as per the PBS indications. * CONTROLLED DRUG *
		200 microgram	See above
		300 microgram	See above
fentanyl	intravenous infusion injection	400 microgram	See above
		600 microgram	See above
		800 microgram	See above
Ferric carboxymaltose	Injection	10 micrograms/mL 100mL	* CONTROLLED DRUG * See above See above
		1 g/20 mL	For discharge and outpatient use when oral iron preparations are ineffective or cannot be used. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		500 mg/10 mL	See above See above
Ferric derisomaltose	Injection	1 g/10 mL, Vial	For discharge and outpatient use when oral iron preparations are ineffective or cannot be used. See above
		500 mg/5 mL, Vial	See above
Ferrous fumarate + folic acid	Tablet		

Drug	Form	Strength	Restriction
Ferrous sulfate	Modified release tablet Oral liquid	310 mg (iron 100 mg) + 350 microgram	
		325 mg (iron 105 mg)	250mL: Children too young to swallow tablets or capsules
		30 mg/ml (iron 6 mg/ml)	See above
Fexofenadine	Tablet	60 mg	
		120 mg	
		180 mg	
Filgrastim	Injection	120 microgram/0.2 ml, Syringe	* For use in accord with PBS Section 100 indications *
		300 microgram/0.5 ml, Syringe	See above
		480 microgram/0.5 ml, Syringe	See above
Finerenone	Tablet	10 mg	* For discharge and outpatient use as per the PBS indications *
		20 mg	See above
			See above
Fingolimod	Capsule		* For discharge and outpatient use as per the PBS indications *
			See above
		500 microgram	See above
Flecainide	Injection Tablet	150 mg/15 mL	
		50 mg	
		100 mg	
flecainide acetate "rosemont"	oral liquid solution		Paediatric cardiac specialists for use in accord with Special Access Scheme (SAS) arrangements *
			Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
		5mg per mL 300mL	See above
flucloxacillin	injection		All preparations restricted to treatment of Staphylococcal infections
			See above
		250mg	See above
Flucloxacillin	Capsule		All preparations restricted to treatment of Staphylococcal infections
			See above
		250 mg	See above
	Injection	500 mg	See above
			See above
		1 g	See above
	Powder for oral liquid	500 mg	See above
			See above
		125 mg/5 ml	See above
Fluconazole	Capsule	250 mg/5 ml	See above
		50 mg	(a) treatment of cryptococcal meningitis when amphotericin is contraindicated or not tolerated

Drug	Form	Strength	Restriction
		100 mg	(b) treatment of serious and life threatening candidiasis (c) treatment of oropharyngeal/oesophageal candidiasis in immunosuppressed patients (d) maintenance therapy for cryptococcal meningitis in immunosuppressed patients (e) secondary prophylaxis of oropharyngeal candidiasis in immunosuppressed patients (f) prevention of candida sepsis in patients undergoing chemotherapy for leukaemia or in patients receiving a bone marrow transplant for haematological malignancy (g) inpatient use as part of a single 150mg oral dose for the acute treatment of uncomplicated vaginal candidiasis; (h) for use by Sexual Health Services as part of a single 150mg oral fluconazole dose for the acute treatment of microbiologically confirmed uncomplicated vaginal candidiasis.
			(a) treatment of cryptococcal meningitis when amphotericin is contraindicated or not tolerated (b) treatment of serious and life threatening candidiasis (c) treatment of oropharyngeal/oesophageal candidiasis in immunosuppressed patients (d) maintenance therapy for cryptococcal meningitis in immunosuppressed patients (e) secondary prophylaxis of oropharyngeal candidiasis in immunosuppressed patients (f) prevention of candida sepsis in patients undergoing chemotherapy for leukaemia or in patients receiving a bone marrow transplant for haematological malignancy (g) inpatient use as part of a single 150mg oral dose for the acute treatment of uncomplicated vaginal candidiasis; (h) for use by Sexual Health Services as part of a single 150mg oral fluconazole dose for the acute treatment of microbiologically confirmed uncomplicated vaginal candidiasis.
		200 mg	(a) treatment of cryptococcal meningitis when amphotericin is contraindicated or not tolerated (b) treatment of serious and life threatening candidiasis (c) treatment of oropharyngeal/oesophageal candidiasis in immunosuppressed patients (d) maintenance therapy for cryptococcal meningitis in immunosuppressed patients (e) secondary prophylaxis of oropharyngeal candidiasis in immunosuppressed patients (f) prevention of candida sepsis in patients undergoing chemotherapy for leukaemia or in patients receiving a bone marrow transplant for haematological malignancy
			(a) treatment of cryptococcal meningitis when amphotericin is contraindicated or not tolerated (b) treatment of serious and life threatening candidiasis (c) treatment of oropharyngeal/oesophageal candidiasis in immunosuppressed patients (d) maintenance therapy for cryptococcal meningitis in immunosuppressed patients (e) secondary prophylaxis of oropharyngeal candidiasis in immunosuppressed patients (f) prevention of candida sepsis in patients undergoing chemotherapy for leukaemia or in patients receiving a bone marrow transplant for haematological malignancy
	Injection	100 mg/50 mL	(a) treatment of cryptococcal meningitis when amphotericin is contraindicated or not tolerated (b) treatment of serious and life threatening candidiasis (c) treatment of oropharyngeal/oesophageal candidiasis in immunosuppressed patients (d) maintenance therapy for cryptococcal meningitis in immunosuppressed patients (e) secondary prophylaxis of oropharyngeal candidiasis in immunosuppressed patients (f) prevention of candida sepsis in patients undergoing chemotherapy for leukaemia or in patients receiving a bone marrow transplant for haematological malignancy
		200 mg/100 mL	<i>See above</i>
	Powder for oral liquid	50 mg/5 ml	(a) treatment of cryptococcal meningitis when amphotericin is contraindicated or not tolerated (b) treatment of serious and life threatening candidiasis (c) treatment of oropharyngeal/oesophageal candidiasis in immunosuppressed patients (d) maintenance therapy for cryptococcal meningitis in immunosuppressed patients (e) secondary prophylaxis of oropharyngeal candidiasis in immunosuppressed patients (f) prevention of candida sepsis in patients undergoing chemotherapy for leukaemia or in patients receiving a bone marrow transplant for haematological malignancy But only for: Patients who cannot swallow capsules and meet one of the above criteria
flucytosine	capsule	500mg	For use in accord with Special Access Scheme (SAS) arrangements <i>See above</i> <i>See above</i>
Flucytosine	Injection		For systemic yeast infections and subcutaneous mycoses (Prescribers please note: Danger of drug resistance - laboratory monitoring recommended) <i>See above</i> <i>See above</i>
		2.5 g/250 mL	

Drug	Form	Strength	Restriction
Fludarabine	Injection	50 mg	For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS Intermediate or high risk chronic lymphocytic leukaemia where first line treatment (including either cyclo-phosphamide or chlorambucil) has proven ineffective or is contraindicated OR For Specialist Haematologists for use in induction and consolidation in relapsed and/or refractory acute myeloid leukaemia, or in patients with contraindication to anthracyclines. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		50 mg/2 mL	<i>See above</i>
	Tablet	10 mg	General use for TGA approved indications; and Specialist Haematologists for the treatment of relapsed and/or refractory low grade lymphoma in patients who have received at least 2 alternate prior therapies. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
Fludrocortisone	Tablet	100 microgram	
Flumazenil	Injection	500 microgram/5 mL	For inpatient use only.
Flumetasone pivalate + clioquinol	Ear drops	0.02% + 1%	
Fluorescein	Diagnostic strip	1 mg	
	Eye drops	2%	Inpatient: 0.5mL: For inpatient use only
	Injection	500 mg/5 mL	
fluorometholone in polyvinyl alcohol	Eye drops	0.1%-1.4% 5mL	Specialist Ophthalmologists  <i>See above</i> <i>See above</i>
Fluorouracil	Cream	5%	
	Injection		* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		1 g/20 mL	<i>See above</i>
		2.5 g/50 mL	<i>See above</i>
		5 g/100 mL	<i>See above</i>
		500 mg/10 mL	<i>See above</i>

Fluoxetine

Drug	Form	Strength	Restriction
	Capsule		
	Tablet	20 mg	For major depressive disorders or obsessive compulsive disorder.
Flupentixol decanoate	Injection	20 mg	For major depressive disorders or obsessive compulsive disorder.
			Specialist Psychiatrists where other antipsychotic agents are ineffective or contraindicated
		20 mg/mL	See above
		40 mg/2 mL	See above
		100 mg/mL	See above
Flutamide	Tablet		
		250 mg	* For discharge and outpatient use as per the PBS indications * See above
Fluticasone furoate + umeclidinium + vilanterol	Powder for inhalation		
			For use as per the PBS indications.
		100 microgram/actuation + 62.5 microgram/actuation +	See above
		25 microgram/actuation	
		200 microgram/actuation + 62.5 microgram/actuation +	See above
Fluticasone propionate	Inhalation	25 microgram/actuation	
			For use as per the PBS indications.
		50 microgram/actuation	See above
		125 microgram/actuation	See above
		250 microgram/actuation	See above
Fluticasone propionate + salmeterol	Inhalation		
			* For use as per the PBS indications *
		50 microgram/actuation + 25 microgram/actuation	See above
		125 microgram/actuation + 25 microgram/actuation	
		250 microgram/actuation + 25 microgram/actuation	(a) For initiation by specialist physicians in patients with severe asthma in line with PBS asthma criteria; (b) For continuation of therapy in existing patients, but consider reducing dose of fluticasone.
Fluvoxamine	Tablet		For major depressive disorders or obsessive compulsive disorder.
			See above
		50 mg	See above
		100 mg	See above
Folic acid	Injection		
		15 mg/mL	
	Tablet		
		5 mg	
		500 microgram	
Folinic acid	Injection		
		50 mg/5 mL	
		300 mg/30 mL	
	Tablet		
		15 mg	
			For use as per PBS indications for Related Pharmaceutical Benefits used in conjunction with Efficient Funding of Chemotherapy - Section 100 arrangements
Fondaparinux	Injection		

Drug	Form	Strength	Restriction
		2.5 mg/0.5 mL	a) Patients with NSTEMI undergoing invasive or medical management (except for those going directly for emergency (less than 120 min) invasive management [PCI]); or b) For use as VTE prophylaxis in patients with a history of heparin-induced thrombocytopenia (HIT) where rivaroxaban is inappropriate; c) For use as an alternative anticoagulant therapy for management of HIT in patients with a calculated GFR greater than 30 mL/min where rivaroxaban is inappropriate. Note: patients must be under the care of a Consultant Physician with consideration for an additional Haematology consultation. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
formaldehyde	solution	4% 2 litre 37% 2 litre	
Fosaprepitant	Injection	150 mg	For use where the enteral route is not suitable, providing use is in line with the following: For use as per PBS indications for Related Pharmaceutical Benefits used in conjunction with Efficient Funding of Chemotherapy - Section 100 arrangements.
Fosfomycin	Granules	3 g	For treatment of urinary tract infections with isolates resistant to all other appropriate antibiotics, or in patients intolerant to all other oral options * On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. * <i>See above</i> <i>See above</i>
Fosnetupitant + palonosetron	Injection	235 mg + 250 microgram, Vial	For use where the enteral route is not suitable, providing use is in accord with PBS indications for Related Pharmaceutical Benefits used in conjunction with Efficient Funding of Chemotherapy - Section 100 arrangements. <i>See above</i>
Framycetin sulfate + gramicidin + dexamethasone	Ear drops	0.5% + 0.005% + 0.05%	
Fulvestrant	Injection	250 mg/5 mL	* For discharge and outpatient use as per the PBS indications *
Funnel web spider antivenom	Injection	125 units, Vial	
Furosemide	Injection	20 mg/2 mL 250 mg/25 mL	
	Oral liquid	10 mg/ml	30mL
	Tablet	20 mg 40 mg 500 mg	
Fusidate	Tablet		



Drug	Form	Strength	Restriction
Gabapentin	Capsule	250 mg	* On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
			a) partial epilepsy not controlled by other drugs as per the PBS indications; b) continuation of existing patients being treated for neuropathic pain; c) pain management in paediatric patients under the acute and/or persistent pain service. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		100 mg	Note: Initiate pregabalin in preference to gabapentin for neuropathic pain where clinically appropriate.
		300 mg	Caution: Consider potential for abuse or diversion with this medicine.
Galsulfase	Injection	400 mg	See above
Ganciclovir	Injection	5 mg/5 mL	For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program
			Preferably on the advice of an Infectious Diseases Physician or a Clinical Microbiologist; and In accord with PBS Section 100 indications.
		500 mg	See above
Gelatin + pectin + carmellose sodium	Paste		See above
Gemcitabine	Injection	16.7% + 16.7% + 16.7% - 5g and 15g	
			* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		1 g/26.3 mL	See above
		2 g/52.6 mL	See above
Gemeprost	Pessary	200 mg/5.3 mL	See above
			Specialist Obstetricians with approval of Medical Superintendent
			Note: Special storage requirement of below -10 degrees centigrade
		1 mg	See above
Gemfibrozil	Tablet		See above
		600 mg	
Gemtuzumab ozogamicin	Injection		
		5 mg	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
Gentamicin	Injection		See above
		0.3%	
		80 mg/2 mL	
gentamicin	Eye drops		For short term treatment (up to 72 hrs maximum); ongoing treatment on the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol.
gentamicin			Ophthalmologists

Drug	Form	Strength	Restriction
	eye drops		See above
		1.5% 10mL	See above
gentian alkaline	(A.P.F. 14) 200mL	200mL	
Gilteritinib	Tablet	40 mg	* For discharge and outpatient use as per the PBS indications * See above
Glecaprevir + pibrentasvir	Tablet	100 mg + 40 mg	For discharge and outpatients only, in accord with PBS General Schedule/Section 100 indications
Gliclazide	Modified release tablet	30 mg 60 mg	
	Tablet	80 mg	
Glimepiride	Tablet	1 mg	
		2 mg	
		3 mg	
		4 mg	
Glucagon hydrochloride	Injection	1 mg	
glucose	injection	50% 50mL	
		50% 50mL minijet	
	intravenous infusion	5% (200 Cal per litre) 1 Litre	
		5% (200 Cal per litre) 100mL (Double Pack)	
		5% (200 Cal per litre) 100mL (Single Pack)	
		5% (200 Cal per litre) 250mL	
		5% (200 Cal per litre) 250mL (non-PVC)	
		5% (200 Cal per litre) 500mL	
		10% (400 Cal per litre) 500mL	
		25% (1000 Cal per litre) 1 Litre	
		50% (2000 Cal per litre) 500mL	
Glucose	oral gel		Paediatric Use - for initial supply; for newly diagnosed diabetics; and Paediatricians and registered midwives for newborn hypoglycaemia - for buccal use only.
		40% (15g glucose in 37.5g tube) - Glutose 15®	See above
Glucose and ketone indicator urine	Diagnostic strip		(a) For diabetic clinic (b) Paediatric service medical staff or authorised prescribers for use in paediatric patients on a medically recommended ketogenic diet under the care of QCH Neurosciences or using the protocols of the tertiary referral centre for ketogenic diet.
		1 diagnostic strip	See above See above
Glucose indicator blood			Hospital use "FreeStyle Optium Neo H" (a) For use in hospitals and clinics.

Drug	Form	Strength	Restriction
			(b) Paediatric service medical staff or authorised prescribers for use in paediatric patients on a medically recommended ketogenic diet under the care of QCH Neurosciences or using the protocols of the tertiary referral centre for ketogenic diet. "StatStrip" For use in neonates. Community use "FreeStyle Optium" For use in remote area aboriginal health services - Stock can be ordered through "Healthy Living NT", in accord with National Diabetes Services Scheme (NDSS) supply arrangements. <i>See above</i> <i>See above</i>
	Diagnostic strip	1 diagnostic strip	
Glucose indicator urine	Diagnostic strip	1 diagnostic strip	
glutaral (glutaraldehyde)	buffered solution	2% 5 litre	For specific instrument decontamination (eg Endoscopes) in a controlled environment
glycerol	ear drops	7mL	
	liquid	sterile 14mL 200mL	
Glycerol	Suppository	1.4 g 2.8 g 700 mg	
Glycerol + magnesium sulfate dried	Paste	44% + 48%	
Glyceryl trinitrate	Injection	50 mg/10 mL	Note: Special giving sets are required for the administration of this preparation <i>See above</i>
	Ointment	0.2%	
	Patch	5 mg/24 hours 10 mg/24 hours	
	Spray	400 microgram/actuation	* For discharge and outpatient use as per the PBS indications * <i>See above</i>
	Sublingual tablet	600 microgram	As of August 2020: QHMAC endorses use of the S19A 300microgram glyceryl trinitrate sublingual tablet while supplies of the 600microgram tablet are not available <i>See above</i>
Glycine	Solution	1.5% (30 g/2 L)	Bladder irrigation during transurethral resection
Glycopyrronium bromide	Injection	200 microgram/mL	
glycopyrronium bromide (glycopyrrolate) (QH-CP)			For oral or enteral administration for the management of respiratory secretions and/or hypersalivation in patients receiving palliative care or with complex neurological conditions. * Where

Drug	Form	Strength	Restriction
Glycopyrronium bromide (glycopyrrolate) (SAS)	oral liquid suspension	0.5mg/mL, 100mL	a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
			See above
	tablet	1mg	For oral or enteral administration for the management of respiratory secretions and/or hypersalivation in patients receiving palliative care or with complex neurological conditions. * For use in accord with Special Access Scheme (SAS) arrangements ** Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
			See above
Glycopyrronium bromide + neostigmine	Injection	500 microgram/mL + 2.5 mg/mL	See above
Golimumab	Injection	50 mg/0.5 mL	* For discharge and outpatient use as per the PBS indications *
		100 mg/mL	See above
Goserelin	Implanted drug delivery system	3.6 mg	For (a) advanced carcinoma of the prostate - for outpatient use only (b) Short term treatment (up to 6 months) of visually proven endometriosis for patients who cannot tolerate intranasal nafarelin (c) Hormone dependent breast cancer in line with the PBS indications
		10.8 mg	a) For discharge and outpatient use as per the PBS indications. b) Paediatric oncology staff for use in paediatric patients receiving chemotherapy and/or radiation that has a high risk of premature ovarian failure.
			* When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
Granisetron	Injection	3 mg/3 mL	For patients on cytotoxic chemotherapy or radiotherapy as per the PBS indications
	Tablet	2 mg	For paediatric patients on cytotoxic chemotherapy or radiotherapy for whom ondansetron is ineffective.
Griseofulvin	Tablet		Specialist Staff, Country Medical Superintendents and Endorsed Podiatrists in a shared care arrangement for use in recalcitrant laboratory proven tinea infections.
		125 mg	See above
		500 mg	See above
Guanfacine	Modified release tablet	1 mg	* For discharge and outpatient use as per the PBS indications (ADHD) *
		2 mg	See above
		3 mg	See above
		4 mg	See above
haemodiafiltration fluid (containing 1.2mmol/L phosphate) "Phoxilium"			Intensive care staff for use in ICU patients who require continuous renal replacement therapy

Drug	Form	Strength	Restriction
haemofiltration citrate replacement fluid (calcium free) "PrismOcal"	intravenous infusion injection	5000mL	See above
	fluid	5000mL	See above
haemofiltration citrate replacement fluid (citrate 18, citric acid 0, sodium 140, chloride 86 mmol/L) "Prismocitrate 18/0"			Intensive Care Staff for use in ICU patients who require haemofiltration and where systemic anticoagulation is contraindicated.
	fluid	5000mL	See above
haemofiltration replacement fluid "Hemosol B0"			Intensive Care Staff for use in ICU patients who are critically ill with acute kidney injury/ kidney failure requiring haemofiltration and who are not able to receive systemic anticoagulation without significant risk of bleeding and death.
	fluid	5000mL	See above
Haemophilus B influenza vaccine			At risk patients
	injection	0.5 mL	See above
Haloperidol			See above
	Injection	5 mg/mL	
	Oral liquid	2 mg/ml	For inpatient use only.
	Tablet	1.5 mg 5 mg 500 microgram	Caution: Avoid use for behavioural disturbance in dementia.
Haloperidol decanoate			
	Injection	50 mg/mL 150 mg/3 mL	
heparin			
	intravenous infusion	25 000 units in 50mL pre-filled syringe 1000 units in 0.9% sodium chloride 500mL	
Heparin			
	Injection	25 000 units/5 mL 1000 units/mL 5000 units/mL 5000 units/0.2 mL 5000 units/5 mL	
Hepatitis B vaccine			
	Injection	10 microgram/0.5 mL, Paediatric Formulation 20 microgram/1mL 40 microgram/1mL, Dialysis Formulation	For use in chronic kidney disease Stage 4 and 5 patients likely to progress to renal replacement therapy, dialysis patients, haematopoietic stem cell transplant recipients, and people with HIV infection.

Drug	Form	Strength	Restriction
homatropine	eye drops	1% 5mL 2% 15mL	
Homatropine	Eye drops	2% 0.5mL	For inpatient use only. <i>See above</i>
Human chorionic gonadotrophin	Injection	1500 units 5000 units	
Human papillomavirus quadrivalent vaccine	Injection	0.5 mL Vial	For suitable haematopoietic stem cell transplant recipients who are not eligible for National Immunisation Program (NIP) funded (VIVAS) stock
hyaluronic acid + lidocaine	injection	hyaluronic acid 20mg/mL + lidocaine 3mg/mL injectable gel, syringe	a) For use by Ear, Nose and Throat (ENT) specialist for vocal cord medialisation b) For use by Ear, Nose and Throat (ENT) specialist for injection of type 1 and 2 laryngeal clefts and in deep interarytenoid notch with proven aspiration or laryngeal penetration on swallow assessment. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
Hyaluronidase	Injection	1500 units	
Hydralazine	Injection	20 mg	
	Tablet	25 mg 50 mg	
Hydrochlorothiazide	Tablet	25 mg	
Hydrochlorothiazide + triamterene	Tablet	25 mg + 50 mg	
Hydrocortisone	Tablet	4 mg 20 mg	For adrenal hyperplasia <i>See above</i> <i>See above</i>
Hydrocortisone acetate	Cream	1%	30g
	Enema	10%	
	Eye ointment	1%	
	Ointment		

Drug	Form	Strength	Restriction
		1%	30g
Hydrocortisone sodium succinate	Injection	100 mg	
Hydrogen peroxide	Solution	sterile 3% (10 vol) 30mL 6% 175mL	For use in neurosurgery.
hydrogen peroxide	mouthwash	3% 200mL	
Hydromorphone	Injection	2 mg/mL	Not to be held on imprest except in stand-alone palliative care units and areas where nursing staff are familiar with use. a) For use in pain clinics and cancer pain for patients with severe pain which is not responding to non-opioid and first/second line opioid analgesics or where these agents are inappropriate or not tolerated; b) For use in palliative care for patients with severe pain which is not responding to non-opioid and first line opioid analgesics or where these agents are inappropriate or not tolerated. Caution: The risk of drug dependence is high. * CONTROLLED DRUG *
		10 mg/mL	Not to be held on imprest except in stand-alone palliative care units and areas where nursing staff are familiar with use. a) For use in pain clinics and cancer pain for patients with severe pain which is not responding to non-opioid and first/second line opioid analgesics or where these agents are inappropriate or not tolerated; b) For use in palliative care for patients with severe pain which is not responding to non-opioid and first line opioid analgesics or where these agents are inappropriate or not tolerated. Caution: This is a high potency injection. The risk of drug dependence is high. * CONTROLLED DRUG *
	Oral liquid	1 mg/ml	Not to be held on imprest except in stand-alone palliative care units and areas where nursing staff are familiar with use. a) For use in pain clinics and cancer pain for patients with severe pain which is not responding to non-opioid and first/second line opioid analgesics or where these agents are inappropriate or not tolerated; b) For use in palliative care for patients with severe pain which is not responding to non-opioid and first line opioid analgesics or where these agents are inappropriate or not tolerated. Caution: The risk of drug dependence is high. * CONTROLLED DRUG *
	Tablet	2 mg	Caution: TGA advises that the S19A brands (Rhodes and Hikma /West-Ward) contain sulfites
		4 mg	Not to be held on imprest except in stand-alone palliative care units and areas where nursing staff are familiar with use. a) For use in pain clinics and cancer pain for patients with severe pain which is not responding to non-opioid and first/second line opioid analgesics or where these agents are inappropriate or not tolerated; b) For use in palliative care for patients with severe pain which is not responding to non-opioid and first line opioid analgesics or where these agents are inappropriate or not tolerated. Caution: The risk of drug dependence is high. * CONTROLLED DRUG *
			See above

Drug	Form	Strength	Restriction
Hydroxocobalamin	Injection	8 mg	See above
hydroxocobalamin "cyanokit"	injection	1 mg/mL	
		2.5g x 2	For cyanide poisoning
Hydroxycarbamide (hydroxyurea)	Capsule	500 mg	
hydroxycarbamide (hydroxyurea) (SAS)	oral liquid	100mg/mL	On the advice of a paediatric haematologist, for the treatment of paediatric patients with sickle cell disease. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained * See above
Hydroxychloroquine	Tablet	200 mg	For use by an authorised prescriber in accordance with the Medicines and Poisons (Medicines) Regulation 2021. Prescribers are authorised to prescribe hydroxychloroquine if: (a) they are one of the following specialist practitioners: dermatologist, emergency medicine physician, haematologist, immunologist, infectious disease physician, intensive care physician, nephrologist, paediatrician, rheumatologist, specialist physician in general medicine, a dentist who is a specialist registrant in oral medicine; or (b) they are a medical practitioner or nurse practitioner who is continuing treatment with hydroxychloroquine that was initiated by one of these specialist practitioners. Medical practitioners and nurse practitioners who are continuing treatment with hydroxychloroquine must mark the prescription with the words 'Continuing treatment'. See above See above
hydroxypropylmethyl-cellulose	injection	20mg per mL 1mL	Ophthalmologists See above See above
Hyoscine butylbromide	Injection	20 mg/mL	
	Tablet	10 mg	For inpatient use only
Hyoscine hydrobromide	Chewable tablet	300 microgram	On the advice of a Psychiatrist for clozapine induced hypersalivation. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
	Injection	400 microgram/mL	
Hypromellose	Eye drops	0.5%	
Hypromellose + carbomer-980	Eye gel		



Drug	Form	Strength	Restriction
Ibrutinib	Capsule	0.3% + 0.2%	
		140 mg	Specialist haematologists for discharge and outpatient use as per the PBS indications <i>See above</i>
Ibuprofen	Chewable tablet	100 mg	For patients who are unable to swallow tablets whole or for whom the 200mg tablets are unsuitable. Note: The Advil 100mg chewable tablets are scored, which allows doses in 50mg increments to be administered.
		200 mg	
	Oral liquid	100 mg/5 ml	Paediatric inpatient use.
	Tablet	400 mg	
Icatibant	injection - prefilled syringe	30 mg/3 mL	For outpatient use, as per the PBS indications. <i>See above</i>
Icodextrin + sodium chloride + sodium lactate + calcium chloride + magnesium chloride	Peritoneal dialysis solution	187.5 g/2.5 L + 13.5 g/2.5 L + 11.25 g/2.5 L + ...	For peritoneal dialysis patients with refractory fluid retention despite fluid restriction, the use of high percentage glucose dialysates and high doses of loop diuretics. <i>See above</i> <i>See above</i>
Idarubicin	Capsule	5 mg	For acute myelogenous leukaemia (AML). <i>See above</i>
		10 mg	<i>See above</i>
	Injection	5 mg/5 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		10 mg/10 mL	<i>See above</i> <i>See above</i>
Idarucizumab	Injection	2.5 g/50 mL	Specialist Staff or rural senior medical officers for management of serious bleeding in patients anticoagulated with dabigatran or for reversal of dabigatran when emergency invasive procedures are required that cannot await restoration of normal haemostasis expected on withholding dabigatran. Note: Dose is 5 g (two x 2.5 g vials). <i>See above</i> <i>See above</i>
Idursulfase	Injection	6 mg/3 mL	For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program
Ifosfamide	Injection	1 g	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		2 g	<i>See above</i>
			<i>See above</i>
Iloprost	Inhalation solution	20 microgram/2 mL	* For use in accord with PBS Section 100 indications * <i>See above</i> <i>See above</i>
Imatinib	Capsule	100 mg	* For use as per the PBS indications *

Drug	Form	Strength	Restriction
Imiglucerase	Tablet	400 mg	See above
		100 mg	For use as per the PBS indications where the capsule is not suitable.
		400 mg	* For use as per the PBS indications *
	Injection	200 units 400 units	For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program See above
Imipenem + cilastatin	Injection	500 mg + 500 mg	On the advice of an infectious diseases physician for use in atypical mycobacteria or nocardia. See above See above
Imipramine	Tablet	10 mg 25 mg	
Imiquimod	Cream	5% 250mg Sachet (12)	a) For use as per the PBS indications (for superficial basal cell carcinoma); b) Sexual Health Physicians, Infectious Disease Physicians or Gynaecologists - where other therapy has failed.
Immunisations funded under Queensland and Commonwealth immunisation programs			<p>QHMAC endorses the use of immunisations in accordance with the National Immunisation Program (NIP) and other funded Queensland and Commonwealth immunisation programs for all eligible patients. For information on State and Commonwealth programs outside of the NIP, refer to Immunisation Schedule Queensland at:  <a href="https://www.health.qld.gov.au/clinical-practice/guidelines-procedures/diseases-infection/immunisation/schedule">https://www.health.qld.gov.au/clinical-practice/guidelines-procedures/diseases-infection/immunisation/schedule</a>  Further information relating to eligibility for the NIP can be found at the Immunisation Schedule Queensland at:  <a href="https://www.health.qld.gov.au/clinical-practice/guidelines-procedures/diseases-infection/immunisation/schedule">https://www.health.qld.gov.au/clinical-practice/guidelines-procedures/diseases-infection/immunisation/schedule</a> or by contacting the Queensland Health Immunisation Program (QHIP) <a href="mailto:Immunisation@health.qld.gov.au">Immunisation@health.qld.gov.au</a>  When administering NIP immunisations, immunisers must ensure adherence to NIP eligibility criteria and all documentation requirements are met. This includes consulting the Australian Immunisation Handbook (AIH), Australian Immunisation Register (AIR) and complying with the mandatory recording of relevant immunisations on the AIR within 24 hours of administration, and no more than 10 working days after the immunisation.  Please note that the LAM does not individually list immunisations available under these programs for indications specified within each program's eligibility criteria.  Selected immunisations are listed on the LAM, however, for indications outside the funded NIP or state programs.</p>
Immunoglobulin products available through the National Blood Authority (NBA)			<p>See above</p> <p>QHMAC endorses the use of immunoglobulin products in accordance with the patient eligibility criteria specified in the national blood arrangements, managed by the National Blood Authority (NBA). If outside NBA eligibility criteria seek approval via local process.  Please note that the LAM does not individually list all immunoglobulin products available under the national blood arrangements.</p> <p>See above See above</p>
Inclisiran			

Drug	Form	Strength	Restriction
IncobotulinumtoxinA	Injection	284 mg/1.5 ml, Syringe	* For discharge and outpatient use as per the PBS indications * <i>See above</i>
	Injection	100 units	For use in outpatients, day admitted patients or inpatients admitted for less than 24 hours duration in accord with PBS Section 100 indications.
Indapamide	Modified release tablet	1.5 mg	
indigo carmine	injection	40mg in 5mL (0.8%)	
indocyanine green			Surgical consultants, hepatologists and registrars for patients undergoing pre-operative assessment for liver resection; Gynaecological oncologists for intraoperative mapping of suspected cervical or endometrial cancer and biopsy of sentinel lymph nodes. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
	powder for injection	25mg in 5mL	<i>See above</i> <i>See above</i>
Indometacin	Capsule	25 mg	
	Injection	1 mg	
	Suppository	100 mg	
Infliximab (Remsima)	injection (subcutaneous)	120 mg/mL	* For use as per the PBS indications * <i>See above</i>
Infliximab (Renflexis)	Powder for injection	100 mg	a) For discharge, outpatient and day admitted patient use in accord with PBS Section 100 indications. b) For first dose inpatient use for acute severe ulcerative colitis in accordance with PBS Section 100 criteria. In children under 14 years with Crohn disease or ulcerative colitis, it is recommended a paediatric gastroenterologist is consulted prior to initiation of infliximab.
influenza virus polyvalent vaccine			FOR STOCK PURCHASED FROM CENTRAL PHARMACY: At risk patients who are not eligible for National Immunisation Program (NIP) funded (VIVAS) stock and hospital staff FOR NIP FUNDED VIVAS STOCK: High risk persons who meet NIP eligibility criteria and would benefit from opportunistic vaccination. NOTE: If using VIVAS stock ensure adherence to eligibility criteria and any documentation requirements Refer: <a href="https://www.health.qld.gov.au/clinical-practice/guidelines-procedures/diseases-infection/immunisation/service-providers/influenza">https://www.health.qld.gov.au/clinical-practice/guidelines-procedures/diseases-infection/immunisation/service-providers/influenza</a>
	injection	0.5mL	<i>See above</i> <i>See above</i>
inhalation aid - masks for use with spacer devices	inhalation aid	mask sizes appropriate for infant, child, adult	
inhalation aid - spacer device			

Drug	Form	Strength	Restriction
	inhalation aid	spacer device	
Insulin aspart (Fiasp Penfill)	Injection	100 units/ml, 3 mL Cartridge	
Insulin aspart (Novorapid Flexpen)	Injection	100 units/mL	
Insulin aspart (Novorapid Penfill)	Injection	100 units/mL	
Insulin aspart + Insulin aspart protamine (Novomix 30 Flexpen)	Injection	30 units/mL + 70 units/mL pen device	
Insulin aspart + Insulin aspart protamine (Novomix 30 Penfill)	Injection	30 units/mL + 70 units/mL	
Insulin degludec + Insulin aspart (Ryzodeg 70/30 Flextouch)	Injection	70 units/ml + 30 units/ml, 3 mL Pen device	
Insulin degludec + Insulin aspart (Ryzodeg 70/30 Penfill)	Injection	70 units/ml + 30 units/ml, 3 mL Cartridge	
Insulin detemir (Levemir Flexpen)	Injection	100 units/mL	Type 1 diabetes
Insulin detemir (Levemir Penfill)	Injection	100 units/mL	Type 1 diabetes
Insulin glargine (Optisulin Solostar)	Injection	100 units/mL	Note: Optisulin is an alternative brand to Lantus. Note: From 1 July 2020, Lantus brand will be removed from the PBS.
Insulin glargine (Optisulin)	Injection	100 units/mL	Note: Optisulin is an alternative brand to Lantus. Note: From 1 July 2020, Lantus brand will be removed from the PBS.
Insulin glargine (Toujeo Solostar)	Injection	300 units/mL	* For discharge and outpatient use as per the PBS indications * For continuing therapy in inpatients already established on this high-concentration insulin who are able to self-administer or in conjunction with a local facility prescribing protocol. Initiation in inpatients requires IPA approval. Caution: High-concentration insulin. The insulin is NOT to be withdrawn from the prefill device using a needle and syringe. A dose adjustment may be required when converting between glargine 100 units/mL and glargine 300 units/mL — seek advice from an endocrinologist if required.
Insulin glulisine (Apidra Solostar)	Injection		

Drug	Form	Strength	Restriction
Insulin isophane human (Protaphane Innolet)	Injection	100 units/mL	
		100 units/mL	
Insulin isophane human (Protaphane Penfill)	Injection	100 units/mL	
		100 units/mL	
Insulin lispro (Humalog Kwikpen)	Injection	100 units/mL	
		100 units/mL	
Insulin lispro (Humalog)	Injection	100 units/mL	
		100 units/mL	
Insulin lispro + Insulin lispro protamine (Humalog Mix25 Kwikpen)	Injection	25 units/mL + 75 units/mL	
		25 units/mL + 75 units/mL	
Insulin lispro + Insulin lispro protamine (Humalog Mix25)	Injection	25 units/mL + 75 units/mL	
		25 units/mL + 75 units/mL	
Insulin lispro + Insulin lispro protamine (Humalog Mix50 Kwikpen)	Injection	50 units/mL + 50 units/mL	
		50 units/mL + 50 units/mL	
Insulin lispro + Insulin lispro protamine (Humalog Mix50)	Injection	50 units/mL + 50 units/mL	
		50 units/mL + 50 units/mL	
Insulin neutral human (Actrapid Penfill)	Injection	100 units/mL	
		100 units/mL	
Interferon alfa-2b	Injection	10 million units/mL	Clinical Haematologists and Oncologists for treatment of hairy cell leukaemia
		2 million units/0.5 mL	* For use in accord with PBS Section 100 indications *
Interferon gamma-1b	Injection	2 million units/0.5 mL	See above
		0.5mL	See above
intraocular staining solution "membrane blue"	intraocular solution for injection	0.5mL	Specialist Ophthalmologists
		0.5mL	Specialist Ophthalmologists
iodine + alcohol	Solution	1% + 70%, 100 mL	
		1% + 70%, 100 mL	
iodine and boric acid	powder for insufflation	Iodine 0.75% Potassium Iodide 0.75% Boric Acid	
		98.5% - 10g	
iodine and lactose			

Drug	Form	Strength	Restriction
iodine and potassium	powder for insufflation	Iodine 0.8% Potassium Iodide 0.4% Lactose 98.8% - 10g	
	solution alcoholic	2.5% -2.5%, 500mL	
	solution aqueous (Lugol's)	5% - 10%, 100mL	
	solution sterile	5% - 10%, 50mL	
ipecacuanha	emetic syrup (A.P.F.)	100mL	
Ipilimumab	Injection		* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		50 mg/10 mL	See above
		200 mg/40 mL	See above
Ipratropium	Inhalation	21 microgram/actuation	
	Inhalation solution	250 microgram/mL	For use where treatment with this drug delivered from an oral pressurised inhalation device via a large volume spacer is inappropriate.
		500 microgram/mL	See above
Irbesartan	Tablet		For patients unable to tolerate ACE inhibitors because of cough or angioedema, or patients intolerant of other antihypertensive therapy.
		75 mg	See above
		150 mg	See above
		300 mg	See above
Irinotecan	Injection	40 mg/2 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		100 mg/5 mL	See above
		500 mg/25 mL	See above
Iron polymaltose	Injection		
		100 mg/2 mL	For use when oral iron preparations are ineffective or cannot be used.
Iron sucrose	Injection		For use when oral iron preparations are ineffective or cannot be used.
			* When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		100 mg/5 mL	See above
Isoflurane	Inhalation solution		
		1 ml/ml	
isoniazid			For children who cannot swallow tablets.

Drug	Form	Strength	Restriction
Isoniazid	solution	20mg per mL 100mL	See above
		100 mg	See above
Isoprenaline	Injection	1 in 5000 (1 mg/5 mL) 1 in 5000 (200 microgram/mL)	
Isosorbide mononitrate	Modified release tablet	60 mg 120 mg	
Isotretinoin	Capsule	10 mg 20 mg	Specialist Dermatologists and Specialist Physicians for severe cystic acne only. Caution: This drug causes birth defects. Isotretinoin has been reported to cause other frequent and potentially serious toxicity See above See above
Itraconazole	Oral liquid	10 mg/ml	On the advice of an Infectious Diseases Physician or a Clinical Microbiologist for patients who cannot swallow capsules and meet one of the following criteria; (a) aspergillosis, sporotrichosis or histoplasmosis infections (b) treatment and maintenance therapy in AIDS patients with disseminated or chronic pulmonary histoplasmosis infection (c) treatment of oropharyngeal/oesophageal candidiasis in immunosuppressed patients NOTE: This preparation is not interchangeable with other itraconazole preparations.
Itraconazole (Itranox)	Capsule	100 mg	For paediatric patients only, on the advice of an Infectious Diseases Physician or a Clinical Microbiologist for: aspergillosis, sporotrichosis or histoplasmosis infections. NOTE: This preparation is not interchangeable with other itraconazole preparations. See above See above
Itraconazole (Lozanoc)	Capsule	50 mg	On the advice of an Infectious Diseases Physician or a Clinical Microbiologist for (a) aspergillosis, sporotrichosis or histoplasmosis infections (b) treatment and maintenance therapy in AIDS patients with disseminated or chronic pulmonary histoplasmosis infection (c) treatment of oropharyngeal/oesophageal candidiasis in immunosuppressed patients. NOTE: This preparation is not interchangeable with other itraconazole preparations.
Ivabradine	Tablet	5 mg 7.5 mg	Cardiologists and Radiologists to reduce heart rate in patients in sinus rhythm undergoing CT coronary angiography who do not respond to maximal doses of betablockers or are unable to tolerate beta blockers (or when a beta blocker is contraindicated); For use in chronic heart failure, as per the PBS indications. For use in chronic heart failure, as per the PBS indications.
Ivacaftor	Granules	25 mg, Sachet 50 mg, Sachet	* For use in accord with PBS Section 100 indications * See above See above See above

Drug	Form	Strength	Restriction
Ivermectin	Tablet	75 mg, Sachet	See above
		150 mg	See above
		3 mg	Treatment after approval by an Infectious Diseases physician or a Clinical Microbiologist or when used in accord with an infectious diseases approved protocol of adults and children with Strongyloides stercoralis or Sarcoptes scabiei (Crusted scabies).
Ketamine	Injection		(a) For use as a general anaesthetic agent in areas where anaesthesia is delivered; (b) For use as an analgesic adjuvant under the supervision of an acute pain service, or in emergency departments, where standard analgesics in appropriate doses are insufficient to control pain; (c) For use as an analgesic adjuvant in the treatment of persistent pain under the supervision of specialists in pain medicine and palliative care; (d) For use in the field by practitioners trained to administer ketamine in emergency situations where standard anaesthetic and analgesic agents are contraindicated. The above restrictions apply to the parenteral route. * CONTROLLED DRUG ** When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		200 mg/2 mL	See above
Ketoconazole	Shampoo	2%	For immunologically compromised patients; For use as per the PBS indications
ketone indicator - blood	diagnostic strip	test strips	"FreeStyle Optium H" (a) For diagnosis and management of diabetic ketoacidosis (b) Paediatric service medical staff or authorised prescribers for use in paediatric patients on a medically recommended ketogenic diet under the care of QCH Neurosciences or using the protocols of the tertiary referral centre for ketogenic diet. "StatStrip" For use in neonates.
Ketoprofen	Modified release capsule	100 mg	
		200 mg	
Ketorolac	Injection	10 mg/mL	For postoperative pain where commonly indicated opioids are best avoided * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
		30 mg/mL	(a) postoperative pain where commonly indicated opioids are best avoided; and (b) management of migraine or ureteric colic, as a single dose, when oral NSAID therapy is not tolerated or is considered inappropriate. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
King brown snake antivenom			



Drug	Form	Strength	Restriction
Labetalol	Injection	18 000 units, Vial	The emergency treatment of severe hypertension when prompt and urgent reduction of blood pressure is essential
	Injection	50 mg/10 mL	
	Tablet	100 mg 200 mg	
Lacosamide	Injection	200 mg/20 mL	Specialist Neurology Staff as an adjunctive treatment for epilepsy when oral lacosamide has already been established but is temporarily not feasible.
	Oral liquid	10 mg/ml	For initiation by a Specialist Neurologist or Paediatrician as an adjunctive treatment for epilepsy in paediatric patients as per the PBS indications. For continuing use in paediatric patients established on therapy as per PBS indications where tablets are unsuitable.
	Tablet	50 mg	Specialist Neurology Staff as an adjunctive treatment for epilepsy as per the PBS indications.
		100 mg 150 mg 200 mg	See above See above See above
Lactulose	Oral liquid	3.34 g/5 ml	
Lamivudine	Oral liquid	10 mg/ml	* For use in accord with PBS Section 100 indications *
	Tablet	100 mg	* For use in accord with PBS Section 100 indications *
		150 mg 300 mg	See above See above
Lamivudine + zidovudine	Tablet	150 mg + 300 mg	* For use in accord with PBS Section 100 indications *
			See above
Lamotrigine	Tablet	5 mg	For epilepsy not controlled by other drugs
		25 mg	See above
		50 mg	See above
		100 mg	See above
		200 mg	See above
Lanadelumab	Injection	300 mg/2 mL	Specialist Immunology Staff for outpatient use only as per the PBS indications in the routine prevention of recurrent attacks of hereditary angioedema (C1-esterase-inhibitor deficiency or dysfunction) in patients aged 12 years and older. Not for inpatient use.
			See above
Lanreotide	Injection	60 mg/0.5 mL	* For use in accord with PBS Section 100 indications *
			See above

Drug	Form	Strength	Restriction
Lansoprazole	Orally disintegrating tablet	90 mg/0.5 mL	See above
		120 mg/0.5 mL	See above
		15 mg	See above
		30 mg	See above
Lanthanum	Chewable tablet		For use in accord with PBS Section 100 indications (for initiation and stabilisation of treatment); For use as per the PBS indications (for maintenance therapy).
		1 g	See above
		500 mg	See above
		750 mg	See above
Lapatinib	Tablet		* For use as per the PBS indications *
		250 mg	See above
			See above
Laronidase	Injection	500 units/5 mL	For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program
Latanoprost	Eye drops		Specialist Ophthalmologists as monotherapy for the reduction of intraocular pressure in patients with open-angle glaucoma and ocular hypertension who are intolerant of or insufficiently responsive to other intraocular pressure medication.
		0.005%	See above
			See above
Latanoprost + timolol	Eye drops		For reduction of elevated intra-ocular pressure as per the PBS indications.
		0.005% + 0.5%	See above
			See above
Leflunomide	Tablet		Physicians for use when other disease modifying drugs are inappropriate
		10 mg	See above
		20 mg	See above
			See above
Lenalidomide	Capsule		* For use in accord with PBS Section 100 indications *
		5 mg	See above
		10 mg	See above
		15 mg	See above
		20 mg	See above
		25 mg	See above
Lenvatinib	Capsule	4 mg	Specialist oncologists and hepatologists for discharge and outpatient use as per the PBS indications.
		10 mg	Specialist oncologists for discharge and outpatient use as per the PBS indications.
Lercanidipine	Tablet	10 mg	
		20 mg	
Letrozole			* For use as per the PBS indications *

Drug	Form	Strength	Restriction
Leuporelin	Tablet	2.5 mg	See above
			See above
	Modified release injection	7.5 mg intramuscular depot and subcutaneous depot	* For discharge and outpatient use as per the PBS indications * Note: The combination product Bi Eligard cp is not on the List of Approved Medicines.
		22.5 mg intramuscular depot and subcutaneous depot	INTRAMUSCULAR DEPOT 22.5 mg (a) For discharge and outpatient use as per the PBS indications. (b) For continuation of pubertal suppression in children and adolescents (less than 18 years of age) with persistent gender dysphoria who had commenced receiving leuporelin modified release injection prior to 28 January 2025, in accordance with the Health Service Directive. Treatment must have previously been initiated: By specialists who have a credentialled scope of clinical practice that includes assessment and treatment of gender diverse children and adolescents AND In accordance with the current version of the Australian Standards of Care and Treatment Guidelines for trans and gender diverse children and adolescents where care is coordinated by a multidisciplinary service. Treatment may only be continued: - In patients who had already commenced receiving a puberty blocker prior to the Health Service Directive being issued on 28 January 2025. By a specialist medical prescriber if care continues to be coordinated by a multi-disciplinary service in accordance with the current version of the Australian Standards of Care and Treatment Guidelines for trans and gender diverse children and adolescents. When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au). SUBCUTANEOUS DEPOT 22.5 mg * For discharge and outpatient use as per the PBS indications * Note: The combination product Bi Eligard cp is not on the List of Approved Medicines.
		30 mg intramuscular depot and subcutaneous depot and intramuscular paediatric depot	* For discharge and outpatient use as per the PBS indications * Note: The combination product Bi Eligard cp is not on the List of Approved Medicines.
		45 mg subcutaneous depot	(a) For discharge and outpatient use as per the PBS indications. (b) For continuation of pubertal suppression in children and adolescents (less than 18 years of age) with persistent gender dysphoria who had commenced receiving either this presentation or leuporelin MR intramuscular injection 22.5mg prior to 28 January 2025, in accordance with the Health Service Directive. Note: The transition from leuporelin MR intramuscular injection 22.5mg to leuporelin MR subcutaneous injection 45mg should only occur following review by specialists who have a credentialled scope of clinical practice that includes assessment and treatment of gender diverse children and adolescents. Thereafter treatment may be continued by a specialist medical prescriber if care continues to be coordinated by a multidisciplinary service in accordance with the current version of the Australian Standards of Care and Treatment Guidelines for trans and gender diverse children and adolescents. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) * Note: The combination product Bi Eligard cp is not on the List of Approved Medicines.
levamisole	tablet	50mg (SAS)	Nephrologists for use in paediatric patients with steroid dependent nephrotic syndrome or frequently relapsing nephrotic syndrome.



Drug	Form	Strength	Restriction
	Intrauterine drug delivery system	19.5 mg	Specialist Staff, Nurse Practitioners and authorised nursing staff who are trained in IUD/IUS insertion and removal. This device is indicated for contraception only.
		52 mg	Specialist Staff, Nurse Practitioners and authorised nursing staff who are trained in IUD/IUS insertion and removal. This device is indicated for contraception, menorrhagia and endometrial protection with menopausal hormone therapy (MHT).
	Tablet	1.5 mg	For use as an emergency oral contraceptive within 72 hours of unprotected intercourse
		30 microgram	Specialist Staff, Nurse Practitioners and authorised nurses (only in remote areas where there is no medical specialist or nurse practitioner) for treatment of menstrual disorders and/or contraception. Suitable choice for women unable to use oestrogen hormonal methods of contraception.
	Levonorgestrel + ethinylestradiol	Tablet	125 microgram + 50 microgram 150 microgram + 30 microgram
Levosimendan	Injection	2.5 mg/mL (SAS)	a) Paediatric Cardiac Intensivists for use when other inotropes have failed or are inappropriate; b) Specialist Cardiology or Intensive Care Staff for use up to 24 hours for the management of patients with acute decompensated heart failure to facilitate weaning from continuous inotropic and/or mechanical circulatory support. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
Levothyroxine	Tablet	50 microgram 75 microgram 100 microgram 200 microgram	
Lidocaine	Cream	4%	
	Gel	2%, 10 g Syringe	
	Injection	0.5% (25 mg/5 mL)	
		1% (50 mg/5 mL)	
		1% (200 mg/20 mL)	
		2% (40 mg/2 mL)	
		2% (100 mg/5 mL)	
		2% (400 mg/20 mL)	
		10% (500 mg/5 mL)	Cardiac arrhythmias
	Lotion	4%	
	Ointment	5%	
		10%	For dental use
	Oral liquid	2%	
	Spray	2%	
		10%	For inpatient use only
lidocaine (lignocaine), tetracaine (amethocaine), adrenaline (epinephrine) "Laceraine"			

Drug	Form	Strength	Restriction
Lidocaine + adrenaline (epinephrine)	topical gel	4.2%-0.5%-0.2%, 4mL	For topical anaesthesia during suturing of uncomplicated lacerations on the face and scalp in children. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
	Injection	0.5% (100 mg/20 mL) + 1 in 200 000 (100 microgram/20 mL) 1% (50 mg/5 mL) + 1 in 100 000 (50 microgram/5 mL) 1% (200 mg/20 mL) + 1 in 200 000 (100 microgram/20 mL) 2% (44 mg/2.2 mL) + 1 in 80 000 (27.5 microgram/2.2 mL) 2% (400 mg/20 mL) + 1 in 200 000 (100 microgram/20 mL)	
Lidocaine + cetrimide	Dressing	5% + 0.15%	For dental use
	Gel	50mg + 0.15%	For dental use
Lidocaine + chlorhexidine	Gel	2% + 0.05%	Ophthalmologists See above See above
		4% + 0.25%	
Lidocaine + glucose	Injection	0.4% (2 g/500 mL) + 5% (25 g/500 mL)	
Lidocaine + phenylephrine	Nasal spray	5% + 0.5%	
Lidocaine + prilocaine	Cream	2.5% + 2.5%	For dental use
	Gel	2.5% + 2.5%	
	Patch	25 mg/g + 2.5%	
Lincomycin	Injection	600 mg/2 mL	* On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
Linezolid	Tablet	600 mg	(a) On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol; (b) For treatment after approval by the Medical Advisor Tuberculosis and Infectious Diseases, Communicable Diseases Branch or delegate OR Director Regional Tuberculosis Control Unit. The Medical Advisor Tuberculosis and Infectious Diseases should be contacted for any multi-drug or extremely drug resistant cases and can be contacted during business hours via (07) 3328 9724 or email at: <a href="mailto:cdmu@health.qld.gov.au">cdmu@health.qld.gov.au</a> Contact information for Regional TB Control Units is available here.

Drug	Form	Strength	Restriction
			* When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
liothyronine	injection	20mcg	For use according to Special Access Scheme (SAS) requirements.
Liothyronine	Tablet	20 microgram	
Lipegfilgrastim	Injection	6 mg/0.6 mL	For discharge, outpatient and day admitted patient use in accord with PBS Section 100 indications.
Lisinopril	Tablet	5 mg 10 mg 20 mg	Paediatric cardiac specialists See above See above
lisinopril	oral liquid suspension	1mg per mL, 100mL	Paediatric cardiac specialists
Lithium carbonate	Modified release tablet	450 mg	
	Tablet	250 mg	
Lomustine	Capsule	10 mg 40 mg 100 mg	
Loperamide	Capsule	2 mg	
Lopinavir + ritonavir	Oral liquid	400 mg/5 ml + 100 mg/5 ml	* For use in accord with PBS Section 100 indications *
	Tablet	200 mg + 50 mg	* For use in accord with PBS Section 100 indications *
Loratadine	Oral liquid	1 mg/ml	For use in children where a solid oral dosage form is unsuitable.
	Tablet	10 mg	
Lorazepam	Injection	4 mg/ml, Ampoule	(a) For management of acute behavioural disturbance where de-escalation attempts have failed and oral medications have failed or are impossible to administer to the patient. For Mental Health Alcohol and Other Drugs (MHAOD) Inpatient Services, refer to statewide guidelines (for adults and older adults and for children and adolescents) (b) Treatment of catatonia where oral formulations are not appropriate.
	Tablet	1 mg	(a) use with cancer chemotherapy;

Drug	Form	Strength	Restriction
			(b) use with anaesthetics; (c) use in ICU; (d) For management of acute behavioural disturbance where de-escalation attempts have failed. For Mental Health Alcohol and Other Drugs (MHAOD) Inpatient Services, refer to statewide guidelines (for adults and older adults and for children and adolescents) (e) Specialist Palliative Care practitioners for sublingual use when swallowing is not possible (f) Treatment of catatonia * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
Lorlatinib	Tablet	25 mg 100 mg	Specialist medical oncology staff * For discharge and outpatient use as per the PBS indications * <i>See above</i> <i>See above</i> <i>See above</i>
lubricating gel sterile	prefilled syringe sachet tube	6mL and 11mL prefilled syringe 2.7g sachet 42g tube	For use in operating theatres for patients under general anaesthetic.
Lumacaftor + ivacaftor	Granules  Tablet	75 mg + 94 mg 100 mg + 125 mg 150 mg + 188 mg  100 mg + 125 mg 200 mg + 125 mg	* For use in accord with PBS Section 100 indications * <i>See above</i> <i>See above</i>  * For use in accord with PBS Section 100 indications * <i>See above</i>
Lurasidone	Tablet	40 mg 80 mg	* For use as per the PBS indications * <i>See above</i> <i>See above</i> <i>See above</i>
Macitentan	Tablet	10 mg	* For use in accord with PBS Section 100 indications *
Macrogol-3350	Powder for oral liquid	1 g/g	For use in patients who are: (a) unresponsive to, or unable to tolerate, existing combinations of laxatives; or (b) on large doses of opioid analgesics.
Macrogol-3350 + sodium chloride + bicarbonate + potassium chloride	Powder for oral liquid	13.125 g + 350.7 mg + 178.5 mg + ...	For use in patients who are (a) unresponsive to existing combinations of laxatives; or (b) on large doses of opioid analgesics.
Magnesium	aspartate tablet chloride injection	500mg (each tablet contains 1.55 mmol of magnesium)	



Drug	Form	Strength	Restriction
Magnesium + zinc	Capsule	480 mg/5 mL (each 5 mL ampoule contains 5 mmol of magnesium)	
		magnesium oxide heavy 564.2 mg + magnesium phosphate pentahydrate 175 mg + magnesium amino acid chelate 135 mg + zinc oxide 2.49 mg (each capsule contains 16.45 mmol magnesium + 0.03 mmol zinc)	For patients with high dose magnesium requirements.
Magnesium compound	oral liquid	50mg/mL (each mL contains 2mmol of magnesium)	For use in paediatrics and neonates for the enteral management of hypomagnesaemia, where LAM listed solid dose forms are not appropriate.
Magnesium sulfate	injection	2.5 g/5 mL (each 5mL vial contains 10 mmol of magnesium)	
	powder "epsom salts"	1 g/g	
Malathion	Lotion	0.5%	Organophosphate head lice preparation
Mannitol	Injection	20% (100 g/500 mL)	
	Powder for inhalation	pack containing 40mg capsules x 280 and 2 inhalers "bronchitol"	* For use in accord with PBS Section 100 indications *
mannitol "Aridol"	diagnostic kit	including capsules plus inhalation device	For bronchial provocation tests in respiratory laboratories
Maraviroc	Tablet	150 mg	* For use in accord with PBS Section 100 indications *
		300 mg	<i>See above</i>
Mavacamten	Capsule	2.5 mg	* For discharge and outpatient use as per the PBS indications *
		5 mg	<i>See above</i>
		10 mg	<i>See above</i>
		15 mg	<i>See above</i>
Measles + mumps + rubella live vaccine	Injection		(a) For use in accord with QH policy for staff immunisation; (b) For haematopoietic stem cell transplant recipients who are not eligible for National Immunisation Program (NIP) funded vaccines; (c) For patients planned for solid-organ transplantation who are not eligible for National Immunisation Program (NIP) funded vaccines. Seek expert opinion if vaccination is required within four weeks of the scheduled date of transplant.
Mebendazole		1 Vial	<i>See above</i>
		1 Vial	<i>See above</i>

Drug	Form	Strength	Restriction
	Oral liquid	100 mg/5 ml	Alternative treatment of adults and children with Ancylostoma caninum (Eosinophilic enterocolitis), Ancylostoma duodenale/Necator americanus (Hookworm), Ascaris lumbricoides (Roundworm), Trichuris trichiuria (Whipworm) or Enterobius vermicularis (Pinworm).
	Tablet	100 mg	Alternative treatment of adults and children with Ancylostoma caninum (Eosinophilic enterocolitis), Ancylostoma duodenale/Necator americanus (Hookworm), Ascaris lumbricoides (Roundworm), Trichuris trichiuria (Whipworm) or Enterobius vermicularis (Pinworm).
Mecasermin	Injection	10 mg/ml, 4 mL Vial	* For use in accord with PBS Section 100 indications * <i>See above</i>
Medroxyprogesterone	Injection	150 mg/mL	Specialist Staff, Nurse Practitioners and authorised nurses (only in remote areas where there is no medical specialist or nurse practitioner) for treatment of menstrual disorders and/or contraception.
	Tablet	2.5 mg 5 mg 10 mg 100 mg 200 mg 500 mg	
Mefenamic acid	Capsule	250 mg	Gynaecologists
Mefloquine	Tablet	250 mg	For treatment of Plasmodium falciparum infection on the advice of an Infectious Diseases Physician or a Clinical Microbiologist
Melphalan	Injection	50 mg	For use in persons with anatomical or functional asplenia, haematopoietic stem cell transplant recipients, or requiring treatment with eculizumab.
	Tablet	2 mg	
Meningococcal A + meningococcal C + meningococcal W135 + meningococcal Y conjugate vaccine	Injection		<i>See above</i>
Meningococcal B 4 component vaccine	Injection	0.5 mL Syringe	For use in persons with anatomical or functional asplenia or requiring treatment with eculizumab. <i>See above</i> <i>See above</i>
Mepivacaine	Injection	3% (66 mg/2.2 mL)	For dental use
Mepivacaine + adrenaline (epinephrine)	Injection	2% (44 mg/2.2 mL) + 1 in 100 000 (22 microgram/2.2 mL)	For dental use
mepivacaine caudal			

Drug	Form	Strength	Restriction
Mepolizumab	injection	1.5% 20mL	
	Injection	100 mg	For discharge, outpatient and day admitted patient use in accord with PBS Section 100 indications.
Mercaptamine (cysteamine)	Capsule	50 mg	For treatment of patients with cystinosis.
		150 mg	<i>See above</i>
mercaptamine (cysteamine)	(QH-CP) eye drops	0.5%, 15mL	For treatment of patients with cystinosis. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
Mercaptopurine	Oral liquid	20 mg/ml	Oncology consultants and paediatricians for paediatric patients where the solid dose form is unsuitable
	Tablet	50 mg	
Meropenem	Injection	1 g	On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol.
		500 mg	<i>See above</i>
Mesalazine	Enema	1 g/100 ml	For the treatment of acute distal inflammatory bowel disease with a maximum ONE month supply for any single exacerbation. Caution: These items may not be linking to the correct MIMs dosing information. Refer to brand specific dosing information - the different brands are NOT interchangeable.
		2 g/60 ml	<i>See above</i>
	Enteric tablet	500 mg	For the treatment of inflammatory bowel disease where sulfasalazine cannot be tolerated or its use is inappropriate.
		1 g/application	For the treatment of acute distal inflammatory bowel disease with a maximum ONE month supply for any single exacerbation.
	Modified release granules	1 g	For the treatment of inflammatory bowel disease where sulfasalazine cannot be tolerated or its use is inappropriate. Caution: These items may not be linking to the correct MIMs dosing information. Refer to brand specific dosing information - the different brands are NOT interchangeable.
		2 g	<i>See above</i>
	Modified release tablet	500 mg	<i>See above</i>
		1 g	For the treatment of inflammatory bowel disease where sulfasalazine cannot be tolerated or its use is inappropriate.
	Suppository	1.2 g	Gastroenterologists for use in ulcerative colitis as per the PBS indications.
		1 g	For the treatment of acute distal inflammatory bowel disease with a maximum ONE month supply for any single exacerbation.

Mesna

Drug	Form	Strength	Restriction
	Injection	1 g/10 mL	* For use as per PBS indications for Related Pharmaceutical Benefits used in conjunction with Efficient Funding of Chemotherapy - Section 100 arrangements. * <i>See above</i>
		400 mg/4 mL	
	Tablet	400 mg	Specialist Oncology / Haematology Staff
Mesterolone	Tablet	25 mg	
Metaraminol	Injection		Note: The 5mg/10mL presentation is available as a vial and a pre-filled syringe
		3 mg/6 mL	<i>See above</i>
		5 mg/10 mL	<i>See above</i>
Metformin	Modified release tablet	10 mg/mL	<i>See above</i>
		1 g	
	Tablet	500 mg	For discharge and outpatient use only
		1 g 500 mg 850 mg	
methacholine	broncho provocation test set of 6x10mL		
		0.25, 0.5, 1, 2, 4 and 8mg/mL	Specialist Staff for diagnostic use
Methadone	Injection	10 mg/mL	a) For use in persistent pain clinics and cancer pain for patients with chronic severe disabling pain requiring daily, continuous, long term therapy which is not responding to non-opioid and first/second line opioid analgesics or where these agents are inappropriate or not tolerated. b) For use in palliative care for patients with chronic severe disabling pain which is not responding to non-opioid and first line opioid analgesics or where these agents are inappropriate or not tolerated. Caution: The risk of drug dependence is high. Patient must not be opioid naïve. * CONTROLLED DRUG *
	syrup and oral solution not containing sorbitol, sugar, preservatives or alcohol	5 mg/ml	a) For use in accord with PBS S100 indications; b) For patients in burns units; c) For patients in Specialist pain clinics. * CONTROLLED DRUG *
	Tablet	10 mg	a) For use in persistent pain clinics and cancer pain for patients with chronic severe disabling pain requiring daily, continuous, long term therapy which is not responding to non-opioid and first/second line opioid analgesics or where these agents are inappropriate or not tolerated. b) For use in palliative care for patients with chronic severe disabling pain which is not responding to non-opioid and first line opioid analgesics or where these agents are inappropriate or not tolerated. Caution: The risk of drug dependence is high. Patient must not be opioid naïve. * CONTROLLED DRUG *

Drug	Form	Strength	Restriction
methenamine hippurate (hexamine hippurate)	Tablet	1 g	Prescribers Note Acidification of urine not necessary with use
methionine	tablet	500mg	For treatment of paracetamol overdose <i>See above</i> <i>See above</i>
Methotrexate	Injection	1 g/10 mL 5 mg/2 mL 5 g/50 mL 7.5 mg/0.15 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * See above See above (a) For discharge and outpatient use as per the PBS indications; (b) For use by, or in consultation with, a paediatric rheumatologist for children with non-infectious (inflammatory) uveitis. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) * Caution: This item is not linking to the correct MIMs dosing information. Please refer to other reference sources.
		10 mg/0.2 mL 15 mg/0.3 mL 20 mg/0.4 mL 25 mg/0.5 mL, Syringe 50 mg/2 mL	<i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i>
		500 mg/20 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * or Specialist Rheumatologists; Specialist Staff for pharmacological management of ectopic pregnancy. When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au)
	Tablet	2.5 mg 10 mg	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
Methoxsalen	Injection	100 microgram/5 mL (SAS)	Specialist oncology staff, for paediatric patients receiving extracorporeal photopheresis at the Queensland Children's Hospital managed by the Bone Marrow Transplant team. Caution: This drug is for ex vivo administration and must not be injected directly into the patient. * For use in accord with Special Access Scheme (SAS) arrangements ** Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
		200 microgram/10 mL	* For use in accord with PBS Section 100 indications * Caution: This drug is for ex vivo administration and must not be injected directly into the patient.

Methoxy polyethylene glycol-epoetin beta (Mircera)

Drug	Form	Strength	Restriction
	Injection		For use in accord with PBS Section 100 indications for patients who reside in remote areas. Mircera® is — methoxy polyethylene glycol-epoetin beta
		30 microgram/0.3 mL	See above
		50 microgram/0.3 mL	See above
		75 microgram/0.3 mL	See above
		100 microgram/0.3 mL	See above
		120 microgram/0.3 mL	See above
		200 microgram/0.3 mL	See above
Methoxyflurane	Inhalation solution	360 microgram/0.6 mL	See above
		99.9% (999 mg/g)	(a) Specialist staff and registrars in the haematology unit for analgesia during bone marrow biopsy procedures; (b) Specialist staff, registrars, and registered nurses with extended scope in gynaecology, for the relief of pain in patients requiring gynaecology procedures. (c) For use by clinicians in rural and remote locations to provide short-term pain relief to patients with acute pain in the pre-hospital and facility setting, in line with authorisation requirements and the Medicines and Poisons (Medicines) Regulation 2021. (d) For use in the emergency department and/or urgent care settings in conscious and haemodynamically stable patients in accordance with a locally approved protocol for - i) emergency relief of moderate to severe pain that is refractory to the use of enteral analgesia ii) short emergency procedures as an alternative to using parenteral analgesia or procedural sedation. NOTE: Not to be used in combination with other sedating agents.
Methyl salicylate	Liniment	25%	
Methyldopa	Tablet	250 mg	
methyldopa	tablet	125mg	
Methylene blue	Injection	50 mg/5 mL	* When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
Methylphenidate	Modified release capsule	10 mg	For use as per the PBS indications (ADHD) * CONTROLLED DRUG *
		20 mg	See above
		30 mg	See above
		40 mg	See above
		60 mg	See above
	Modified release tablet	18 mg	For use as per the PBS indications (ADHD) * CONTROLLED DRUG *
		27 mg	See above
		36 mg	See above
		54 mg	See above

Drug	Form	Strength	Restriction
Methylprednisolone	Tablet	10 mg	a) The treatment of narcolepsy; b) Use as per the PBS indications (ADHD) and in accordance with State/Territory law. * CONTROLLED DRUG *
	ointment (fatty)	0.1%	On the advice of Dermatology for use as per the PBS indications.
	sodium succinate injection	1 g 40 mg 500 mg	
Methylprednisolone acetate	Modified release injection		For intralesional; intra-articular use
		40 mg/mL	<i>See above</i> <i>See above</i>
methylosanilinium chloride (crystal violet C14255) and brilliant green (bonneys blue)	paint		
		0.5%-0.5% in 45% Ethanol, 100mL	
Metoclopramide	Injection		
	Tablet	10 mg/2 mL 10 mg	
Metoprolol	Injection		
	Modified release tablet	5 mg/5 mL	
		23.75 mg	* For use as per the PBS indications *
		47.5 mg	<i>See above</i>
		95 mg	<i>See above</i>
		190 mg	<i>See above</i>
metoprolol	oral liquid	Tablet	
		50 mg 100 mg	
			Paediatric cardiac specialists <i>See above</i> <i>See above</i>
Metronidazole	Injection		
		500 mg/100 mL	
	Oral liquid		
	Suppository	200 mg/5 ml	
		500 mg	
	Tablet	200 mg 400 mg	
mexiletine	capsule		
		50mg (SAS) 100mg (SAS)	* For use in accord with Special Access Scheme (SAS) arrangements * <i>See above</i>

Drug	Form	Strength	Restriction
Mianserin	Tablet	150mg (SAS)	See above
		250mg (SAS)	See above
		10 mg	For severe depression. <i>See above</i>
		20 mg	<i>See above</i>
Micafungin	Injection	50 mg	For paediatric use on the advice of an Infectious Diseases Physician or a Clinical Microbiologist for prophylaxis or treatment of severe systemic candida infections that are resistant to fluconazole therapy, or where fluconazole is strongly contraindicated; or in accord with an infectious diseases approved protocol.
Miconazole	cream 25g	2%	Caution - recurrent or persistent symptoms of vulvovaginal candidiasis require microbiological assessment.
	cream 30g	2%	For use as per the PBS indications for the treatment of a fungal or a yeast infection in an Aboriginal or Torres Strait Islander person. Caution - recurrent or persistent symptoms of vulvovaginal candidiasis require microbiological assessment.
	oral gel	2%	For systemic fungal infections susceptible to this agent
Midazolam	Injection	5 mg/mL	Glass ampoule 5mg/mL Specialist Staff for use in procedures, palliative care patients, emergency departments and mental health facilities Plastic ampoule 5mg/mL Intranasal, sublingual or sub-buccal administration for: a) The emergency treatment of acute seizures in both adults and children; and b) Specialist Paediatricians for outpatient management of prolonged seizures in children. Limit of 10 ampoules per supply. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		5 mg/5 mL	
		15 mg/3 mL	For use in intensive care units
		50 mg/10 mL	See above
	oromucosal liquid, pre-filled syringe	5 mg/0.5 ml, Syringe	For discharge and outpatient use as per the PBS indications, in conjunction with an epilepsy care plan.
		7.5 mg/0.75 ml, Syringe	<i>See above</i>
		10 mg/ml, Syringe	<i>See above</i>
Midostaurin	Capsule	25 mg	* For use in accord with PBS Section 100 indications * Note: Contact Central Pharmacy for advice on the required process to order inpatient stock.
Mifepristone	Tablet		



Drug	Form	Strength	Restriction
		200 mg	Specialist obstetrics and gynaecology medical practitioners for use in the termination of an intra-uterine pregnancy, in sequential combination with misoprostol, as per the Queensland Clinical Guideline: Termination of pregnancy. Specialist obstetrics and gynaecology medical practitioners for use in the medical management of second trimester pregnancy loss, in sequential combination with misoprostol, as per the Queensland Clinical Guideline: Early pregnancy loss.
Mifepristone (&) Misoprostol	combination pack	200 mg (&) 200 microgram	For use in the termination of an intra-uterine pregnancy, as per the Queensland Clinical Guideline: Termination of pregnancy. Refer to separate LAM listings of mifepristone tablet 200mg and misoprostol tablet 200 microgram if required for use in the medical management of second trimester pregnancy loss. <i>See above</i> <i>See above</i>
Migalastat	Capsule	123 mg	For Fabry disease as per the PBS indications.
Miglustat	Capsule	100 mg	For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program <i>See above</i> <i>See above</i>
Milrinone	Injection	10 mg/10 mL	Specialist Physicians where other positive inotropes have been shown to be ineffective
Minocycline	Tablet	50 mg	
Minoxidil	Tablet	10 mg	
Mirtazapine	Orally disintegrating tablet	15 mg 30 mg 45 mg	For patients with major depressive disorders who have swallowing difficulties or require monitoring for compliance <i>See above</i> <i>See above</i> <i>See above</i>
	Tablet	15 mg 30 mg 45 mg	For major depressive disorders <i>See above</i> <i>See above</i> <i>See above</i>
Misoprostol	Tablet	200 microgram	(a) For reduction in the incidence of gastrointestinal complications in patients who have a history of peptic ulcer disease and in whom NSAID therapy is essential; (b) For second line management of primary post partum haemorrhage; (c) Specialist Staff for the therapeutic termination of pregnancy as per the Queensland Maternity and Neonatal Clinical Guideline for therapeutic termination of pregnancy (d) Specialist Staff for the management of missed abortion, as per the Queensland Maternity and Neonatal Clinical Guideline for early pregnancy loss. (e) Specialist obstetrics and gynaecology staff for cervical dilation prior to intrauterine surgical intervention. [Note: not for routine use prior to IUD insertion] * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines ( <a href="http://www.catag.org.au">www.catag.org.au</a> ) *
Mitomycin			

Drug	Form	Strength	Restriction
Mitozantrone	Injection	2 mg 10 mg 20 mg	
	Injection	20 mg/10 mL 25 mg/12.5 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * See above
	Injection	20 mg/10 mL	Medical staff skilled in airway support
Mivacurium	Injection		
Moclobemide	Tablet	150 mg 300 mg	For major depressive disorders See above See above
Molnupiravir	Capsule	200 mg	For discharge and outpatient use as per the PBS indications where nirmatrelvir + ritonavir (Paxlovid) cannot be used. See above
Mometasone	Cream		
	Lotion	0.1% 15g and 50g	
	Ointment	0.1% 0.1% 15g and 50g	
Monobasic sodium phosphate + dibasic sodium phosphate	Enema	19 g/118 mL + 7 g/118 mL, 133 mL	a) Adult patients for bowel preparation for colonoscopy; b) For the treatment of severe constipation/impaction which is unresponsive to, or inappropriate for, treatment with oral laxatives; c) For palliative care patients on long term opioid analgesia resulting in an ongoing problem with faecal impaction, after trying first line oral and rectal laxatives; d) For addition to dialysate to increase phosphate levels in haemodialysis patients, particularly those who dialyse for extended times. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
	Oral liquid	417.8 mg/mL + 95.6 mg/mL	Adult patients for bowel preparation for colonoscopy
			Gynaecologists and their registrars for gynaecological procedures
monsel's ferric subsulfate	gel	21%, 15mL	See above See above
morphine	intravenous infusion injection	1mg/1mL 100mL	
Morphine	Injection	120 mg/1.5 mL	Use in syringe pumps only for severe disabling pain not responding to non-opioid analgesics or where these agents are inappropriate or not tolerated.

Drug	Form	Strength	Restriction
			Caution: The risk of drug dependence is high. * CONTROLLED DRUG *
	Injection	10 mg/mL	* CONTROLLED DRUG *
	Injection	5 mg/mL 30 mg/mL	For use in neonates and paediatric patients only * CONTROLLED DRUG * * CONTROLLED DRUG *
	Intrathecal injection	500 microgram/mL	Anaesthetists for intrathecal postoperative analgesia. * CONTROLLED DRUG ** Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
	Modified release capsule	10 mg	a) For use in patients with chronic severe pain requiring daily, continuous, long term therapy which is not responding to non-opioid or first-line opioid analgesics or where these agents are inappropriate or not tolerated. b) For use in severe pain which is not responding to non-opioid analgesics in patients who are either opioid tolerant or expected to have prolonged post-operative or post-traumatic states. c) For use in chronic breathlessness, as per the PBS indications. Caution: The risk of drug dependence is high. * CONTROLLED DRUG *
		20 mg	See above
		50 mg	a) For use in patients with chronic severe pain requiring daily, continuous, long term therapy which is not responding to non-opioid or first-line opioid analgesics or where these agents are inappropriate or not tolerated. b) For use in severe pain which is not responding to non-opioid analgesics in patients who are either opioid tolerant or expected to have prolonged post-operative or post-traumatic states. Caution: The risk of drug dependence is high. * CONTROLLED DRUG *
	Modified release tablet	100 mg	See above
		5 mg	a) For use in patients with chronic severe pain requiring daily, continuous, long term therapy which is not responding to non-opioid or first-line opioid analgesics or where these agents are inappropriate or not tolerated. b) For use in severe pain which is not responding to non-opioid analgesics in patients who are either opioid tolerant or expected to have prolonged post-operative or post-traumatic states. Caution: The risk of drug dependence is high. * CONTROLLED DRUG *
		10 mg	See above
		15 mg	See above
		30 mg	See above
		60 mg	See above
		100 mg	See above
	Oral liquid	1 mg/ml	Specialist paediatricians for use in neonates with neonatal abstinence syndrome. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines ( <a href="http://www.catag.org.au">www.catag.org.au</a> ) * * CONTROLLED DRUG *
		2 mg/ml	For use in patients with severe pain which is not responding to non-opioid and first line opioid analgesics or where these agents are inappropriate or not tolerated. Caution: The risk of drug dependence is high. * CONTROLLED DRUG *
		5 mg/ml	For use in patients with severe pain which is not responding to non-opioid and first line opioid analgesics or where these agents are inappropriate or not tolerated. Caution: The risk of drug dependence is high. * CONTROLLED DRUG *

Drug	Form	Strength	Restriction
morphine sulfate	Tablet	10 mg/ml	See above
		10 mg	a) For use in cancer pain for patients with severe disabling pain which is not responding to non-opioid and first line opioid analgesics or where these agents are inappropriate or not tolerated. b) For use in palliative care for patients with severe disabling pain which is not responding to non-opioid analgesics or where these agents are inappropriate or not tolerated. Caution: The risk of drug dependence is high. * CONTROLLED DRUG *
		20 mg	See above
morphine sulfate	oral liquid	2 mg/mL, 100 mL	For use in patients with severe pain which is not responding to non-opioid and first line opioid analgesics or where these agents are inappropriate or not tolerated. Caution: The risk of drug dependence is high. * CONTROLLED DRUG *
morphine sulfate (QH-CP)	oral liquid	1 mg/mL, 30 mL	Specialist paediatricians for use in neonates with neonatal abstinence syndrome. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained * * CONTROLLED DRUG *
Moxifloxacin	Injection	400 mg/250 mL	For use after approval by an Infectious Diseases Physician or a Clinical Microbiologist or in accord with an Infectious Diseases approved protocol: a) For empirical therapy of patients with community acquired pneumonia or acute bacterial meningitis who have immediate hypersensitivity to penicillin and cannot be given cephalosporin; b) For patients with an infection caused by an organism with proven resistance to antibiotic agents apart from moxifloxacin, or who have severe allergy to standard agents where moxifloxacin is the most appropriate therapy available; OR For treatment after approval by the Medical Advisor Tuberculosis and Infectious Diseases, Communicable Diseases Branch or delegate OR Director Regional Tuberculosis Control Unit. The Medical Advisor Tuberculosis and Infectious Diseases should be contacted for any multi-drug or extremely drug resistant cases and can be contacted during business hours via (07) 3328 9724 or email at: <a href="mailto:cdmu@health.qld.gov.au">cdmu@health.qld.gov.au</a> Contact information for Regional TB Control Units is available here. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines ( <a href="http://www.catag.org.au">www.catag.org.au</a> ) * See above
	Tablet		1) For use after approval by an Infectious Diseases Physician or a Clinical Microbiologist or in accord with an Infectious Diseases approved protocol: a) For empirical therapy of patients with community acquired pneumonia or acute bacterial meningitis who have immediate hypersensitivity to penicillin and cannot be given cephalosporin; b) For patients with an infection caused by an organism with proven resistance to antibiotic agents apart from moxifloxacin, or who have severe allergy to standard agents where moxifloxacin is the most appropriate therapy available; OR For treatment after approval by the Medical Advisor Tuberculosis and Infectious Diseases, Communicable Diseases Branch or delegate OR Director Regional Tuberculosis Control Unit. The Medical Advisor Tuberculosis and Infectious Diseases should be contacted for any multi-drug or extremely drug resistant cases and can be contacted during business hours via (07) 3328 9724 or email at: <a href="mailto:cdmu@health.qld.gov.au">cdmu@health.qld.gov.au</a> Contact information for Regional TB Control Units is available here. 2) For the treatment of confirmed Mycoplasma genitalium infection in patients 16 years or older, known or suspected to be resistant to macrolide therapy, or unable to tolerate macrolide therapy, or in patients whose partner has infection which is known or suspected to be resistant to macrolide

Drug	Form	Strength	Restriction
			therapy in accordance with the Australian STI Management Guidelines. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		400 mg	See above
Moxonidine	Tablet	200 microgram 400 microgram	As add-on therapy for severe refractory hypertension except in congestive heart failure See above See above
multi-test urine strips (for pH, Protein, Glucose, Ketone, Bilirubin and Urobilinogen)	diagnostic strip	strip	
Mupirocin	Ointment	ointment 15g and nasal ointment 3g	Mupirocin 2% ointment 15g - unrestricted Mupirocin 2% nasal ointment 3g - For decolonisation of MRSA following approval by Infectious Diseases Physicians, Clinical Microbiologists or infection control practitioners or in accord with recommended practices for the prevention and control of infections in dialysis settings; and on the advice of Infectious Diseases Physicians or Clinical Microbiologists to assist in preventing recurrent furunculosis.
Mycobacterium bovis (Bacillus Calmette and Guerin (BCG)) Danish strain	Injection	30 mg	* For use as per PBS indications for Related Pharmaceutical Benefits used in conjunction with Efficient Funding of Chemotherapy - Section 100 arrangements. *
Mycobacterium bovis (BCG) live vaccine	Injection	1.5 mg Vial	For vaccination after approval by the Medical Advisor Tuberculosis and Infectious Diseases, Communicable Diseases Branch or delegate OR Director Regional Tuberculosis Control Unit. The Medical Advisor Tuberculosis and Infectious Diseases should be contacted for any multi-drug or extremely drug resistant cases and can be contacted during business hours via (07) 3328 9724 or email at: cdmu@health.qld.gov.au Contact information for Regional TB Control Units is available here. See above See above
Mycobacterium bovis BCG Connaught strain	Injection	81 mg	Specialist Urologists for bladder cancer See above See above
Mycobacterium bovis BCG Tice strain	Injection	500 million CFU	Specialist Urologists for bladder cancer; * For use as per PBS indications for Related Pharmaceutical Benefits used in conjunction with Efficient Funding of Chemotherapy - Section 100 arrangements. * See above See above
Mycophenolate	Enteric tablet	180 mg	(a) for patients with lupus nephritis as per the PBS Section 100 indications; (b) for continuation of therapy in existing transplant patients.
	mofetil capsule	360 mg	See above

Drug	Form	Strength	Restriction
	mofetil powder for oral liquid	250 mg	(a) For use as per the PBS indications; and (b) for use in management of rejection in liver transplant patients who are intolerant of, or unsuitable for treatment with azathioprine. [Brand Note: Pharmacor Mycophenolate is the sole brand listed]
		1 g/5 ml	Use where a dose is unable to be given via a capsule or tablet: (a) For use in accord with PBS indications; and (b) for use in management of rejection in liver transplant patients who are intolerant of, or unsuitable for treatment with azathioprine. [Brand Note: Pharmacor Mycophenolate is the sole brand listed]
	mofetil tablet	500 mg	(a) For use as per the PBS indications; and (b) for use in management of rejection in liver transplant patients who are intolerant of, or unsuitable for treatment with azathioprine. [Brand Note: Pharmacor Mycophenolate is the sole brand listed]
nadolol	tablet		For use in patients under cardiac specialist care, for the treatment of congenital long QT syndrome and other hereditary malignant arrhythmic conditions. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
		40mg	See above
		80mg	See above
Nafarelin	Nasal spray		
		200 microgram/actuation	For treatment of visually proven endometriosis
Naloxone	Injection	1 mg/mL	For discharge and outpatient use.
	Nasal spray	400 microgram/mL	
		1.8 mg/actuation	For use in discharge and outpatients.
Naltrexone	Tablet	50 mg	Drug and alcohol treatment physicians for use with a comprehensive treatment program for alcohol dependence with the goal of maintaining abstinence.
Nanoparticle albumin-bound paclitaxel	Injection	100 mg	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
Naproxen	Tablet	250 mg	
		500 mg	
Natalizumab	Injection	150 mg/ml, Syringe	* For use in accord with PBS Section 100 indications *
		300 mg/15 ml, Vial	See above
Neomycin sulfate	Tablet	500 mg	
Neostigmine	Injection		

Drug	Form	Strength	Restriction
Netupitant + palonosetron	Capsule	2.5 mg/mL 500 microgram/mL	* For use as per PBS indications for Related Pharmaceutical Benefits used in conjunction with Efficient Funding of Chemotherapy - Section 100 arrangements. *
		300 mg + 500 microgram	
Nevirapine	Modified release tablet	400 mg	* For use in accord with PBS Section 100 indications *
			See above
	Oral liquid	10 mg/ml	See above
			See above
	Tablet	200 mg	See above
Nicorandil	Tablet		As a second line agent when conventional antianginal therapy is ineffective
		10 mg	See above
		20 mg	See above
Nicotine	Chewing gum	2 mg	For adolescents (over 12 years of age) who cannot tolerate stronger strength nicotine replacement therapy (NRT) and demonstrate skin sensitivity to nicotine patches.
		4 mg	For management of nicotine withdrawal in compliance with the Queensland Government Smoking Cessation Clinical Pathway
	Inhalation	15 mg	Inpatient: For short term use in mental health inpatients in high dependency units or psychiatric intensive care units.
	Lozenge	2 mg	For adolescents (over 12 years of age) who cannot tolerate stronger strength nicotine replacement therapy (NRT) and demonstrate skin sensitivity to nicotine patches.
		4 mg	For management of nicotine withdrawal in compliance with the Queensland Government Smoking Cessation Clinical Pathway.
	oral spray	1 mg/actuation	For short term use in mental health inpatients in secure mental health rehabilitation units, high dependency units or psychiatric intensive care units. For supervised administration only.
	Patch	7 mg/24 hours	For management of nicotine withdrawal in adolescents and pregnant patients
		14 mg/24 hours	See above
		21 mg/24 hours	Inpatient: For management of nicotine withdrawal in compliance with the Queensland Government Smoking Cessation Clinical Pathway. Outpatient: For discharge and outpatient use as per the PBS indications where the patient has committed to quit and has entered, or is entering, the necessary counselling and support program.
Nicotinic acid	Tablet		
		250 mg	
Nifedipine	Modified release tablet	20 mg	For use in tocolysis. 10mg tablet: Inpatient management of acute hypertension in paediatric patients where other
		30 mg	
		60 mg	
	tablet / capsule		

Drug	Form	Strength	Restriction
			antihypertensive medications are contraindicated or not tolerated. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
		10 mg	See above
		20 mg	See above
Nilotinib	Capsule	150 mg 200 mg	Specialist Haematologists for use as per the PBS indications. See above
Nimodipine	Injection	10 mg/50 mL	Specialist Neurosurgeons
	Tablet	30 mg	Specialist Neurosurgeons
Niraparib	Capsule	100 mg	For discharge and outpatient use as per the PBS restrictions.
nirmatrelvir + ritonavir (Paxlovid) tablet 150 mg + 100 mg	tablet		For discharge and outpatient use as per the PBS indications OR For use in paediatric patients on the advice of an infectious diseases specialist or microbiologist for the treatment of COVID-19 for those at high risk of deterioration from COVID-19 disease. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		150 mg + 100 mg	See above
Nitisinone	Capsule	2 mg 5 mg 10 mg 20 mg	For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program See above See above See above See above
	Oral liquid	4 mg/ml	See above
	Tablet	2 mg 5 mg 10 mg	See above See above See above
Nitrazepam	Tablet	5 mg	
Nitrofurantoin	Capsule	50 mg 100 mg	
Nitroprusside	Injection	50 mg	
Nivolumab			



Drug	Form	Strength	Restriction
Nivolumab + relatlimab	Injection	40 mg/4 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		100 mg/10 mL	See above See above
Noradrenaline (norepinephrine)	Injection	240 mg/20 ml + 80 mg/20 ml, Vial	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		1 in 1000 (2 mg/2 mL)	
Norethisterone	Tablet	5 mg	Specialist Staff, Nurse Practitioners and authorised nurses (only in remote areas where there is no medical specialist or nurse practitioner) for treatment of menstrual disorders and/or contraception. Suitable choice for women unable to use oestrogen hormonal methods of contraception.
		350 microgram	
Norethisterone + mestranol	Tablet	1 mg + 50 microgram	
Norfloxacin	Tablet	400 mg	For serious bacterial urinary tract infections unresponsive to other agents wherever possible on the advice of an Infectious Diseases Physician or a Clinical Microbiologist
Nortriptyline	Tablet	10 mg	
		25 mg	
Nusinersen	Intrathecal injection	12 mg/5 mL	* For use in accord with PBS Section 100 indications *
Nystatin	Cream	100 000 units/g	15g
	Oral liquid	100 000 units/ml	24mL: For children and Specialist Staff for adults
	Tablet	500 000 units	
	Vaginal cream	20 000 units/g	75g. Caution - recurrent or persistent symptoms of vulvovaginal candidiasis require microbiological assessment
oatmeal colloidal.	application	100% 1kg	For use with children with burns
Obinutuzumab	Injection	1 g/40 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
Ocrelizumab	Injection	300 mg/10 mL	* For use in accord with PBS Section 100 indications *
Ocriplasmin	Intraocular injection		

Drug	Form	Strength	Restriction
Octreotide	Injection	375 microgram/0.3 mL	Specialist ophthalmologists for outpatient use as per the PBS indications
		50 microgram/mL	(a) For use in accord with PBS Section 100 indications; (b) For the treatment of suspected variceal haemorrhage. Endoscopy to prove variceal haemorrhage must be performed within 24 hours or therapy should be ceased. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		100 microgram/mL	(a) For use in accord with PBS Section 100 indications; (b) For the treatment of suspected variceal haemorrhage. Endoscopy to prove variceal haemorrhage must be performed within 24 hours or therapy should be ceased. (c) For use in chyle leaks post surgery. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
	Modified release injection	500 microgram/mL	(a) For use in accord with PBS Section 100 indications; (b) For the treatment of suspected variceal haemorrhage. Endoscopy to prove variceal haemorrhage must be performed within 24 hours or therapy should be ceased. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		10 mg	For use in accord with PBS Section 100 indications only to treat vasoactive intestinal peptide secreting tumour (VIPoma) and for continuation of therapy in existing patients.
		20 mg	See above
		30 mg	See above
Ofloxacin	Eye drops	0.3%	For the treatment of severe conjunctivitis or keratitis where first line antibacterial therapy has failed or is inappropriate
Olanzapine	Injection	10 mg	For management of acute behavioural disturbance where de-escalation attempts have failed and oral medications have failed or are impossible to administer to the patient. For Mental Health Alcohol and Other Drugs (MHAOD) Inpatient Services, refer to statewide guidelines (for adults and older adults and for children and adolescents) For use in delirium, refer to statewide guidance
	Orally disintegrating tablet	5 mg	(a) For use as per the PBS indications; (b) For management of acute behavioural disturbance where de-escalation attempts have failed. For Mental Health Alcohol and Other Drugs (MHAOD) Inpatient Services, refer to statewide guidelines (for adults and older adults and for children and adolescents); For use in delirium, refer to statewide guidance (c) For use in alcohol and drug withdrawal in line with statewide guidelines. (d) For use by haematologists and oncologists for treatment of breakthrough nausea and vomiting in patients on highly emetogenic chemotherapy, for a maximum of 3 days therapy. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines

Drug	Form	Strength	Restriction
			(www.catag.org.au) *
			[NOTE] Olanzapine wafer and orally disintegrating tablet presentations are equivalent for the purposes of substitution. Preference should be given to the presentation that is listed in the current QH medication supply contract.
		10 mg	<i>See above</i>
		20 mg	* For use as per the PBS indications *
			[NOTE] Olanzapine wafer and orally disintegrating tablet presentations are equivalent for the purposes of substitution. Preference should be given to the presentation that is listed in the current QH medication supply contract.
	Tablet	2.5 mg	(a) For use as per the PBS indications; (b) For management of acute behavioural disturbance where de-escalation attempts have failed. For Mental Health Alcohol and Other Drugs (MHAOD) Inpatient Services, refer to statewide guidelines (for adults and older adults and for children and adolescents); For use in delirium, refer to statewide guidance. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		5 mg	(a) For use as per the PBS indications; (b) For use by haematologists and oncologists for treatment of breakthrough nausea and vomiting in patients on highly emetogenic chemotherapy, for a maximum of 3 days therapy. (c) For management of acute behavioural disturbance where de-escalation attempts have failed. For Mental Health Alcohol and Other Drugs (MHAOD) Inpatient Services, refer to statewide guidelines (for adults and older adults and for children and adolescents); For use in delirium, refer to statewide guidance. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		7.5 mg	(a) For use as per the PBS indications; (b) For management of acute behavioural disturbance where de-escalation attempts have failed. For Mental Health Alcohol and Other Drugs (MHAOD) Inpatient Services, refer to statewide guidelines (for adults and older adults and for children and adolescents); For use in delirium, refer to statewide guidance. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		10 mg	(a) For use as per the PBS indications; (b) For use by haematologists and oncologists for treatment of breakthrough nausea and vomiting in patients on highly emetogenic chemotherapy, for a maximum of 3 days therapy. (c) For management of acute behavioural disturbance where de-escalation attempts have failed. For Mental Health Alcohol and Other Drugs (MHAOD) Inpatient Services, refer to statewide guidelines (for adults and older adults and for children and adolescents); For use in delirium, refer to statewide guidance. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's

Drug	Form	Strength	Restriction
	Wafer	5 mg	<p>advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *</p> <p>(a) For use as per the PBS indications;</p> <p>(b) For management of acute behavioural disturbance where de-escalation attempts have failed. For Mental Health Alcohol and Other Drugs (MHAOD) Inpatient Services, refer to statewide guidelines (for adults and older adults and for children and adolescents) For use in delirium, refer to statewide guidance</p> <p>(c) For use in alcohol and drug withdrawal in line with statewide guidelines.</p> <p>(d) For use by haematologists and oncologists for treatment of breakthrough nausea and vomiting in patients on highly emetogenic chemotherapy, for a maximum of 3 days therapy. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *</p> <p>[NOTE]Olanzapine wafer and orally disintegrating tablet presentations are equivalent for the purposes of substitution. Preference should be given to the presentation that is listed in the current QH medication supply contract.</p> <p><i>See above</i></p> <p>* For use as per the PBS indications *</p> <p>[NOTE] Olanzapine wafer and orally disintegrating tablet presentations are equivalent for the purposes of substitution. Preference should be given to the presentation that is listed in the current QH medication supply contract.</p>
		10 mg	
		20 mg	
Olanzapine pamoate	Modified release injection	210 mg 300 mg 405 mg	<p>Specialist Psychiatrists for schizophrenia in patients who have been prescribed oral olanzapine (as a second or third line antipsychotic) and have responded to this therapy, but are non-compliant. Patients must consent to remain on site for at least two hours after each injection for physical observations.</p> <p><i>See above</i></p> <p><i>See above</i></p> <p><i>See above</i></p> <p><i>See above</i></p>
Olaparib	Tablet	100 mg 150 mg	<p>For discharge and outpatient use as per the PBS indications.</p> <p><i>See above</i></p> <p><i>See above</i></p>
Omalizumab	Injection	75 mg/0.5 mL 150 mg/mL	<p>For discharge, outpatient and day admitted patient use in accord with PBS Section 100 indications</p> <p><i>See above</i></p> <p><i>See above</i></p>
Omeprazole	Enteric capsule	20 mg	<p>Only for compounding suspension if Central Pharmacy supply is unavailable. Caution - need for ongoing therapy/dose to be reviewed every 3 - 6 months.</p>
	Enteric tablet	10 mg	<p>For use in line with the enteral proton pump inhibitor (PPI) table available on the QH LAM website. Caution – need for ongoing therapy/dose to be reviewed every 3 to 6 months. Note: Losec contains enteric-coated pellets which can be dispersed.</p>
	Injection	40 mg	<p>For use in children less than 1 year (a) in ICU;</p>

Drug	Form	Strength	Restriction
omeprazole ADVZ	powder for oral liquid	2mg per mL	(b) after endoscopy with high risk stigmata of re-bleeding; or (c) in major upper gastrointestinal haemorrhage
			For use in children over 1 month (corrected gestational age) in line with the enteral proton pump inhibitor (PPI) table available on the QH LAM website. Caution – need for ongoing therapy/dose to be reviewed every 3-6 months.
omeprazole QH-CP	oral liquid suspension	2mg per mL, 100mL	For use in neonates (and children under 1 month corrected gestational age) in line with the enteral proton pump inhibitor (PPI) table available on the QH LAM website. Caution – need for ongoing therapy/dose to be reviewed every 3 – 6 months.
Onasemnogene abeparvovec	Injection	20 trillion vector genomes/mL, 8.3 mL vial (in varying quantities)	* For use in accord with PBS Section 100 indications *
Onasemnogene abeparvovec (&) Onasemnogene abeparvovec	combination pack	20 trillion vector genomes/mL, 5.5 mL vial (&) 20 trillion vector genomes/mL, 8.3 mL vial (in varying quantities)	* For use in accord with PBS Section 100 indications *
Ondansetron	Injection	4 mg/2 mL	* When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		8 mg/4 mL	See above
	Oral liquid	4 mg/5 ml	For discharge and outpatient use as per the PBS indications in patients who cannot use any other forms of ondansetron. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		4 mg	(a) For discharge and outpatient use as per the PBS indications; (b) Use in postoperative nausea and vomiting (PONV) in children; (c) For use within Emergency Departments for acute gastroenteritis in children in accordance with Children's Health Queensland Guideline - Gastroenteritis - Emergency Management of Children * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
	Orally disintegrating tablet	8 mg	* When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		4 mg	* When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *

Drug	Form	Strength	Restriction
Opicapone	Capsule	8 mg	See above
		50 mg	* For use as per the PBS indications *
Ornipressin	Injection	5 units/mL	
Orphenadrine	Modified release tablet	100 mg	
ortho-phthalaldehyde chemical disinfectant	solution	0.5%, 5 litre	
Oseltamivir	Capsule	30 mg	(1) On the advice of an Infectious Diseases Physician or a Clinical Microbiologist or in accordance with an Infectious Diseases / Clinical Microbiology approved protocol for: a) Treatment of inpatients who have clinically suspected or laboratory proven influenza who are at high risk of severe disease (not for general use in Emergency Departments unless admission is intended); b) Prophylaxis of inpatients who are close contacts of inpatients with laboratory proven influenza on the advice of an infectious diseases physician, clinical microbiologist or infection control practitioner. Oseltamivir therapy should be ceased if influenza polymerase chain reaction (PCR) test of a nasopharyngeal swab or aspirate is negative. OR (2) In accord with a QH pandemic influenza protocol.
		45 mg	See above
		75 mg	See above
	Powder for oral liquid	6 mg/ml	(1) On the advice of an Infectious Diseases Physician or a Clinical Microbiologist or in accordance with an Infectious Diseases / Clinical Microbiology approved protocol for: a) Treatment of inpatients who have clinically suspected or laboratory proven influenza who are at high risk of severe disease (not for general use in Emergency Departments unless admission is intended); b) Prophylaxis of inpatients who are close contacts of inpatients with laboratory proven influenza on the advice of an infectious diseases physician, clinical microbiologist or infection control practitioner. Oseltamivir therapy should be ceased if influenza polymerase chain reaction (PCR) test of a nasopharyngeal swab or aspirate is negative. OR (2) In accord with a QH pandemic influenza protocol.
Osimertinib	Tablet		Specialist oncology staff * For discharge and outpatient use as per the PBS indications *
		40 mg	See above
		80 mg	See above
Oxaliplatin	Injection	100 mg/20 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		200 mg/40 mL	See above
Oxazepam	Tablet		
		15 mg	

Drug	Form	Strength	Restriction
Oxcarbazepine	Oral liquid	30 mg	
		60 mg/ml	250mL: For epilepsy not controlled by other drugs
		150 mg	For epilepsy not controlled by other drugs
		300 mg	See above
		600 mg	See above
Oxybuprocaine	Eye drops	0.4%	Inpatient: 0.5mL: For inpatient use only
Oxybutynin	Tablet	5 mg	Treatment of detrusor overactivity where conservative measures have failed
Oxycodone	Capsule	10 mg	For use on the advice of a palliative care physician, for patients with severe pain which is not responding to non-opioid analgesics or where these agents are inappropriate or not tolerated. All other use requires individual patient approval. Caution: The risk of drug dependence is high. * CONTROLLED DRUG *
		20 mg	See above
		10 mg/mL	For use by Pain or Palliative Medicine Specialists and Oncologists where (a) morphine or hydromorphone is contraindicated or provides inadequate analgesia; or (b) transdermal opioids provide inadequate analgesia. Caution: The risk of drug dependence is high. * CONTROLLED DRUG *
	Injection	20 mg/2 mL	See above
		10 mg	a) For use in patients with chronic severe pain requiring daily, continuous, long term therapy which is not responding to non-opioid or first line opioid analgesics or where these agents are inappropriate or not tolerated.
			b) For use in severe pain which is not responding to non-opioid analgesics or where these agents are inappropriate or not tolerated, in patients who are either opioid tolerant or expected to have prolonged post-operative or post-traumatic states. Caution: The risk of drug dependence is high. * CONTROLLED DRUG*
	Modified release tablet	15 mg	See above
		20 mg	See above
		30 mg	See above
		40 mg	See above
		80 mg	For use on the advice of a palliative care physician in patients with chronic severe pain requiring daily, continuous, long term therapy which is not responding to non-opioid or first line opioid analgesics or where these agents are inappropriate or not tolerated. Caution: The risk of drug dependence is high. * CONTROLLED DRUG*
	Oral liquid	1 mg/mL 20mL and 250mL	20mL pack size
			For paediatric use - for severe pain not responding to non-opioid analgesics or where these agents are inappropriate or not tolerated, in patients who:
			a) cannot swallow tablets or capsules and

Drug	Form	Strength	Restriction
Oxycodone + naloxone	Tablet	5 mg	<p>b) are intolerant to morphine or for whom morphine is thought to be inappropriate. Caution: The risk of drug dependence is high. 250mL pack size For severe pain not responding to non-opioid analgesics or where these agents are inappropriate or not tolerated, in patients who:</p> <p>a) cannot swallow tablets or capsules or b) are intolerant to morphine or for whom morphine is thought to be inappropriate. Caution: The risk of drug dependence is high. * CONTROLLED DRUG *</p> <p>* When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *</p> <p>For use in patients with severe pain which is not responding to non-opioid analgesics or where these agents are inappropriate or not tolerated. A maximum quantity of 10 tablets for discharge and outpatient use, except for palliative care patients. Caution: The risk of drug dependence is high. * CONTROLLED DRUG *</p>
	Modified release tablet	<p>2.5 mg + 1.25 mg</p> <p>5 mg + 2.5 mg 10 mg + 5 mg 15 mg + 7.5 mg 20 mg + 10 mg 30 mg + 15 mg 40 mg + 20 mg 60 mg + 30 mg</p> <p>80 mg + 40 mg</p>	<p>a) For use in patients with chronic severe pain requiring daily, continuous, long term therapy which is not responding to non-opioid or first line opioid analgesics or where these agents are inappropriate or not tolerated. b) For use in severe pain which is not responding to non-opioid analgesics, in patients who are either opioid tolerant or expected to have prolonged post-operative or post-traumatic states. Caution: The risk of drug dependence is high. * CONTROLLED DRUG *</p> <p><i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i></p> <p>For discharge and outpatient use on the advice of a palliative care physician in patients with chronic severe pain requiring daily, continuous, long term therapy which is not responding to non-opioid or first line opioid analgesics or where these agents are inappropriate or not tolerated. Caution: The risk of drug dependence is high. * CONTROLLED DRUG *</p> <p><i>See above</i></p>
Oxymetazoline	Nasal spray	0.05%	<p>On the advice of an Ear Nose and Throat specialist for inpatients whose reason for admission to hospital is for the treatment of severe acute sinusitis or severe acute orbital cellulitis secondary to sinus infections. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *</p>
oxyquinoline sulfate, acetic acid and ricinoleic acidIc "Aci-gel"	jelly	0.025%-0.94%-0.75%, 100g	
Oxytocin			



Drug	Form	Strength	Restriction
Oxytocin + ergometrine	Injection	5 units/mL 10 units/mL	
	Injection	5 units/mL + 500 microgram/mL	
Ozanimod	Capsule	920 microgram	For discharge and outpatient use for relapsing-remitting multiple sclerosis only, as per the PBS indication. <i>See above</i>
ozanimod	combination pack	230 microgram (&) 460 microgram	For discharge and outpatient use for relapsing-remitting multiple sclerosis only, as per the PBS indication. <i>See above</i> <i>See above</i>
Paclitaxel	Injection		* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		30 mg/5 mL	<i>See above</i>
		100 mg/16.67 mL	<i>See above</i>
		100 mg/16.7 mL	<i>See above</i>
		150 mg/25 mL	<i>See above</i>
		300 mg/50 mL	<i>See above</i>
Palbociclib	Tablet		For discharge and outpatient use as per the PBS indications where ribociclib is not suitable or not tolerated. Usual individual patient approval (IPA) process applies for continuation of therapy in admitted patients. Caution: For patients admitted to hospital on palbociclib, seek advice from a medical oncologist before continuing therapy.
		75 mg	<i>See above</i>
		100 mg	<i>See above</i>
		125 mg	<i>See above</i>
Paliperidone	Modified release injection		Specialist Psychiatrists for the treatment of schizophrenia. Caution: Note different dosing intervals between products and ensure appropriate product selection. Invega Sustenna, a once-monthly long-acting injection – paliperidone modified release injection 25 mg, 50 mg, 75 mg, 100 mg, 150 mg Invega Trinza, a 3-monthly long-acting injection – paliperidone modified release injection 175 mg/0.875 mL, 263 mg/1.315 mL, 350 mg/1.75 mL, 525 mg/2.625 mL. Invega Hafyera, a 6-monthly long-acting injection – paliperidone modified release injection 700 mg/3.5 mL, 1 g/5 mL.
		1 g/5 mL, Syringe	<i>See above</i>
		25 mg	<i>See above</i>
		50 mg	<i>See above</i>
		75 mg	<i>See above</i>
		100 mg	<i>See above</i>
		150 mg	<i>See above</i>
		175 mg/0.875 mL	<i>See above</i>
		263 mg/1.315 mL	<i>See above</i>
			<i>See above</i>

Drug	Form	Strength	Restriction
Palonosetron	Injection	350 mg/1.75 mL	See above
		525 mg/2.625 mL	See above
		700 mg/3.5 mL, Syringe	See above
		250 microgram/5 mL	* For use as per PBS indications for Related Pharmaceutical Benefits used in conjunction with Efficient Funding of Chemotherapy - Section 100 arrangements. *
Pamidronate disodium	Injection	15 mg/5 mL	(a) treatment of Paget's Disease; (b) severe hypercalcaemia where zoledronic acid is inappropriate or not tolerated; (c) in accord with PBS Section 100 indications * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		30 mg/10 mL	See above
		90 mg/10 mL	(a) severe hypercalcaemia where zoledronic acid is inappropriate or not tolerated; (b) use in accord with PBS Section 100 indications * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
Pancreatic extract (Creon) lipase + amylase + protease	enteric coated granules "Creon Micro"	5000 units/100 mg + 3600 units/100 mg + 200 units/100 mg	
		modified release capsule	
		"Creon 10,000" 10 000 units + 8000 units + 600 units "Creon 25,000" 25 000 units + 18 000 units + 1000 units "Creon 35,000" 35 000 units + 25 200 units + 1400 units	
Panitumumab	Injection		* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		100 mg/5 mL	See above
		400 mg/20 mL	See above
			See above
Pantoprazole	Enteric tablet	20 mg	For use in line with the enteral proton pump inhibitor (PPI) table available on the QH LAM website. Caution – need for ongoing therapy/dose to be reviewed every 3 – 6 months.
		40 mg	See above
	Injection	40 mg	For use (a) in ICU; (b) after endoscopy with high risk stigmata of re-bleeding; or (c) in major upper gastrointestinal haemorrhage
Papaverine	Injection	30 mg/mL	

Drug	Form	Strength	Restriction
para-aminosalicylic acid		120 mg/10 mL	
	Powder for oral liquid	4g	For treatment after approval by the Medical Advisor Tuberculosis and Infectious Diseases, Communicable Diseases Branch or delegate OR Director Regional Tuberculosis Control Unit. The Medical Advisor Tuberculosis and Infectious Diseases should be contacted for any multi-drug or extremely drug resistant cases and can be contacted during business hours via (07) 3328 9724 or email at: <a href="mailto:cdmu@health.qld.gov.au">cdmu@health.qld.gov.au</a> Contact information for Regional TB Control Units is available here. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
Paracetamol	Effervescent tablet	500 mg	For patients with cancer therapy associated mucositis; patients unable to swallow tablets; and in pre-operative areas for use in preference to IV paracetamol.
	Injection	1 g/100 mL	For a maximum of 48 hours for patients unable to take paracetamol by the oral or nasogastric route.
	Oral liquid	24 mg/ml	Children too young to swallow tablets or capsules Care should be taken to avoid accidental overdosage. Caution: - This item is not linking to the correct MIMs dosing information. Please refer to other reference sources. - There are temporarily three different concentrations of paracetamol oral liquid on the LAM as various stock lines are experiencing fluctuations in supply due to coronavirus disease (COVID-19). Holding several concentrations of liquid paracetamol at a site may increase the risk of medication misadventure and should be avoided where practicable.
		50 mg/ml	Care should be taken to avoid accidental overdosage. Caution: - This item is not linking to the correct MIMs dosing information. Please refer to other reference sources. - There are temporarily three different concentrations of paracetamol oral liquid on the LAM as various stock lines are experiencing fluctuations in supply due to coronavirus disease (COVID-19). Holding several concentrations of liquid paracetamol at a site may increase the risk of medication misadventure and should be avoided where practicable.
		100 mg/ml	Care should be taken to avoid accidental overdosage. Caution: There are temporarily three different concentrations of paracetamol oral liquid on the LAM as various stock lines are experiencing fluctuations in supply due to coronavirus disease (COVID-19). Holding several concentrations of liquid paracetamol at a site may increase the risk of medication misadventure and should be avoided where practicable.
	Suppository	125 mg	
		250 mg	
	Tablet	500 mg	
		500 mg	
Paracetamol + codeine	Tablet	500 mg + 30 mg	For use in patients with severe pain which is not responding to non-opioid analgesics or where these agents are inappropriate or not tolerated. In view of safety concerns, codeine is not recommended for use in breastfeeding women, in children under 12 years of age or in children up to 18 years of age after tonsillectomy and/or adenoidectomy.

Drug	Form	Strength	Restriction
paraffin	cream	100g and 500g	
	eye drops	7.5mL	
	liquid	5g tube 200mL	
	oral liquid emulsion	33% 200mL and 500mL 50% 450mL	
Paraffin	Eye ointment	1 g/g	
paraffin white soft	application	5g sterile tube, 100g, 470g/500g	
paraffin white soft and paraffin liquid	ointment	50%-50%, 500g	Epidermolysis Bullosa patients only.  <i>See above</i> <i>See above</i>
paraffin yellow soft	application	100g	
Paraldehyde	Injection	5 mL/5 mL	(Do not use with plastic syringe - only glass)
Parecoxib	Injection	40 mg	For use as a single peri-operative dose for the management of post-operative pain.
PARENTERAL NUTRITION ADULT SOLUTION WITH ELECTROLYTES: amino acids 25.3g/L, glucose 82.5g/L, clinoleic, electrolytes mmol/L (Na 21.0, K 16.0, Ca 2.0, Mg 2.2, PO4 8.5), 700kcal/L (eg 'PeriOlimel N4-600E')			
	intravenous infusion	2L	For use by a Parenteral Nutrition team (or local equivalent) in adult patients unable to maintain nutrition orally or enterally and in whom central parenteral nutrition is either not readily available (i.e. no central access) or the presumed duration of parenteral nutrition is between 3 to 7 days.
PARENTERAL NUTRITION STANDARD ADULT SOLUTION - alternate lipid source, higher protein - with electrolytes; Amino acids 50-60g/L, glucose 100-125g/L, electrolytes mmol/L (Na 35-40, K 30, Ca 2-4, Mg 4-5, PO4 10-15), 1000-1200kcal/L (eg 'Olimel N9')			
	intravenous infusion	2L	For intravenous therapy when oral or enteral feeding is not possible and when patients require a higher kcal:g nitrogen ratio (eg burns, neurosurgery, BMT) or when a product containing fish oil is not suitable.

Drug	Form	Strength	Restriction
PARENTERAL NUTRITION STANDARD ADULT SOLUTION - alternate lipid source, higher protein - without electrolytes; Amino acids 50-60g/L, glucose 100-125g/L, 1000-1200kcal/L (eg 'Olimel N9 electrolyte free')	intravenous infusion	2L	For intravenous therapy when oral or enteral feeding is not possible and when patients require a higher kcal:g nitrogen ratio (eg burns, neurosurgery, BMT) or when a product containing fish oil is not suitable.
PARENTERAL NUTRITION STANDARD ADULT SOLUTION WITH ELECTROLYTES: Fat emulsion with amino acids 40-50g/L, glucose 100-125g/L, electrolytes mmol/L (Na 35-40, K 30, Ca 2-4, Mg 4-5, PO4 10-15), 1000-1200kcal/L (eg 'SMOFKabiven')	intravenous infusion	1L 2L	For intravenous therapy when oral or enteral feeding is not possible. See above
PARENTERAL NUTRITION STANDARD ADULT SOLUTION WITHOUT ELECTROLYTES: Fat emulsion with amino acids 40-50g/L, glucose 100-125g/L, 1000-1200kcal/L (eg 'SMOFKabiven electrolyte free')	intravenous infusion	2L	For intravenous therapy when oral or enteral feeding is not possible.
PARENTERAL NUTRITION STANDARD PAEDIATRIC SOLUTION, high energy density, high protein, high glucose, with electrolytes (30/200): Amino Acids 30g/L, Glucose 200g/L, electrolytes mmol/L (Na 50, K 30, Mg 4, Ca 6, PO4 6, Cl 59.2, Acet 58.5) 917kcal/L	intravenous infusion single chamber bag	1L	Specialist paediatricians for intravenous therapy when oral or enteral feeding is not possible.
PARENTERAL NUTRITION STANDARD PAEDIATRIC SOLUTION, low energy density, low protein, low glucose, with electrolytes (20/100): Amino acids 20g/L, Glucose 100g/L, electrolytes mmol/L (Na 50, K 30, Mg 4, Ca 6, PO4 6, Cl 47.4, Acet 50.4) 479kcal/L			

Drug	Form	Strength	Restriction
	intravenous infusion single chamber bag	1L	Specialist paediatricians for intravenous therapy when oral or enteral feeding is not possible.
PARENTERAL NUTRITION STANDARD PAEDIATRIC SOLUTION, medium energy density, medium protein, medium glucose, with electrolytes (25/150): Amino acids 25g/L, Glucose 150g/L, electrolytes mmol/L (Na 50, K 30, Mg 4, Ca 6, PO4 6, Cl 57.2, Acet 54.5) 699kcal/L	intravenous infusion single chamber bag	1L	Specialist paediatricians for intravenous therapy when oral or enteral feeding is not possible.
Paroxetine	Tablet	20 mg	For major depressive disorders or obsessive-compulsive disorder or panic disorder
Pasireotide embonate	Modified release injection	20 mg 40 mg 60 mg	* For use in accord with PBS Section 100 indications * See above See above
Patent blue V	injection	125mg in 5mL (2.5%)	Lymphangiography. See above See above
Patiomer	Powder for oral liquid	8.4 g, Sachet 16.8 g, Sachet	Specialist medical practitioners (renal medicine) and renal Nurse Practitioners for the management of hyperkalaemia in dialysis patients in the event of a missed dialysis session due to natural disaster. See above See above
Patisiran	Injection	10 mg/5 ml, Vial	For discharge, outpatient and day admitted patient use in accord with PBS Section 100 indications. See above
Pazopanib	Tablet	200 mg 400 mg	* For discharge and outpatient use as per the PBS indications * See above See above
Pegaspargase	Injection	3750 units/5 mL	Haematologists, for the treatment of Acute Lymphoblastic Leukaemia.
Pegcetacoplan	Injection	1.08 g/20 ml, Vial	For discharge, outpatient and day admitted patient use in accord with PBS Section 100 indications for the treatment of paroxysmal nocturnal haemoglobinuria (PNH). See above See above
Pegfilgrastim	Injection	6 mg/0.6 mL	For use in accord with PBS Section 100 indications
Peginterferon alfa-2a			

Drug	Form	Strength	Restriction
Pegvisomant	Injection	135 microgram/0.5 mL	For discharge, outpatient and day admitted patient use in accord with PBS Section 100 indications
		180 microgram/0.5 mL	See above
	Injection		* For use in accord with PBS Section 100 indications *
			See above
		10 mg	See above
15 mg		See above	
Pembrolizumab	Injection	20 mg	See above
			* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
			See above
		100 mg/4 mL	See above
Pemetrexed	Injection		* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
			See above
		1 g	See above
		100 mg	See above
		500 mg	See above
Penicillamine	Tablet		
		125 mg	
Pentamidine	Injection	250 mg	
		300 mg	On the advice of an infectious diseases physician or a clinical microbiologist as second line therapy for treatment of severe Pneumocystis jirovecii pneumonia or prophylaxis
Pentoxifylline	Modified release tablet		
		400 mg	For use in combination with d-alpha-tocopherol (vitamin E), on the advice of Maxillofacial surgery team (MaxFacs) and Ear Nose and Throat (ENT) team for use in combination with surgical intervention for the treatment of osteonecrosis of the jaw for up to six months. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
PEP starter pack A			For post exposure prophylaxis in accordance with Queensland Health guidelines on the management of non-occupational exposure to HIV, and occupational exposure to blood and body fluids in conjunction with Post-exposure Prophylaxis for HIV: Australian National Guidelines. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
	tablet		See above
		Kit containing 3 x tenofovir with emtricitabine tablet 300mg-200mg	See above
PEP starter pack B			For post exposure prophylaxis in accordance with Queensland Health guidelines on the management of non-occupational exposure to HIV, and occupational exposure to blood and body fluids in conjunction with Post-exposure Prophylaxis for HIV: Australian National Guidelines. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *

Drug	Form	Strength	Restriction
Perhexiline	tablet	Kit containing 3 x tenofovir with emtricitabine tablet 300mg-200mg PLUS 6 x raltegravir tablet 400mg	See above
	Tablet	100 mg	See above
Periciazine	Tablet	2.5 mg 10 mg	Specialist Psychiatrists See above See above
Perindopril	Tablet	2.5 mg 5 mg 10 mg	
Perindopril + indapamide	Tablet	5 mg + 1.25 mg	Hypertension in patients who are not adequately controlled with either indapamide or perindopril monotherapy.
Permethrin	Cream	5%	
	Lotion	5%	
Pertuzumab	Injection	420 mg/14 mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
Pethidine	Injection	50 mg/mL 100 mg/2 mL	Anaesthetists, Obstetricians and Country Medical Superintendents. Use in general ward areas and Emergency Departments is discouraged. * CONTROLLED DRUG * See above
Pheniramine	Oral liquid	15 mg/5 ml	
	Tablet	45.3 mg	
Phenobarbital	Injection	200 mg/mL	Note: For use in Status Epilepticus in children, refer to the statewide paediatric guideline. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
	Oral liquid	15 mg/5 ml	
	Tablet	30 mg	Patients unable to swallow tablets
phenol	injection	5% in Oil 5mL 6%, 10mL (aqueous)	



Drug	Form	Strength	Restriction
Phenoxybenzamine	Capsule	10 mg	For treatment of severe vasospastic disorders
Phenoxymethylpenicillin	Capsule	250 mg	Children too young to swallow tablets or capsules See above
		500 mg	
	Oral liquid	125 mg/5 ml	
		250 mg/5 ml	
Phentolamine	Injection	10 mg/mL	* For use in accord with Special Access Scheme (SAS) arrangements ** Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
Phenylephrine	Eye drops	2.5%	For inpatient use only. See above
		10%	
	Injection	10 mg/mL (1%)	For anaesthetics
phenylephrine	nasal drops	0.25% 15mL	
Phenytoin	Capsule	30 mg	Note: For use in Status Epilepticus in children, refer to the statewide paediatric guideline <i>See above</i>
		100 mg	
	Chewable tablet	50 mg	
	Injection	100 mg/2 mL	
		250 mg/5 mL	
	Oral liquid	30 mg/5 ml	Children too young to swallow tablets or capsules
phosphate	injection	sodium dihydrogen phosphate (No K Phos) - (10mL vial contains - phosphate 10mmol, sodium 10mmol)	
phosphate (Elemental Phosphorus 436mg per 50mL, Na 434 mmol/L, PO4 280 mmol/L) Parfitt's Mixture	mixture	50mL	
Phosphorus	Effervescent tablet	500 mg	
physostigmine	injection	1mg in 2mL	
Phytomenadione	Capsule	10 mg	

Drug	Form	Strength	Restriction
Picosulfate	Injection	2 mg/0.2 mL 10 mg/mL	
	Oral liquid	7.5 mg/ml	For constipation in palliative care patients where other agents are not tolerated.
Picosulfate + magnesium oxide + citric acid	Powder for oral liquid	10 mg + 3.5 g + 12 g	On the advice of a paediatric gastroenterologist for use in paediatric patients requiring bowel cleansing prior to bowel examination by endoscopy, radiography or surgery.
Pilocarpine	Eye drops	1% 2% 3% 4%	For inpatient use only.
	eye drops minims	2%	
pilocarpine	eye drops	0.125% 15mL	
Pimecrolimus	Cream	1%	Dermatologists and ophthalmologists for discharge and outpatient use as per the PBS indications .
Pindolol	Tablet	5 mg 15 mg	
Pioglitazone	Tablet	15 mg 30 mg 45 mg	* For use as per the PBS indications * <i>See above</i> <i>See above</i> <i>See above</i>
Piperacillin + tazobactam	Injection	4 g + 500 mg	On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol.
Pirfenidone	Capsule	267 mg	* For discharge and outpatient use as per the PBS indications *
Pizotifen	Tablet	500 microgram	
plague vaccine	injection	1.5 x 1,000,000,000 organisms in 0.5mL	
plastic wound dressing	spray	aerosol	
Plerixafor	Injection	24 mg/1.2 mL	* For use in accord with PBS Section 100 indications *

Drug	Form	Strength	Restriction
Pneumococcal 13 valent conjugate vaccine	Injection	0.5 mL Syringe	Patients who are not eligible for National Immunisation Program (NIP) funded (VIVAS) stock and are at highest increased risk of invasive pneumococcal disease due to (i) functional or anatomical asplenia, (ii) cochlear implant, (iii) unrepairable cerebrospinal fluid leak, (iv) stem cell transplant, (v) HIV with CD4 count <200, (vi) solid organ transplant - to be given pre-transplant in cardiac, lung and high-risk (ABO-incompatible or paired kidney exchange program) renal patients. <i>See above</i> <i>See above</i>
Pneumococcal 23 valent vaccine	Injection	0.5 mL Vial	For persons who are not eligible for National Immunisation Program (NIP) funded (VIVAS) stock and are at high risk of pneumococcal infections. <i>See above</i> <i>See above</i>
podophyllotoxin	application	0.5%, paint 3.5mL	
Poloxamer	Oral liquid	100 mg/ml	Children too young to swallow tablets or capsules
Polyvalent Australian snake antivenom	Injection	1 Vial	
Polyvinyl alcohol	Eye drops	1.4%	
polyvinyl alcohol with povidone	eye drops	1.4% with 0.6%, 0.4mL	Where other ocular lubricants are inappropriate
Pomalidomide	Capsule	3 mg 4 mg	* For use in accord with PBS Section 100 indications * <i>See above</i>
Ponatinib	Tablet	15 mg 45 mg	* For discharge and outpatient use as per the PBS indications * <i>See above</i>
Poractant alfa	Intratracheal suspension	120 mg/1.5 mL 240 mg/3 mL	For use in respiratory distress in neonates on the advice of a neonatologist (which can be retrospective) <i>See above</i> <i>See above</i>
Posaconazole	Injection	300 mg/16.7 mL	After advice on each individual case by an infectious diseases physician or a clinical microbiologist for treatment of severe invasive fungal infections unable to be treated by standard systemic antifungal therapy and where oral therapy is unsuitable or gastrointestinal disease causes impaired absorption. Patients should be transitioned to oral posaconazole as soon as feasible.
	Modified release tablet		

Drug	Form	Strength	Restriction
		100 mg	(a) After advice on each individual case by an infectious diseases physician or a clinical microbiologist for treatment of severe invasive fungal infections unable to be treated by standard systemic antifungal therapy; or (b) As part of an infectious diseases approved protocol for prophylaxis of invasive fungal infections, including both yeasts and moulds, in patients who are at high risk of developing these infections, defined as follows: (i) Neutropenic patients with anticipated neutropenia (an absolute neutrophil count of less than 500 cells per cubic millimetre) for at least 10 days, who are receiving chemotherapy for acute myelogenous leukaemia or myelodysplastic syndrome. (ii) Graft versus host disease (GVHD) patients with acute GVHD grades II to IV or extensive chronic GVHD, who are receiving intensive immunosuppressive therapy after allogeneic haematopoietic stem cell transplant for up to 6 months. Extension past this time requires individual patient approval. NOTE: This preparation is not interchangeable with other posaconazole preparations.
	Oral liquid	40 mg/ml	For paediatric patients who are unable to swallow posaconazole tablets (a) on the advice of an infectious diseases physician or a clinical microbiologist for treatment of severe invasive fungal infections unable to be treated by standard systemic antifungal therapy; or (b) as part of an infectious diseases approved protocol for prophylaxis of invasive fungal infections, including both yeasts and moulds, in patients who are at high risk of developing these infections, defined as follows: (i) Neutropenic patients with anticipated neutropenia (an absolute neutrophil count of less than 500 cells per cubic millimetre) for at least 10 days, who are receiving chemotherapy for acute myelogenous leukaemia or myelodysplastic syndrome. (ii) Graft versus host disease (GVHD) patients with acute GVHD grades II to IV or extensive chronic GVHD, who are receiving intensive immunosuppressive therapy after allogeneic haematopoietic stem cell transplant for up to 6 months. Extension past this time requires individual patient approval. NOTE: This preparation is not interchangeable with other posaconazole preparations.
Potassium acetate	Injection	2.45 g/5 mL	
Potassium chloride	Injection	750 mg/10 mL	For use only in critical care, oncology/haematology and paediatric high dependency units for the replacement of potassium when an intravenous potassium premix preparation does not fulfil the needs of the patient.
	Modified release tablet	600 mg (potassium 8 mmol)	
potassium chloride	intravenous infusion in glucose and sodium chloride	20mmol/L (0.15%) in Glucose 3.3% and Sodium Chloride 0.3% (125 Cal per litre) (Potassium 20, Sodium 51, Chloride 71 mmol per litre) 20mmol/L (0.15%) in Glucose 5% Sodium Chloride 0.45% (200 Cal per litre) (Potassium 20, Sodium 77, Chloride 97mmol per litre) 20mmol/L (0.15%) in Glucose 5% and Sodium Chloride 0.9% 40mmol/L (0.298%) in in Glucose 3.3% and Sodium Chloride 0.3% (125 Cal per litre) (Sodium 50, Potassium 40, Chloride 90 mmol per litre)	
	intravenous infusion in sodium chloride		

Drug	Form	Strength	Restriction
Potassium chloride + potassium bicarbonate + potassium carbonate	intravenous infusion in sodium chloride "mini bag"	20mmol/L (0.15%) in Sodium Chloride 0.9% (Potassium 20, Sodium 154, Chloride 174 mmol per litre)	For use only via a central line in critical care or in oncology/haematology units or under the authorisation of a consultant if the patient is in a non-critical care environment, for severe hypokalaemia (serum potassium equal to or less than 2.5mmol/L). Appropriate monitoring is required.
		40mmol/L (0.298%) in Sodium Chloride 0.9% (Sodium 150, Potassium 40, Chloride 190 mmol per litre)	
	oral liquid	10mmol/100mL in Sodium Chloride 0.29% (Potassium 10, Sodium 5, Chloride 15 mmol per 100mL bag) 40mmol/100mL (2.98%) in Sodium Chloride 0.9% (Sodium 15, Potassium 40, Chloride 55 mmol per 100mL)	
	solution	10% (20mmol potassium in 15mL), 500mL	
Potassium citrate	Effervescent tablet	595 mg + 384 mg + 152 mg (total potassium 14 mmol)	
potassium citrate	Modified release tablet	1.08 g (potassium 10 mmol)	For the prevention of renal calculi in patients with hypocitraturia.
	oral liquid solution	2g/10mL	Carbohydrate Containing Formula (APF) (2g/10mL, 200mL): For the prevention of renal calculi in patients with hypocitraturia. Carbohydrate Free Formula (QH-CP) (2g/10mL, 200mL): Paediatric service medical staff or authorised prescribers for use in paediatric patients on a medically recommended ketogenic diet under the care of the QCH Neurosciences or using the protocols of the tertiary referral centre for ketogenic diet.
Potassium permanganate	Powder	1 g/g	
povidone-iodine	aqueous solution	[*STERILE*] 10% tube (30mL) or sachet (22.5mL)	Procedures where sterile povidone-iodine is clinically indicated in the health facility's perioperative unit and procedural areas. Use alternative products if sterile povidone-iodine is not clinically required.
	aqueous swab	10%, 100mL and 500mL	
	ointment sachet	pack 100 10%	
	surgical hand wash	10%, 1.5g 10%, 25g	
	swab stick	7.5%, 1.5L 7.5%, 500mL	
		swab	
Pralatrexate	Injection	20 mg/mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *

Drug	Form	Strength	Restriction
Pralidoxime iodide	Injection	2.5% (500 mg/20 mL)	
Pramipexole	Modified release tablet	1.5 mg 3 mg 4.5 mg 375 microgram 750 microgram	For the treatment of Parkinson disease as per the PBS indications. See above See above See above See above
	Tablet	1 mg 125 microgram 250 microgram	For the treatment of Parkinson Disease as per the PBS indications For the treatment of Parkinson Disease and severe primary restless legs as per the PBS indications See above
Pravastatin	Tablet	20 mg 40 mg	* For use as per the PBS indications * See above
Praziquantel	Tablet	600 mg	Treatment after approval by an Infectious Diseases physician or a Clinical Microbiologist or when used in accord with an infectious diseases approved protocol of adults and children with Schistosomiasis, Hymenolepis nana (Dwarf tapeworm), Taenia saginata, Opisthorchis viverrine or Clonorchis sinensis or as an adjunct to surgical therapy of hydatid disease.
Prazosin	Tablet	1 mg 2 mg 5 mg	
Prednisolone	Tablet	1 mg 5 mg 25 mg	
Prednisolone acetate + phenylephrine	Eye drops	1% + 0.12%	Specialist Ophthalmologists
Prednisolone sodium phosphate	Enema	20 mg/100 ml	
	Eye drops	0.5%	Specialist Ophthalmologists
	Oral liquid	5 mg/ml	
	Suppository	5 mg	
Pregabalin	Capsule		* For use as per the PBS indications * Note: Initiate pregabalin in preference to gabapentin for neuropathic pain where clinically appropriate Caution: Consider potential for abuse or diversion with this medicine

Drug	Form	Strength	Restriction
		25 mg	See above
		75 mg	See above
		150 mg	See above
		300 mg	See above
Prilocaine	Injection	0.5% (250 mg/50 mL) (hyperbaric) 2% (100 mg/5 mL), Ampoule	Anaesthetists for intrathecal administration for spinal anaesthesia in short-term surgical procedures.
	Intrathecal injection		
Prilocaine + felypressin	Injection	3% (66 mg/2.2 mL) + 0.066 units/2.2 mL	For dental use
Primaquine	Tablet	7.5 mg	
Primidone	Tablet	250 mg	
Probenecid	Tablet	500 mg	
Procaine benzylpenicillin	Injection	1.5 g/3.4 mL	
Procarbazine	Capsule	50 mg	
Prochlorperazine	Injection	12.5 mg/mL	
	Suppository	25 mg	
	Tablet	5 mg	
Progesterone	Pessary	200 mg	Medical specialist staff in Obstetrics and Gynaecology for: a) Prevention of preterm birth in women with shortened cervix and those with short cervixes in singleton pregnancies. b) Threatened first trimester miscarriage with a viable intrauterine pregnancy (confirmed on ultrasound) AND vaginal bleeding AND a history of recurrent miscarriage. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
Promethazine	Injection	50 mg/2 mL	Caution - Administration of promethazine hydrochloride injection, regardless of the route, can cause severe chemical irritation and tissue damage due to extravasation or unintentional intra-arterial injection. Adverse reactions include burning, pain, thrombophlebitis, tissue necrosis and gangrene. Due to the risks of intravenous injection, the preferred route of administration of promethazine is orally unless a central venous line is used. Deep intramuscular injection could be used in exceptional circumstances. Subcutaneous injection is contraindicated.

Drug	Form	Strength	Restriction
	Oral liquid	5 mg/5 ml	Caution - not to be used for anaphylaxis.
	Tablet		For use in children where a solid oral dosage form is unsuitable.
		10 mg 25 mg	
Propantheline	Tablet	15 mg	
Propofol	Injection	1 g/100 mL 200 mg/20 mL 500 mg/50 mL	
propranolol	oral liquid	10mg in 5mL, 100mL	For paediatric use only.
Propranolol	Tablet	10 mg 40 mg 160 mg	
Propylthiouracil	Tablet	50 mg	For use in adult patients only, second line to carbimazole except for the following cases: (a) patients who are in their first trimester of pregnancy; (b) patients who are allergic to or intolerant of carbimazole; (c) thyroid storm
Protamine sulfate	Injection	50 mg/5 mL	
prothionamide	tablet	250mg	For treatment after approval by the Medical Advisor Tuberculosis and Infectious Diseases, Communicable Diseases Branch or delegate OR Director Regional Tuberculosis Control Unit. The Medical Advisor Tuberculosis and Infectious Diseases should be contacted for any multi-drug or extremely drug resistant cases and can be contacted during business hours via (07) 3328 9724 or email at: <a href="mailto:cdmu@health.qld.gov.au">cdmu@health.qld.gov.au</a> Contact information for Regional TB Control Units is available here. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
Pseudoephedrine	Tablet	60 mg	Patients with autonomic insufficiency
Psyllium husk powder	Powder for oral liquid		
psyllium husk powder	powder for oral liquid sachet	5g	
Pyrantel	Tablet	125 mg	Alternative treatment of adults and children with Enterobius vermicularis (Pinworm), Ancylostoma caninum (Eosinophilic enterocolitis), Ancylostoma duodenale/Necator americanus (Hookworm) or Ascaris lumbricoides (Roundworm).



Drug	Form	Strength	Restriction
Pyrazinamide	Tablet	500 mg	
Pyridostigmine	Modified release tablet	180 mg	
	Tablet	10 mg 60 mg	
Pyridoxine	Tablet	25 mg	
Pyrimethamine	Tablet	25 mg	
Quetiapine	Modified release tablet		For use in schizophrenia following failure of aripiprazole, risperidone, olanzapine, amisulpride or lurasidone; For use in bipolar disorder as per the PBS indications and for bipolar depression as per the TGA indications.
		50 mg	See above
		150 mg	See above
		200 mg	See above
		300 mg	See above
		400 mg	See above
	Tablet		See above
		25 mg	See above
		100 mg	See above
		200 mg	See above
Quinine	Injection	600 mg/10 mL (6%)	For the treatment of malaria. See above
	Tablet	300 mg	See above See above
Raltegravir	Tablet	400 mg	For use in accord with PBS Section 100 indications For post exposure prophylaxis in accordance with Queensland Health guidelines on the management of non-occupational exposure to HIV, and occupational exposure to blood and body fluids in conjunction with Post-exposure Prophylaxis for HIV: Australian National Guidelines. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		600 mg	* For use in accord with PBS Section 100 indications *
Raltitrexed	Injection	2 mg	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
Ramipril	Tablet	1.25 mg	

Drug	Form	Strength	Restriction
Ranibizumab	Injection	2.5 mg 5 mg 10 mg	
		1.65 mg/0.165 mL	* For discharge and outpatient use as per the PBS indications *
Rasagiline	Tablet	1 mg	For Parkinson disease as per the PBS indications
Rasburicase	Injection	1.5 mg	For use in paediatric patients on the advice of a haematologist or paediatric oncologist, to prevent and treat hyperuricaemia manifestations of tumour lysis syndrome. For use in adult patients, this medicine is not LAM listed - individual patient approval is required. QHMAC guidance on rasburicase use in children and adults is provided below - see 'Guidelines and Other Resources' section.
Ravulizumab	Injection		For discharge, outpatient and day admitted patient use in accord with PBS Section 100 indications for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS).
		1.1 g/11 mL 300 mg/3 mL	See above See above
Red back spider antivenom	Injection	500 units, Vial	
Remdesivir	Injection	100 mg/20 mL	On the advice of a specialist physician: (a) For severe COVID-19 in patients that require oxygen but do not require non-invasive or invasive ventilation; (b) within seven days of symptom onset of mild or moderate COVID-19 (i.e. not requiring oxygen) in unvaccinated, immunocompromised, or pregnant adults who have risk factors for disease progression.
Remifentanyl	Injection		Specialist Anaesthetists for use during induction and/or maintenance of general anaesthesia when endotracheal intubation and controlled ventilation are anticipated * CONTROLLED DRUG *
		1 mg	See above
		2 mg	See above
		5 mg	See above
Resorcinol	cream	15% in antioxidant base (QH-CP)	Dermatologists for use in the treatment of hidradenitis suppurativa. See above
Ribociclib	Tablet	200 mg	* For discharge and outpatient use as per the PBS indications * Usual individual patient approval (IPA) process applies for continuation of therapy in admitted patients. Caution: For patients admitted to hospital on ribociclib, seek advice from a medical oncologist before continuing therapy.
Riboflavin (Trans-epithelial kit) - (Paracel - Vibextra, 2-syringe procedure)			Specialist Ophthalmologists for use in corneal collagen crosslinking (CXL) procedures to treat patients with progressive keratoconus. * For use in accord with Special Access Scheme (SAS) arrangements ** Where a medicine is not

Drug	Form	Strength	Restriction
Riboflavin (VibexRapid)	eye solution	0.25%, 2mL (SAS)	TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained * See above See above
	eye solution	0.1%, 1.5mL (SAS)	Specialist Ophthalmologists for use in corneal collagen crosslinking (CXL) procedures to treat patients with progressive keratoconus. * For use in accord with Special Access Scheme (SAS) arrangements ** Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained * See above See above
Rifabutin	Capsule	150 mg	For use in accord with PBS Section 100 indications; For use as part of combination therapy for Helicobacter Pylori when first-line therapy has failed or for proven resistance to Helicobacter Pylori combination therapy; or * On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
Rifampicin	Capsule	150 mg	a) Treatment of TB and leprosy b) Thoracic physicians for the treatment of Mycobacterium avium complex pulmonary infection in adults; c) all other infections on the advice of an infectious diseases physician, clinical microbiologist, or in conjunction with an antimicrobial stewardship (AMS) team protocol
		300 mg	a) Treatment of TB and leprosy [available as a component of the leprosy WHO calendar packs]; b) Thoracic physicians for the treatment of Mycobacterium avium complex pulmonary infection in adults; c) all other infections on the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol
	Injection	600 mg	For treatment of infections on the advice of an Infectious Diseases Physician or a Clinical Microbiologist
	Oral liquid	100 mg/5 ml	a) Children too young to swallow tablets or capsules * On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. * b) Thoracic physicians for the treatment of Mycobacterium avium complex pulmonary infection in adults.
Rifaximin	Tablet	550 mg	* For discharge and outpatient use as per the PBS indications *
Rilpivirine	Tablet	25 mg	* For use in accord with PBS Section 100 indications *
ringers solution (compound sodium chloride)	injection sterile irrigation solution	500mL Pour bottle	
Riociguat	Tablet		* For use in accord with PBS Section 100 indications *
		1 mg	See above See above

Drug	Form	Strength	Restriction
Risdiplam		1.5 mg	See above
		2 mg	See above
		2.5 mg	See above
		500 microgram	See above
Risedronate	Powder for oral liquid	750 microgram/ml	* For use in accord with PBS Section 100 indications * See above
Risperidone	Tablet	35 mg	* For use as per the PBS indications *
	Modified release injection	25 mg	Specialist Psychiatrists for: a) Schizophrenia for continuation therapy in inpatients, for initiation in inpatients when paliperidone is not clinically suitable, and for outpatient use b) Maintenance treatment, in combination with lithium or sodium valproate, of treatment refractory bipolar I disorder.
		37.5 mg	See above
		50 mg	See above
	Oral liquid	1 mg/ml	100mL: For use as per the PBS indications 30mL: Specialist psychiatrists and paediatricians for (a) behavioural disturbances; (b) schizophrenia; (c) bipolar disorder; and (d) autism spectrum disorder. The PBS indications of risperidone oral solution 1mg per mL, 100mL should be consulted and followed.
	Tablet	1 mg	* For use as per the PBS indications *
		2 mg	See above
		3 mg	See above
		4 mg	See above
		500 microgram	(a) For use as per the PBS indications; (b) For the symptomatic management of severe behavioural disturbance secondary to delirium when non-pharmacological strategies have been unsuccessful and in consultation with a geriatrician or psychiatrist. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
Ritonavir	Oral liquid	600 mg/7.5 ml	* For use in accord with PBS Section 100 indications *
	Tablet	100 mg	* For use in accord with PBS Section 100 indications *
Rituximab (Riximyo)	Injection		Outpatient and day admitted patient use: Specialist physicians for a condition in which rituximab is considered clinically appropriate, as per the PBS S100 HSD and S100 EFC listings. Inpatient use: via individual patient approval (IPA) / other local approval mechanism, except if used for the following indications: (i) On the advice of a haematologist for thrombotic thrombocytopenia purpura (TTP) in patients with

Drug	Form	Strength	Restriction
			suboptimal response to standard treatment (e.g. plasma exchange and high-dose steroids) or with relapsed disease; (ii) Specialist oncologists or haematologists for chemotherapy. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		100 mg/10 mL 500 mg/50 mL	<i>See above</i> <i>See above</i>
Rivaroxaban	Tablet	2.5 mg	(a) For use as per the PBS indications (b) On the advice of paediatric Haematologists for the treatment of venous thromboembolism (lower or upper limb extremity DVT), right atrial thrombosis, pulmonary embolism, catheter related thrombosis, cerebral venous sinus thrombosis, portal vein thrombosis or renal vein thrombosis in paediatric patients. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		10 mg	(a) For use as per the PBS indications; or (b) Venous thromboembolism (VTE) prophylaxis for inpatients previously diagnosed with heparin induced thrombocytopenia (HIT) (c) On the advice of paediatric Haematologists for the treatment of venous thromboembolism (lower or upper limb extremity DVT), right atrial thrombosis, pulmonary embolism, catheter related thrombosis, cerebral venous sinus thrombosis, portal vein thrombosis or renal vein thrombosis in paediatric patients. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		15 mg	(a) For use as per the PBS indications; or (b) For use as an alternative anticoagulant therapy for management of heparin induced thrombocytopenia (HIT) in patients with a calculated GFR greater than 15 mL/min. Note: patients must be under the care of a Consultant Physician with consideration for an additional Haematology consultation. (c) On the advice of paediatric Haematologists for the treatment of venous thromboembolism (lower or upper limb extremity DVT), right atrial thrombosis, pulmonary embolism, catheter related thrombosis, cerebral venous sinus thrombosis, portal vein thrombosis or renal vein thrombosis in paediatric patients. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		20 mg	<i>See above</i>
rivaroxaban granules for oral suspension	granules	1mg/mL	On the advice of paediatric Haematologists for the treatment of venous thromboembolism (lower or upper limb extremity DVT), right atrial thrombosis, pulmonary embolism, catheter related thrombosis, cerebral venous sinus thrombosis, portal vein thrombosis or renal vein thrombosis in paediatric patients.
Rocuronium	Injection		

Drug	Form	Strength	Restriction
Romiplostim	Injection	50 mg/5 mL	Medical staff skilled in airway support
		250 microgram	For discharge, outpatient and day admitted patient use in accord with PBS Section 100 indications
		500 microgram	See above
Ropivacaine	Injection	0.2% (20 mg/10 mL) 0.2% (40 mg/20 mL) 0.2% (200 mg/100 mL) 0.2% (400 mg/200 mL) 0.75% (75 mg/10 mL) 0.75% (150 mg/20 mL) 1% (100 mg/10 mL) 1% (200 mg/20 mL)	See above
ropivacaine (Baxter)	infusion	(0.1%) 200mg in 200mL	
Ropivacaine + fentanyl	epidural infusion	200 mg/100 mL + 200 microgram/100 mL 400 mg/200 mL + 400 microgram/200 mL 400 mg/200 mL + 800 microgram/200 mL	For use in epidural anaesthesia. * CONTROLLED DRUG * See above See above See above
ropivacaine + fentanyl (Baxter)	epidural infusion	(0.1%) 200mg + 400 microgram/200mL, 200mL	* CONTROLLED DRUG *
Rosuvastatin	Tablet	5 mg 10 mg 20 mg 40 mg	* For use as per the PBS indications * See above See above See above See above
Rotigotine	Patch	2 mg/24 hours 4 mg/24 hours 6 mg/24 hours 8 mg/24 hours	(a) For discharge and outpatient use as per the PBS indications; (b) For inpatient use, on the advice of a neurologist or geriatrician, where oral or nasogastric therapy is not possible/suitable. See above See above See above See above
Roxithromycin	Dispersible tablet	50 mg	
	Tablet	150 mg 300 mg	
Rufinamide	Tablet		Neurologists for use as adjunctive therapy in the treatment of seizures associated with Lennox Gastaut Syndrome in patients 4 years of age or older, such patients having had appropriate trials of standard antiepileptic therapies for this condition (valproate, lamotrigine, topiramate, clobazam) unless intolerable side effects or contraindicated.

Drug	Form	Strength	Restriction
Ruxolitinib	Tablet	200 mg	See above
		400 mg	See above
		5 mg	(a) For discharge and outpatient use for myelofibrosis, as per the PBS indications; (b) For discharge, outpatient and day admitted patient use in accord with PBS Section 100 indications.
		10 mg	See above
		15 mg	For discharge and outpatient use for myelofibrosis, as per the PBS indications.
Sacituzumab govitecan	Injection	20 mg	See above
		180 mg	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
Sacubitril + valsartan	Tablet		See above
		24.3 mg + 25.7 mg	See above
		48.6 mg + 51.4 mg	See above
		97.2 mg + 102.8 mg	See above
Salbutamol	Inhalation	100 microgram/actuation	
	Inhalation solution	2.5 mg/2.5 mL	For use where treatment with this drug delivered from an oral pressurised inhalation device via a large volume spacer is inappropriate.
	Injection	5 mg/2.5 mL	See above
		5 mg/5 mL	Obstetric use only
		500 microgram/mL	
	Oral liquid	2 mg/5 ml	Children too young to swallow tablets or capsules
salicylic acid	ointment	(in Soft Paraffin) 3%, 100g (in Soft Paraffin) 5%, 100g (in Soft Paraffin) 12%, 50g (in Soft Paraffin) 20%, 50g	
	paste	(in Paraffin Base) 2% in Zinc Oxide Co Paste, 100g	Lassar's Paste
Salicylic acid	oral gel	8.7%	15g
salicylic acid and lactic acid (A.P.F.)	application	paint 20%-20%, 15mL	
Sapropterin	Powder for oral liquid	500 mg	a) * For use as per the PBS indications * b) For use in infants (under 1 month of age) who have been identified by the Queensland Newborn Screening Program with an elevated phenylalanine level likely related to hyperphenylalaninaemia due to BH4 deficiency or Phenylketonuria (PKU)

Drug	Form	Strength	Restriction
	Soluble tablet	100 mg	a) * For use as per the PBS indications * b) For use in infants (under 1 month of age) who have been identified by the Queensland Newborn Screening Program with an elevated phenylalanine level likely related to hyperphenylalaninaemia due to BH4 deficiency or Phenylketonuria (PKU)
Sea snake antivenom	Injection	1000 units, Vial	
Secukinumab	Injection	150 mg/mL	* For discharge and outpatient use as per the PBS indications *
Selexipag	Tablet	1 mg 1.2 mg 1.4 mg 1.6 mg 200 microgram 400 microgram 600 microgram 800 microgram	* For use in accord with PBS Section 100 indications * <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i>
Selinexor	Tablet	20 mg	For discharge, outpatient and day admitted patient use in accord with PBS Section 100 indications. <i>See above</i>
Semaglutide	Injection	1.34 mg/mL, 2mg/1.5mL (0.25mg or 0.5mg per dose prefilled pen) 1.34 mg/mL, 4mg/3mL (1mg per dose prefilled pen)	* For use as per the PBS indications * <i>See above</i>
Senna leaf powder + fig + date	Bar	1 g/10 g + 3 g/10 g + 3 g/10 g	For inpatient use only.
Sennoside B	Tablet	7.5 mg	
Sertraline	Tablet	50 mg 100 mg	For major depressive disorders or obsessive-compulsive disorder or panic disorder where other treatments have failed or are inappropriate. <i>See above</i> <i>See above</i>
Sesame oil	Nasal spray	1 ml/ml	Patients undergoing radiotherapy to nose and sinuses; for postoperative use following sinus surgery; and for use in inpatients only for the relief of nasal symptoms associated with continuous positive airway pressure (CPAP) therapy. <i>See above</i>
Sevelamer	Tablet	800 mg	For use in accord with PBS Section 100 indications (for initiation and stabilisation of treatment); For use as per the PBS indications (for maintenance therapy).
Sevoflurane	Inhalation solution		



Drug	Form	Strength	Restriction
sildenafil	oral liquid suspension	1 ml/ml	For use down to a minimum fresh gas flow of one litre per minute. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		2mg per mL, 200mL	Paediatric cardiac specialists
Sildenafil	Tablet	20 mg	(a) For use in accord with PBS Section 100 indications; (b) For use under the guidance of paediatric cardiac specialists.
silicone	cream	2.5% 500mL	For back rubbing
Siltuximab	Injection	100 mg	For discharge, outpatient and day admitted patient use in accord with PBS Section 100 indications
		400 mg	See above
Silver nitrate	Stick		
Silver sulfadiazine	Cream	1% 50g, 500g	Specialist Staff, Country Medical Superintendents and Endorsed Podiatrists
Simethicone	Oral liquid	100 mg/ml	Specialist radiological and endoscopic procedures
	Powder	125 mg	Specialist radiological and endoscopic procedures
Simvastatin	Tablet	20 mg	* For use as per the PBS indications *
		40 mg	See above
			See above
Sirolimus	Oral liquid	1 mg/ml	* For use in accord with PBS Section 100 indications *
	Tablet	1 mg	* For use in accord with PBS Section 100 indications *
		2 mg	See above
sirolimus in white soft paraffin QH-CP	ointment	500 microgram	See above
		0.1% 50g	(a) For use in therapy initiated by Tuberous Sclerosis Complex Clinic specialists (paediatric neurologists, renal physicians and dermatologists) in patients with tuberous sclerosis for topical treatment of facial angiofibroma and other dermatological manifestations. (b) Renal physicians and dermatologists for use in adult patients with tuberous sclerosis for topical treatment of facial angiofibroma and other dermatological manifestations. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
		0.5% 50g	See above
			See above
Sitagliptin			* For use as per the PBS indications *

Drug	Form	Strength	Restriction
	Tablet		See above
		25 mg	See above
		50 mg	See above
		100 mg	See above
Sodium acetate	Injection	1.64 g/10 mL	
Sodium alginate + bicarbonate + calcium carbonate	Oral liquid		For infant use only
		500 mg/10 mL + 213 mg/10 mL + 325 mg/10 mL	See above
		500 mg/10 mL + 267 mg/10 mL + 160 mg/10 mL	See above
Sodium aurothiomalate	Injection		
		10 mg/0.5 mL	
		20 mg/0.5 mL	
		50 mg/0.5 mL	
sodium bicarbonate	ear drops	3% in 75% Glycerol, 15mL	
	mouthwash	1% 500mL	
	oral liquid	8.4%, 200mL	
Sodium bicarbonate	Capsule	840 mg	
	Injection	8.4% (8.4 g/100 mL), Vial	
sodium calcium edetate	injection	200mg/mL, 5mL	
sodium chloride	eye drops	5% 10mL	Specialist Ophthalmologists
	inhalation solution	sterile 6% solution for nebulisation 10mL sachet	For use in patients with cystic fibrosis, infants with acute bronchiolitis and for sputum induction as required.
	injection	0.9% (154 mmol per /litre) Injection in glass 50mL	
		0.9% (154 mmol per /litre) in glass 100mL	
		0.9% (154 mmol per /litre) in plastic 100mL	For use in Eye Wards; Eye Outpatients and Eye Casualty
	intravenous infusion injection	0.9% (154 mmol per litre) 1 Litre	
		0.9% (154 mmol per litre) 50mL	
		0.9% (154 mmol per litre) 250mL	
		0.9% (154 mmol per litre) 500mL	
		3% (510 mmol per litre) 250mL	For use only in emergency departments, critical care and high dependency units.
	irrigation solution	sterile 0.9% 1 Litre pour bottle	
		sterile uromatic 0.9% 2 Litre	
		sterile uromatic 0.9% 3 Litre	
		sterile 0.9% 100mL	

Drug	Form	Strength	Restriction
Sodium chloride	pre-filled syringe "PosiFlush" 5mL	sterile 0.9% 500mL	
		0.9%, 5mL	
	Injection	0.9% (45 mg/5 mL) 0.9% (90 mg/10 mL) 0.9% (900 mg/100 mL) 23.4% (40mmol/10 mL)	For use in Eye Wards; Eye Outpatients and Eye Casualty For use only in emergency departments, critical care and high dependency units.
	Soluble tablet	600 mg	
sodium chloride "auspman brand"	oral liquid	2mmol/mL, 100mL	For treatment of hyponatraemia in paediatric patients who are unable to swallow tablets when intravenous therapy is not indicated <i>See above</i> <i>See above</i>
Sodium chloride + potassium chloride + calcium chloride + magnesium chloride + acetate + citric acid	Solution	6.4 mg/ml + 750 microgram/ml + 480 microgram/ml + ...	30mL: Eye casualty only 120mL: Ophthalmologists
sodium chloride + potassium citrate monohydrate + glucose + citric acid	Oral liquid	62.5 mL Sachet	Paediatric Use
	Powder for oral liquid	530 mg + 440 mg (potassium 4 mmol) + 2.91 g + ...	
sodium chloride + sodium gluconate + sodium acetate trihydrate + potassium chloride + magnesium chloride	Injection	5.26 g/L + 5.02 g/L + 3.68 g/L + ...	
sodium chloride + sodium gluconate + sodium acetate trihydrate + potassium chloride + magnesium chloride + glucose	Injection	5.26 g/L + 5.02 g/L + 3.68 g/L + ...	On the advice of paediatric intensivists.
sodium chloride with electrolytes - Sodium Chloride 0.64%, Potassium Chloride 0.075%, Magnesium Chloride 0.03%, Calcium Chloride 0.048%, Sodium Acetate 0.39%, Sodium Citrate 0.17% (Balanced Sterile Salt Solution) (Single use only)	irrigation solution		15mL: Eye Casualty 250mL and 500mL: Ophthalmologists  <i>See above</i> <i>See above</i>
		Sodium Chloride 0.64%, Potassium Chloride 0.075%, Magnesium Chloride 0.03%, Calcium Chloride 0.048%,	

Drug	Form	Strength	Restriction
sodium chloride with glucose	intravenous infusion injection	Sodium Acetate 0.39%, Sodium Citrate 0.17% (Balanced Sterile Salt Solution) (Single use only)	
		sodium chloride 0.3% and glucose 3.3% (125 Cal per litre) (Sodium 51, Chloride 51 mmol per litre) 1 Litre sodium chloride 0.3% and glucose 3.3% (125 Cal per litre) (Sodium 51, Chloride 51 mmol per litre) 500mL sodium chloride 0.45% and glucose 5% (200 Cal per litre) (Sodium 154, Chloride 154 mmol per litre) 1Litre sodium chloride 0.9% and glucose 1% 1 Litre sodium 0.9% chloride and glucose 5% (200 Cal per litre) (Sodium 154, Chloride 154 mmol per litre)	For paediatric perioperative use only.
sodium hyaluronate	intraocular injection	(M.W.=5,000,000) "Healon GV" 14mg/mL, 0.55mL "Healon" 10mg/mL, 0.4mL "Healon" 10mg/mL, 0.85mL "Amvisc Plus" 16mg/mL, 0.8mL	Specialist Ophthalmologists where alternatives are inappropriate Specialist Ophthalmologists See above See above
sodium hyaluronate - chondroitin	intraocular injection	3% - 4%, 0.5mL	Specialist Ophthalmologists
sodium hyaluronate - sodium chondroitin sulfate and sodium hyaluronate "Duovisc Viscoelastic System"	intraocular injection	3%-4%, 0.35mL and 1%, 0.4mL 3%-4%, 0.5mL and 1%, 0.55mL	Specialist Ophthalmologists See above
sodium hypochlorite	solution	2% 500mL, 5 Litres	
	tablet for disinfectant solution	tablet for Disinfectant Solution	Patients with spinal cord injury
sodium lactate compound solution (Hartmann's Solution) and glucose 5% (200 Cal per litre) (Sodium 131, Potassium 5, Calcium 2, Chloride 111, Lactate 29 mmol per litre)	intravenous infusion injection	1 Litre	
sodium lactate compound solution (Sodium 131, Potassium 5, Calcium 2, Chloride 111, Lactate 29 mmol per Litre) "Hartmann's Solution"	intravenous infusion injection	1 Litre 500mL	
Sodium polystyrene sulfonate	Powder	999.3 mg/g	
Sodium tetradecyl sulfate			

Drug	Form	Strength	Restriction
Sodium thiosulfate	Injection	3% (60 mg/2 mL)	
	Injection	25% (2.5 g/10 mL)	As second line treatment for cyanide poisoning.
sodium thiosulfate	lotion	20%, 100mL	
Sofosbuvir + velpatasvir	Tablet	400 mg + 100 mg	For discharge and outpatients only, in accord with PBS General Schedule/Section 100 indications.
Sofosbuvir + velpatasvir + voxilaprevir	Tablet	400 mg + 100 mg + 100 mg	* For discharge and outpatient use in accord with PBS General Schedule/Section 100 indications *
Somatrogon	Injection	24 mg/1.2 ml, Pen device 60 mg/1.2 ml, Pen device	* For use in accord with PBS Section 100 indications * <i>See above</i> <i>See above</i>
Somatropin	Injection	1 mg 1.2 mg 1.4 mg 1.6 mg 1.8 mg 2 mg 5 mg 5 mg/1.5 ml 5 mg/1.5 mL 6 mg/1.03 mL 10 mg/1.5 ml 10 mg/1.5 mL 12 mg 12 mg/1.5 mL 15 mg/1.5 ml 15 mg/1.5 mL 20 mg/2.5 mL 400 microgram 600 microgram 800 microgram	* For use in accord with PBS Section 100 indications * <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i>
Sorafenib	Tablet	200 mg	Specialist Oncologists for outpatient use for advanced hepatocellular carcinoma only, as per the PBS indications. All other use must be on an Individual Patient Approval basis.
sotalol	oral liquid suspension	5mg per mL, 192mL	Paediatric cardiac specialists
Sotalol			

Drug	Form	Strength	Restriction
	Injection		
	Tablet	40 mg/4 mL	
		80 mg 160 mg	
Soya oil	fat emulsion (eg 'intralipid')	20% (100 g/500 mL)	Anaesthetists, Emergency Department Specialists and Rural Generalists for the management of severe local anaesthetic toxicity.
soya oil + medium chain triglycerides + olive oil + fish oil natural	Injection	6 g/100 mL + 6 g/100 mL + 5 g/100 mL + ... 30 g/500 mL + 30 g/500 mL + 25 g/500 mL + ...	For intravenous therapy when oral or enteral feeding is not possible. Note: 100mL is to be used in neonates only For intravenous therapy when oral or enteral feeding is not possible.
spironolactone	oral liquid suspension	2.5mg per mL, 50mL	Patients unable to swallow tablets
Spironolactone	Tablet	25 mg 100 mg	
Sterculia	Granules	620 mg/g	
Stonefish antivenom	Injection	2000 units, Vial	
Streptokinase	Injection	250 000 units	
streptomycin sulfate	injection	1g	* For use in accord with Special Access Scheme (SAS) arrangements *
Succinylated gelatin	Injection	20 g/500 mL	Plasma substitute as an alternative to plasma protein
Sucralfate	Tablet	1 g	
Sucroferric oxyhydroxide	Chewable tablet	2.5 g (iron 500 mg)	* For use in accord with PBS Section 100 indications *
sucrose	oral liquid solution	24% 2mL	
sufentanil	injection	250microgram in 5mL	Palliative Care Specialists and Medical Oncologists for the control of severe disabling pain when other opioids are inappropriate or not tolerated. Caution: The risk of drug dependence is high. CONTROLLED DRUG Where a medicine is not TGA approved, patients should be made fully aware of the status of the

Drug	Form	Strength	Restriction
			medicine and appropriate consent obtained.
Sugammadex	Injection	200 mg/2 mL 500 mg/5 mL	For emergency reversal of rocuronium in patients who cannot be intubated or oxygenated.
Sulfadiazine	Tablet	500 mg	* On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
Sulfasalazine	Enteric tablet	500 mg	
	Tablet	500 mg	
Sulthiame	Tablet	50 mg 200 mg	
Sumatriptan	Injection	6 mg/0.5 mL	For use in hospital under medical supervision
	Nasal spray	20 mg/actuation	For migraine attacks in patients aged 12 years and older, where oral treatment with a triptan is not tolerated.
	Tablet	50 mg	Treatment of migraine attacks in patients failing other therapy.
Sunitinib	Capsule	12.5 mg 25 mg 37.5 mg 50 mg	* For discharge and outpatient use as per the PBS indications * See above See above See above See above
sunscreen (SPF 50+) cream and lotion	cream	75g	
	lotion	500mL	
Suxamethonium	Injection	100 mg/2 mL	Medical staff skilled in airway support
Tacrolimus	Capsule	1 mg 5 mg 500 microgram	
	Modified release capsule	1 mg 3 mg 5 mg 500 microgram	
tacrolimus "ACS"	oral liquid suspension (QH-CP)		

Drug	Form	Strength	Restriction
		1mg in 1mL, 100mL	a) For use in paediatric patients. b) For initiation or maintenance of immunosuppression in adult patients where a dose is unable to be given via a capsule. Note: Monitor patient on transition between different dose forms. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
Tadalafil	Tablet	20 mg	* For use in accord with PBS Section 100 indications *
Taipan snake antivenom	Injection	12 000 units, Vial	
talc	powder	3g aerosol 4g	
Taliglucerase alfa	Injection	200 units	For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program
Tamoxifen	Tablet	10 mg 20 mg	
Tapentadol	Modified release tablet	50 mg 100 mg 150 mg 200 mg 250 mg	Persistent pain specialists for use in patients with chronic severe pain requiring daily, continuous, long term therapy which is not responding to non-opioid or first line opioid analgesics or where these agents are inappropriate or not tolerated. Caution: The risk of drug dependence is high. * CONTROLLED DRUG * <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i> <i>See above</i>
taurolidine + citrate 4% (TauroLock)	catheter lock solution	3mL & 5mL	For use as a line lock for the prevention of blood stream infections and to maintain patency in: a) haemodialysis patients b) patients on home parenteral nutrition who have experienced a central venous catheter line infection <i>See above</i>
taurolidine + citrate 4% + heparin 500 units (TauroLock Hep500)	catheter lock solution	5mL	For use as a line lock for the prevention of blood stream infections and to maintain patency in: a) haemodialysis patients b) patients on home parenteral nutrition who have experienced a central venous catheter line infection.
Teduglutide	Injection	5 mg	For discharge, outpatient and day admitted patient use in accord with PBS Section 100 indications
Teicoplanin	Injection		



Drug	Form	Strength	Restriction
Telmisartan	Tablet	400 mg	* On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
			For patients unable to tolerate ACE inhibitors because of cough or angioedema, or patients intolerant of other antihypertensive therapy.
		40 mg	See above
		80 mg	See above
Temazepam	Tablet	10 mg	
Temozolomide	Capsule		* For discharge and outpatient use as per the PBS indications *
			[Brand Note: Use Temizole brand for all strengths apart from the 180mg strength which is the Juno brand. Use the same brand if the dose requires a combination of strengths].
		5 mg	See above
		20 mg	See above
		100 mg	See above
		140 mg	See above
		180 mg	See above
Tenecteplase	Injection	250 mg	See above
		50 mg	a) treatment of acute ST elevation myocardial infarction; b) fibrinolytic management of obstructed IV access; c) treatment of acute ischaemic stroke with large arterial obstruction documented by angiography prior to emergency endovascular clot retrieval. Dose 0.25mg/kg to maximum 25mg; d) treatment of acute ischaemic stroke in rural hospitals under telehealth consultation with a physician (including Emergency Department physicians) trained and experienced in acute stroke management. Thrombolysis may be initiated within four and a half hours after the onset of stroke symptoms and after exclusion of intracranial haemorrhage by appropriate imaging techniques. Dose 0.25mg/kg to maximum 25mg.
			* When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
Teniposide	Injection	50 mg/5 mL	
Tenofovir alafenamide + emtricitabine + elvitegravir + cobicistat	Tablet		
		10 mg + 200 mg + 150 mg + ...	* For use in accord with PBS Section 100 indications *
Tenofovir disoproxil	Tablet	291 mg	* For use in accord with PBS Section 100 indications *
Tenofovir disoproxil + emtricitabine			(a) For use in accord with PBS S85 (General Schedule) and Section 100 indications; (b) For post exposure prophylaxis in accordance with Queensland Health guidelines on the management of non-occupational exposure to HIV, and occupational exposure to blood and body fluids in conjunction with Post-exposure Prophylaxis for HIV: Australian National Guidelines. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM

Drug	Form	Strength	Restriction
Tenofovir disoproxil + emtricitabine + efavirenz	Tablet	300 mg + 200 mg	formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
			See above
	Tablet	300 mg + 200 mg + 600 mg	* For use in accord with PBS Section 100 indications *
			See above
Terbinafine	Cream	1%	* For use as per the PBS indications *
	Tablet	250 mg	Specialist Staff and Endorsed Podiatrists in a shared care arrangement for (i) microbiologically proven chronic onychomycosis; (ii) extensive tinea unresponsive to griseofulvin or in patients intolerant of griseofulvin
Terbutaline	Injection	500 microgram/mL	General use for TGA approved indications; and for treatment of uterine hyperstimulation / tachysystole. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
	Powder for inhalation	500 microgram/actuation	
Teriparatide	Injection	250 microgram/mL	For discharge and outpatient use as per the PBS indications. Patients must be made fully aware of the 18 month maximum length of PBS subsidised treatment.
Terlipressin	Injection	850 microgram/5 mL	Under the direction of a transplant hepatologist for treatment of patients with hepatorenal syndrome (HRS) Type 1 who are actively being considered for liver transplant.
Testosterone	Gel	1% (12.5 mg/actuation)	* For use as per the PBS indications *
		1% (50 mg/5 g)	See above
Testosterone enantate	Injection	250 mg/mL	(a) For use in confirmed testosterone deficiency. (b) For continued use by Paediatric endocrinologists, and paediatricians under the supervision of a paediatric endocrinologist, for use in adolescents (less than 18 years of age) with persistent gender dysphoria who had commenced receiving this therapy prior to 28 January 2025, in accordance with the Health Service Directive. Treatment must have previously been initiated: By Paediatric endocrinologists, and paediatricians under the supervision of a paediatric endocrinologist, who have a credentialled scope of clinical practice that includes assessment and treatment of gender diverse adolescents AND In accordance with the current version of the Australian Standards of Care and Treatment Guidelines for trans and gender diverse children and adolescents where care is coordinated by a multidisciplinary service. (c) Adult endocrinologists, and adult physicians under the supervision of an adult endocrinologist, for the treatment of persistent gender dysphoria. * When medicines are used in ways other than as specified in the TGA approved product

Drug	Form	Strength	Restriction
			information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
Tetanus immunoglobulin	Injection	250 units	
Tetrabenazine	Tablet	25 mg	
Tetracaine (amethocaine)	Eye drops	1%	Specialist Ophthalmologists
Tetracosactide	Injection	250 microgram/mL	
	Modified release injection	1 mg/mL	
Tetracycline	Capsule	250 mg	
Tezacaftor + ivacaftor (&) Ivacaftor	combination pack	100 mg + 150 mg (&) 150 mg	* For use in accord with PBS Section 100 indications *
Thalidomide	Capsule	50 mg 100 mg	* For use in accord with PBS Section 100 indications * <i>See above</i> <i>See above</i>
Theophylline	Modified release tablet	250 mg 300 mg	
	Oral liquid	133.3 mg/25 ml	To be used where tablets are unsuitable
thiabendazole (tiabendazole)	tablet	500mg	
thiamine	injection 300mg/3mL	300mg/3mL	
Thiamine	injection 100mg/1mL	100 mg/mL	For use only in paediatric patients
	Tablet	100 mg	
Thiopental	Injection	470 mg (equiv 500mg thiopental sodium and sodium carbonate)	Note: The amount of active ingredient differs between brands of thiopental sodium. Refer to Queensland Health memorandum dated 25/11/19
Thiotepa	Injection	15 mg, Vial	Specialist Oncologists and Haematologists for use as per endorsed chemotherapy / Haemopoietic stem cell transplantation (HSCT) protocols. <i>See above</i>

Drug	Form	Strength	Restriction
thrombin "Aspen"		100 mg, Vial	See above
	application	5000 units	Requires SAS category A approval
Thymol + benzoic acid + bicarbonate	Mouthwash	1.5 mg/ml + 8 mg/ml + 3 mg/ml	
Tiagabine	Tablet	5 mg	For partial epilepsy not controlled by other drugs
		10 mg	See above
		15 mg	See above
Ticagrelor	Dispersible tablet	90 mg	(a) For inpatient use in combination with aspirin for treatment of STEMI and high risk non-ST elevation acute coronary syndrome; (b) Use by the Queensland Ambulance Service (QAS) in accordance with the QAS Ticagrelor Drug Therapy Protocol; (c) Interventional radiologists or neurosurgical specialists for inpatient use in proven clopidogrel non-responders identified by the multiplate / VerifyNow P2Y12 assay post neuro-endovascular stent insertion. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
	Tablet	90 mg	(a) To be used in combination with aspirin for treatment of STEMI and high risk non-ST elevation acute coronary syndrome; (b) Interventional radiologists or neurosurgical specialists for use in proven clopidogrel non-responders identified by the multiplate / VerifyNow P2Y12 assay post neuro-endovascular stent insertion. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
Tiger snake antivenom	Injection	3000 units, Vial	
Timolol	Eye drops	0.25%	
		0.5%	
Tinidazole	Tablet	500 mg	* Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
		40 mg	
Tiotropium	Inhalation solution	2.5 microgram/actuation	For use as per the PBS indications.
Tirofiban			

Drug	Form	Strength	Restriction
Tobramycin	Injection	12.5 mg/50 mL	Patients with high-risk acute coronary syndromes (as defined by new transient or persistent ST or T-wave ECG changes and ischaemic pain lasting at least 20 minutes within the previous 12 hours) who are either: 1) undergoing percutaneous coronary intervention (PCI); or 2) continuing to experience repeated episodes of ischaemic chest pain despite maximal medical therapy including combination anti-platelet therapy and therapeutic dose heparin.
	Eye drops	0.3%	Ophthalmologists
	Eye ointment	0.3%	Ophthalmologists
	Inhalation solution	300 mg/5 mL	Specialist respiratory staff or physicians in regional centres with approval from the specialist cystic fibrosis physician for discharge and outpatient use (including use for training purposes in outpatient clinics) for the management of cystic fibrosis patients with Pseudomonas aeruginosa infections as per the PBS indications.
	Injection	80 mg/2 mL	Preservative Free Specialist respiratory staff for nebulised use as treatment of pulmonary infection with Pseudomonas aeruginosa in patients with cystic fibrosis in situations where patients are intolerant to other tobramycin products; and on the advice of an infectious diseases physician for inhalation in non-CF bronchiectasis patients with pseudomonas aeruginosa infection. Injection On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
	Powder for inhalation	28 mg	Specialist respiratory staff or physicians in regional centres with approval from the specialist cystic fibrosis physician for discharge and outpatient use (including use for training purposes in outpatient clinics) for the management of cystic fibrosis patients with Pseudomonas aeruginosa infections as per the PBS indications.
Tocilizumab	Injection	80 mg/4 mL	(a) For use in accord with PBS Section 100 indications; (b) On advice of specialist oncology and haematology staff for the treatment of chimeric antigen receptor (CAR) T-cell induced severe or life-threatening cytokine release syndrome (CRS). (c) On the advice of a specialist physician for the treatment of patients hospitalised with severe or critical COVID-19 with evidence of systemic inflammation where baricitinib cannot be used.
		162 mg/0.9 mL (subcutaneous)	For use as per the PBS indications.
		200 mg/10 mL	(a) For use in accord with PBS Section 100 indications; (b) On advice of specialist oncology and haematology staff for the treatment of chimeric antigen receptor (CAR) T-cell induced severe or life-threatening cytokine release syndrome (CRS). (c) On the advice of a specialist physician for the treatment of patients hospitalised with severe or critical COVID-19 with evidence of systemic inflammation where baricitinib cannot be used.
		400 mg/20 mL	See above
Tolnaftate	Cream	1%	
	Lotion		

Drug	Form	Strength	Restriction
topiramate	oral liquid suspension	1%	For epilepsy not controlled by other medications where: (a) Solid dose forms cannot be swallowed whole; OR (b) Administration via an enteral feeding tube is required AND dispersing the tablet/capsule is considered inappropriate. Refer to 'Don't Rush to Crush' and local procedures for guidance. Note: Monitor patient on transition between different dose forms. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
		5mg/mL, 100mL (QH-CP)	
Topiramate	Capsule	15 mg	For epilepsy not controlled by other drugs <i>See above</i>
		25 mg	<i>See above</i>
	Tablet	25 mg	<i>See above</i>
		50 mg	<i>See above</i>
		100 mg	<i>See above</i>
		200 mg	<i>See above</i>
Topotecan	Injection	4 mg	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
Trabectedin	Injection	1 mg, Vial	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
trace elements with iron - chromium + copper + iron + manganese + iodine + fluoride + molybdenum + selenium + zinc	Injection	53.33 microgram/10 mL + 1.02 mg/10 mL + 5.4 mg/10 mL + ...	
Tramadol	Capsule	50 mg	For use in patients with severe pain which is not responding to non-opioid analgesics or where these agents are inappropriate or not tolerated. A maximum quantity of 10 tablets for discharge and outpatient use, except for palliative care patients.
	Injection	100 mg/2 mL	For use in patients with severe pain which is not responding to non-opioid analgesics or where these agents are inappropriate or not tolerated.
	Modified release tablet	50 mg	a) For use in patients with chronic severe pain requiring daily, continuous, long term therapy which is not responding to non-opioid or short acting first line opioid analgesics or where these agents are inappropriate or not tolerated. b) For use in severe pain which is not responding to non-opioid analgesics in patients who are either opioid tolerant or expected to have prolonged post-operative or post-traumatic states.
		100 mg	<i>See above</i>
		150 mg	<i>See above</i>

Drug	Form	Strength	Restriction
		200 mg	See above
Trametinib	Powder for oral liquid		Specialist Oncologists for discharge and outpatient use as per the PBS indications.
		50 microgram/ml	See above
	Tablet		See above
		2 mg	See above
		500 microgram	See above
Tranexamic acid	Injection		
		1 g/10 mL	(a) Specialist Anaesthetists, Specialist Intensivists, Specialist Surgical Staff and Cardiac Perfusionists for: (i) Major haemorrhage with concomitant hyperfibrinolysis, and (ii) Prophylaxis of intra- and post-operative bleeding during major surgical procedures where there is a high likelihood of transfusion requirement; (b) To treat hypotensive trauma patients with uncontrolled haemorrhage, preferably within one hour, but no later than 3 hours after trauma; (c) For use in uncontrolled bleeding in patients on direct oral anticoagulants in line with the Queensland Health Anticoagulant guideline for hospitalised adult patients ; (d) For management of post-tonsillectomy haemorrhage (primary or secondary) in paediatric patients. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
	Tablet	500 mg/5 mL	See above
		500 mg	
tranexamic acid	mouthwash		
		5% 150mL	
Tranylcypromine	Tablet		
		10 mg	
Trastuzumab (Herceptin SC)	Injection		
		600 mg/5 mL	a) For discharge and outpatient use as per PBS indications; b) For use as per PBS indications for Related Pharmaceutical Benefits used in conjunction with Efficient Funding of Chemotherapy - Section 100 arrangements.
Trastuzumab (Herzuma)	Powder for injection		* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		150 mg, Vial	See above
		440 mg, Vial	See above
Trastuzumab deruxtecan	Injection		
		100 mg, Vial	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
Trastuzumab emtansine	Injection		* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
		100 mg	See above
		160 mg	See above

Drug	Form	Strength	Restriction
Travoprost	Eye drops	0.004%	Specialist Ophthalmologists as monotherapy for the reduction of intraocular pressure in patients with open-angle glaucoma and ocular hypertension who are intolerant of, or insufficiently responsive to, other intraocular pressure medication.
Travoprost + timolol	Eye drops	0.004% + 0.5%	For reduction of elevated intra-ocular pressure as per the PBS indications.
Tretinoin	Capsule	10 mg	Specialist Haematologists and their advanced training registrars in accord with Health (Drugs and Poisons) Regulations 1996 for use in induction, consolidation and maintenance therapy in patients with newly diagnosed or relapsed acute promyelocytic leukaemia (APML).
Triamcinolone	Cream	0.02%	100g: Specialist Staff, Country Medical Superintendents and Endorsed Podiatrists
	Injection	10 mg/mL 40 mg/mL	Intra-articular and intralesion injection <i>See above</i>
	Ointment	0.02%	100g
	Paste	0.1%	5g: Specialist Medical and Dental Staff and Country Medical Superintendents
Triamcinolone + neomycin + gramicidin + nystatin	Ear drops	0.09% + 0.225% + 0.0225% + ...	Applies to 15g ointment and 5g ear ointment.
	Ointment	0.1% + 0.25% + 0.025% + ... ointment and ear ointment	
triamcinolone acetonide	intraocular injection	40mg in 1mL	Specialist ophthalmologists for intraocular oedematous and neovascular disease of the eye. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
triamcinolone hexacetonide	injection suspension	20mg/mL	Paediatric rheumatologists who have TGA authorisation to prescribe triamcinolone hexacetonide. * Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained * <i>See above</i> <i>See above</i>
triclosan	emulsion	1% 200mL	Not for use on neonates
	hand and body wash/skin cleanser	1% 1.5L 1% 125mL 1% 500mL	For use in areas at high risk from MRSA <i>See above</i> <i>See above</i>
	pre-op wash	1% 40mL	
	skin cleanser soap		



Drug	Form	Strength	Restriction
Trifluridine + tipiracil	Tablet	1% 125g	For use in areas at high risk from MRSA
		15 mg + 6.14 mg	Specialist medical oncology staff * For discharge and outpatient use as per the PBS indications *
		20 mg + 8.19 mg	See above
Trihexyphenidyl (benzhexol)	Tablet	2 mg	See above
		5 mg	
Trimethoprim	Tablet	300 mg	
Trimethoprim + sulfamethoxazole	Injection	80 mg/5 mL + 400 mg/5 mL	* On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
	Oral liquid	40 mg/5 ml + 200 mg/5 ml	Patients unable to swallow tablets
	Tablet	80 mg + 400 mg	
		160 mg + 800 mg	
Triptorelin	Injection	3.75 mg	Outpatient: * For discharge and outpatient use as per the PBS indications *
		11.25 mg	See above
		22.5 mg	See above
			See above
trisodium edetate	injection	1g in 5mL	
Tropicamide	Eye drops	0.5%	0.5mL: For inpatient use only.
		0.5%	15mL
		1%	See above
		1%	0.5mL: For inpatient use only.
trypan blue	injection	0.6mg in 0.5mL	Specialist ophthalmologists for use where standard capsulorrhexis is difficult to perform.
Tuberculin PPD (Mantoux) acellular intradermal skin test	Injection	50 tuberculin units/mL	
Typhoid inactivated vaccine	Injection	0.5 mL Syringe	
Ulipristal	Tablet	30 mg	For emergency contraception (EC) up to 120 hours post unprotected intercourse where levonorgestrel EC is not appropriate.
Umeclidinium + vilanterol	Powder for inhalation		For use as per the PBS indications.

Drug	Form	Strength	Restriction
		62.5 microgram/actuation + 25 microgram/actuation	See above
Urea + lactic acid	Cream	10% + 5%	
urea pronalys BP	crystals	99-100% w/w 500g	Specialist Endocrinology Staff for the oral treatment of mild to moderate symptoms of euvolemic hyponatraemia in patients unable to tolerate fluid restrictions or where fluid restrictions have failed See above See above
urokinase	injection	10,000 units 100,000 units 500,000 units	Fibrinolytic management of obstructed IV access; Venous thrombosis; Peripheral arterial occlusion; Haemodialysis shunts See above See above See above
Ursodeoxycholic acid	Capsule	250 mg	(a) For proven primary biliary cholangitis (formerly primary biliary cirrhosis); (b) For relief of pruritus and improvement of liver function in biochemically proven intrahepatic cholestasis of pregnancy. * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
	Oral liquid	50 mg/ml	For proven primary biliary cholangitis (formerly primary biliary cirrhosis).
Ustekinumab	Injection	45 mg/0.5 mL (subcutaneous) 90 mg/ml, Syringe 130 mg/26 mL	* For use as per the PBS indications * See above * For use in accord with PBS Section 100 indications *
Valaciclovir	Tablet	500 mg	a) On the advice of an Infectious Diseases Physician or a Clinical Microbiologist for the treatment of herpes simplex virus in immunocompromised (haematology and oncology) paediatric patients (up to 18 years of age); b) Treatment of immunocompetent patients with herpes zoster in whom the duration of rash is less than 72 hours; c) Intermittent treatment of moderate to severe recurrent genital herpes; d) Herpes zoster in immunocompromised patients; e) Ophthalmic herpes zoster; f) Use in accord with PBS Section 100 indications; g) For prophylaxis of viral infection for up to 12 months following stem cell transplant h) For prophylaxis of viral infection in solid organ transplant (SOT) patients: for up to 3 months following SOT; and for 1 month following treatment of acute rejection of SOT i) For prophylaxis of viral infection in patients receiving chemotherapy for haematological malignancy, during, and up to 3 months post completion of treatment * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
Valganciclovir			* For use in accord with PBS Section 100 indications *

Drug	Form	Strength	Restriction
Valproate	Powder for oral liquid		See above
	Tablet	50 mg/ml	See above
		450 mg	See above
			See above
	Enteric tablet	200 mg 500 mg	
	Injection	400 mg	(a) For maintenance treatment of epilepsy not controlled by other drugs when oral sodium valproate has already been established but is temporarily not feasible. (b) Status epilepticus in adults, and also in children (as per the statewide paediatric guidelines) * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
	Oral liquid		
	Tablet	200 mg/5 ml	Caution: There are reports of fatal hepatotoxicity with this preparation particularly in children
		100 mg	
Vancomycin	Capsule		For the treatment of antibiotic associated colitis due to C. difficile as per the PBS indications.
		125 mg	See above
		250 mg	See above
	Injection		* On the advice of an infectious diseases physician, clinical microbiologist or in conjunction with an antimicrobial stewardship (AMS) team protocol. *
		1 g 500 mg	See above See above
Varenicline	Tablet		
		1 mg	a) For use in Primary Health Care Clinics registered for the PBS Section 100 Remote Area Aboriginal Health Services program b) For use in either community mental health or community alcohol and other drug services as per the PBS indications.
		500 microgram	See above
Varicella-zoster live vaccine	Injection		
		1 each	(a) For use in accord with QH policy for staff immunisation; (b) For haematopoietic stem cell transplant recipients who are not eligible for National Immunisation Program (NIP) funded vaccines; (c) For patients planned for solid-organ transplantation who are not eligible for National Immunisation Program (NIP) funded vaccines. Seek expert opinion if vaccination is required within four weeks of the scheduled date of transplant.
		1350 PFU Vial	
vasopressin	injection	20 pressor Units in 1mL	
Vecuronium	Injection	10 mg	Medical staff skilled in airway support
Vedolizumab	Injection		

Drug	Form	Strength	Restriction
Velaglucerase alfa	Injection	300 mg	* For use in accord with PBS Section 100 indications *
		400 units	For use in accordance with the requirements of the Commonwealth Life Saving Drugs Program
Venetoclax	Tablet	10 mg	Specialist Haematologists for use as per the PBS indications. Note: This strength also available as part of the venetoclax titration pack. Titration pack restriction: Specialist Haematologists for discharge and outpatient use as per the PBS indications.
		50 mg	<i>See above</i>
		100 mg	Specialist Haematologists for discharge and outpatient use as per the PBS indications. Note: This strength also available as part of the venetoclax titration pack. Titration pack restriction: Specialist Haematologists for discharge and outpatient use as per the PBS indications.
Venlafaxine	Modified release capsule		For major depressive disorders
		37.5 mg	<i>See above</i>
		75 mg	<i>See above</i>
		150 mg	<i>See above</i>
Verapamil	Injection		
		5 mg/2 mL	
	Modified release capsule		
		160 mg	
	Modified release tablet		
		180 mg	
	Tablet	240 mg	
		40 mg	
Vericiguat	Tablet	80 mg	On the advice of a cardiologist as per the PBS indications.
			<i>See above</i>
		2.5 mg	<i>See above</i>
		5 mg	<i>See above</i>
		10 mg	<i>See above</i>
Vigabatrin	Powder for oral liquid		For epilepsy not controlled by other drugs
			<i>See above</i>
	Tablet	500 mg	<i>See above</i>
		500 mg	<i>See above</i>
Vinblastine	Injection		
		10 mg/10 mL	* For use in accord with PBS Section 100 indications *
Vincristine	Injection		
		1 mg/mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS *
Vindesine	Injection		
		5 mg	

Drug	Form	Strength	Restriction
Vinorelbine	Capsule	20 mg	* For discharge and outpatient use as per the PBS indications * See above
		30 mg	
	Injection	10 mg/mL	* For use as per the Efficient Funding of Chemotherapy - Section 100 Arrangements Supplement of the PBS * See above
		50 mg/5 mL	
vitamin A	capsule 5000 units	5,000 units	
Vitamin A	capsule 50 000 units	50 000 units	* For use in accord with Special Access Scheme (SAS) arrangements ** Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained *
vitamin A	injection (SAS)	100,000 units/ 2mL	Use where enteral therapy is inappropriate or contraindicated. * For use in accord with Special Access Scheme (SAS) arrangements ** Where a medicine is not TGA approved, patients should be made fully aware of the status of the medicine and appropriate consent obtained * See above
vitamin A	oral solution	5,000 units/ 0.2mL	
vitamin B group with ascorbic acid (ascorbic acid + nicotinamide + pyridoxine + riboflavin + thiamine)	Tablet	45 mg + 45 mg + 700 microgram + ...	
vitamin compound "Penta-vite" 30mL	liquid	"Penta-vite"	Patients unable to swallow tablets See above See above
vitamin compound "VitABDECK"	capsule	"VitABDECK"	For treatment of patients with cystic fibrosis or pancreatic insufficiency See above See above
vitamin compound (containing fat and water soluble vitamins excluding vitamin K) "Cernevit" 5mL	injection	"Cernevit"	
vitamin compound (fat soluble vitamins) "Vitalipid N Adult" 10mL	injection	"Vitalipid N Adult"	For a complete PN multivitamin, use a fat soluble vitamin preparation together with a water soluble vitamin preparation. See above See above
vitamin compound (water soluble vitamins) "Soluvit N"	injection		For a complete PN multivitamin, use a fat soluble vitamin preparation together with a water soluble vitamin preparation. See above



Drug	Form	Strength	Restriction
	Tablet	40 mg/ml	On the advice of an Infectious Diseases Physician or a Clinical Microbiologist or in accordance with an Infectious Diseases/Clinical Microbiology approved protocol for: a) treatment of fungal infections as per the PBS indications; b) prophylaxis of invasive fungal infections including both yeasts and moulds as per the PBS indications and in lung transplant patients.
		50 mg	On the advice of an Infectious Diseases Physician or a Clinical Microbiologist or in accordance with an Infectious Diseases/Clinical Microbiology approved protocol for: a) treatment of fungal infections as per the PBS indications; b) prophylaxis of invasive fungal infections including both yeasts and moulds - in patients unable to tolerate posaconazole - as per the PBS indications and in lung transplant patients.
		200 mg	See above
Vorinostat	Capsule	100 mg	Haematologists for discharge and outpatient use as per the PBS indications
Vosoritide	Injection	1.2 mg, Vial 400 microgram, Vial 560 microgram, Vial	* For discharge and outpatient use as per the PBS indications * See above See above See above See above
Warfarin	Tablet	1 mg 3 mg 5 mg	Note: Marevan® brand continues to be the preferred brand of warfarin for use in QH facilities. As warfarin brands are NOT bioequivalent and should not be interchanged, hospital pharmacies may hold small stocks of Coumadin® brand for continuation of therapy in inpatients, if patient's own supply is unavailable. See above See above See above
Water for injections	Injection	1 L Bag 2 mL glass ampoule 5 mL Ampoule 10 mL Ampoule 20 mL Ampoule 100 mL Vial	
Water for irrigation	Solution	1 L Bottle 2 L Bag 500 mL Bottle	Urology and Renal Units
Wool fat	Ointment	1 g/g	
Zanamivir	Powder for inhalation	5 mg/actuation	On the advice of an Infectious Diseases Physician or a Clinical Microbiologist for a) treatment of laboratory-proven influenza in hospitalised patients within 48 hours of onset of symptoms and b) prophylaxis of hospitalised contacts of laboratory-proven influenza cases in contacts who are at high risk of influenza related morbidity
Zanubrutinib	Capsule		

Drug	Form	Strength	Restriction
Zidovudine	Capsule	80 mg	Specialist haematologists for discharge and outpatient use as per the PBS indications.
		100 mg	* For use in accord with PBS Section 100 indications *
		250 mg	See above
	Oral liquid	See above	See above
		50 mg/5 ml	See above
Zinc	Capsule	50 mg	
Zinc chloride	Injection	10.6 mg/2 mL (5.1mg/2mL elemental zinc)	
zinc oxide	cream	15.25% w/w, 25g	
		15.25% w/w, 60g	
		100g	
	ointment	100g	
Zinc oxide + maize starch + purified talc + chlorphenesin	Powder	25% + 55.85% + 18.07% + ...	
Zinc oxide + peru balsam + benzyl benzoate	Suppository	300 mg + 50 mg + 33 mg	
zinc oxide compound paste (paraffin base) with	paste	Clioquinol 1%, 50g	
		Salicylic Acid 2% and Dithranol 0.1% 100g	
		Salicylic Acid 2% and Dithranol 0.25% 100g	
		Coal Tar Solution 3% 50g	
		100g	
zinc sulfate	oral liquid	Dusting Powder 100g	
		11.3mg (elemental zinc) per mL, 50mL	For use when prescribed by a Burns Unit specialist and when zinc sulfate capsules cannot be used
Ziprasidone	Capsule		For use as per the PBS indications following failure of aripiprazole, risperidone, olanzapine, amisulpride or lurasidone.
		20 mg	See above
		40 mg	See above
		60 mg	See above
		80 mg	See above
Zoledronic acid	Injection	4 mg/5 mL	(a) For use in accord with PBS Section 100 indications;
			(b) Severe hypercalcaemia;
			(c) Paediatricians for the treatment of (i) Osteogenesis imperfecta OR (ii) Primary or secondary osteoporosis in paediatrics with evidence of significant skeletal fragility (e.g. vertebral compression



Drug	Form	Strength	Restriction
			fractures or $\geq 2$ low trauma long bone fractures). * When medicines are used in ways other than as specified in the TGA approved product information, documentation and evaluation should be undertaken with reference to QHMAC's advice in the LAM formulary notes; and the CATAG guiding principles for the quality use of off-label medicines (www.catag.org.au) *
		5 mg/100 mL	* For discharge and outpatient use as per the PBS indications *
Zonisamide	Capsule		Neurology Staff for the treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptics as per the PBS indications.
		25 mg	See above
		50 mg	See above
		100 mg	See above
Zuclopenthixol acetate			Specialist psychiatrists for prolonged acute behavioural disturbance that has not responded to initial treatments as per the Queensland Health guidelines for acute behavioural disturbance management
	Injection		See above
		50 mg/mL	See above
		100 mg/2 mL	See above
Zuclopenthixol decanoate	Injection		
		200 mg/mL	Specialist Psychiatrists where other antipsychotic agents are ineffective or contraindicated